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Therapeutic agents are an integral part of life as we are faced with a myriad of health problems 
that range from inherent conditions such as diabetes to being afflicted by invading organisms 
such as bacteria. A major drawback of current pharmaceutical agents to treat these conditions 
is that they have a limited timescale as they become ineffective due to toxicity and in the case 
of bacterial infection, resistance often develops. To counteract this scenario, pharmaceutical 
research is faced with the arduous task of continuously developing cost-effective therapeutic 
agents that display high bio-efficacies against these pathologies. 
The advent of nanoscience has broadened the area of drug discovery research. The exceptional 
physicochemical properties of nanoparticles make them one of the most interesting and 
promising agents in medicine. Nanomedicine based on noble metal nanoparticles have attracted 
much interest recently and there is a demand for the new biocompatible nanoparticle with 
pharmaceutical applications. Metal nanoparticles in combination with plant extracts have 
gained much importance for medicinal application. For this reason, we explored the synthesis 
of silver and gold nanoparticles using medicinal plants indigenous to South Africa, and their 
application as antibacterial agents. Silver and gold nanoparticles were synthesized using an 
aqueous seed extract of Protorhus longifolia as both reducing and capping agent. The 
nanoparticles were characterized and evaluated for antibacterial properties against both Gram-
positive and -negative bacteria. The nanoparticles displayed antibacterial activity against 
Escherichia coli (ATCC 35218), Klebsiella pneumoniae (ATCC 700603), Staphylococcus 
aureus (ATCC 43300) and Pseudomonas aeruginosa (ATCC 27853). 
Heterocyclic molecules belonging to the class pyridine with 2-amino-4-aryl-6-sulfanyl 
substitution pattern has drawn much attention currently for a variety of biological activities. 
Considering the importance of these pyridine compounds in the medical field, we have 
synthesized several pyridine molecules in a one pot multi-component approach. These 
compounds were screened for their antibacterial potential but did not show good activity. 
However, since this class of compounds has also been shown to have promise as α-glucosidase 
inhibitors, they were tested for antidiabetic properties. Among the derivatives that were 
prepared, compounds containing aromatic substitution at position 6 of the pyridine ring were 
found to be potential α-glucosidase inhibitors. In support of the enzymatic inhibition data, 
molecular docking studies with the α-glucosidase enzyme also confirmed that best affinity 
towards the enzyme occurred when there was aromatic substitution at position 6 of the pyridine 
ring instead of the aliphatic substitution. Importantly, this study is the first to report 2-amino-
v 
 
4-aryl-6-sulfanyl pyridine compounds as potential α-glucosidase inhibitors and thereby 
provides a viable avenue in the generation of new antidiabetic compounds.  
Drug discovery is expensive and time-consuming field. Finding new drug candidates is not 
enough as many potential drug candidates with attractive bioactivities are deemed unsuitable 
as feasible mainstream therapeutic agents, due to their poor pharmaceutical properties such as 
poor solubility, permeability and tolerability. Hence, along with the discovery and development 
of new drugs, focusing on novel strategies promotes rapid implementation of modified drugs 
developed from current candidates that have become ineffective through microbial resistance.  
Cyclodextrins (CD) and their derivatives are important pharmaceutical excipients which can 
decrease side effects of drugs by encapsulating them in a sugar skeleton. We studied the 
inclusion phenomena of chloramphenicol with different cyclodextrins using molecular docking 
and molecular dynamics to identify the most suitable polymer for their encapsulation. 
Chloramphenicol was found to form stronger inclusion complexes with γ-CD than α-CD and 
β-CD. Encapsulation phenomena of chloramphenicol with γ-CD, a nanocomposite constituting 
of chloramphenicol and γ-CD capped silver nanoparticles was synthesized. The surface 
enhanced Raman spectroscopy (SERS) data confirmed the molecular recognition of 
chloramphenicol by cyclodextrin capped silver nanoparticles. The stability of the nanoparticle 
before and after loading with the drug chloramphenicol was determined from zeta potential 
analysis. The antibacterial activities displayed against Pseudomonas aeruginosa (ATCC 
27853), Enterococcus faecalis (ATCC 5129), Klebsiella pneumoniae (ATCC 700603) and 
Staphylococcus aureus (ATCC 43300) confirmed the synergistic antibacterial effect of 
chloramphenicol with γ-cyclodextrin capped silver nanoparticles. The data seems to suggest 
that organic inorganic hybrid molecules obtained by loading chloramphenicol on cyclodextrin 
capped nanoparticles by means of non-covalent interactions enhances the antibacterial activity 
of chloramphenicol. Importantly, this combination strategy resulted in the use of lower 
concentrations of chloramphenicol thereby minimizing its side effects. 
In a proof of concept approach given that cyclodextrin complexion has been shown to result in 
controlled release which directly affects drug efficacy, inclusion phenomena of the anti-
inflammatory drug antipyrine, with different cyclodextrins was studied by computational and 
experimental methods. The supramolecular inclusion complexes of these drugs with γ-CD were 
prepared by a freeze-drying method and characterized using solid state characterization 
techniques such as thermogravimetric analysis, differential scanning calorimetry, X-ray 
diffraction, Fourier transform infrared spectroscopy (FTIR) and scanning electron microscopy 
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(SEM). We were also able to prove the phenomena of inclusion complexation using NMR 
techniques. Results from 1H NMR and 2D NOESY studies supported the mode of inclusion 
phenomenon obtained from theoretical calculations. In addition, we were able to show that the 
antipyrine inclusion complex is nontoxic against the mammalian MDCK-1 cell line.  
 
Solubility of a therapeutic agent is another important factor which contributes to its 
pharmacokinetic properties such as absorption and bioavailability. The solubility of weakly 
basic or acidic drug substances can be increased by converting the therapeutic molecules to 
salts using various organic and inorganic counter ions. The use of organic counter ions is 
preferred in that they can simultaneously increase the solubility and transport of drug substances 
across the absorbing membrane. In this research work we also synthesized novel organic salts 
of ciprofloxacin and norfloxacin using biocompatible quinic acid. The salts were characterized 
by spectroscopic techniques like FTIR-ATR, NMR and mass spectrometry followed by thermal 
analysis (DSC and TGA) and X-ray diffraction. Solubility and octanol-water partition 
coefficients were analyzed. The cytotoxicity studies using the VERO cell lines indicated that 
salts were biocompatible. This study contributes to the importance of salt formation chemistry 
in the pharmaceutical applications in terms of rational design and development of innovative 
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1 Introduction and Project Aims 
1.1 Introduction 
The need for novel pharmaceutical compounds to treat human diseases is ever increasing [1], 
and medicinal compounds can be compiled from a variety of sources. Plant materials are the 
traditional sources of medicinal compounds [2]. Designing, synthesizing and creating a library 
of the compounds in the laboratory is another commonly used approach in identifying novel 
compounds [3]. Along with the development of new medicines, finding new strategies to 
improve the current existing treatments is an important aspect of modern drug discovery 
research [4]. In view of the cost and strain involved in the new drug development, modern drug 
discovery research is increasingly focusing on further modifying, improving and finding new 
formulation of existing pharmacologically active compounds [4, 5]. The approach is attractive 
and helpful in quick development of new treatments. This thesis aims to identify new potentially 
promising sources for medical applications and finding new formulation strategies for the 
improvement of existing therapies. 
1.2 Objectives and scope of study 
The central aim of this study was to develop novel and/or improve currently available 
antibacterial pharmaceutical candidates. The main objectives of this research study are as 
follows: 
 
a. Green synthesis of silver and gold nanoparticles (AgNPs and AuNPs respectively) 
capped with phytochemicals extracted from a South African indigenous medicinal 
plant, and their evaluation as antibacterial agents. 
b. Synthesis of multi-substituted pyridine derivatives bearing a 2-amino-4-aryl-6-
sulfanyl substitution pattern via a one-pot reaction approach and evaluation of their 
antibacterial activities. Since similar molecules have shown good antidiabetic 
properties, these molecules were also investigated foe their α-glucosidase inhibitory 
activity. 
c. Synthesis of and study of chloramphenicol-loaded, cyclodextrin capped silver 
nanomaterials as an innovative method for the improvement of antibacterial efficacy 
of chloramphenicol. The multi-spectrum versatility of this strategy to improve other 
pre-existing pharmaceutical preparations was assessed using the anti-inflammatory 
agent antipyrine.  
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d. Synthesis of quinic acid based organic salts of fluoroquinolones to improve their 
pharmacological properties as antibacterial agents. 
This thesis is divided into seven chapters, including this introductory Chapter 1. In Chapter 
2, a detailed literature review is presented. 
Chapter 3 describes the synthesis of silver and gold nanoparticles from the aqueous seed 
extract of Protorhus longifolia and evaluation of their antibacterial activity. These nanoparticles 
that bear natural medicinal compounds capped to their surfaces, showed potential antibacterial 
activity against bacterial species Escherichia coli (ATCC 35218), Klebsiella pneumoniae 
(ATCC 700603), Staphylococcus aureus (ATCC 43300) and Pseudomonas aeruginosa (ATCC 
27853). Novel plant-derived nanomaterials generated in this study, could provide antibacterial 
treatments with additional benefits, such as lower toxicity and high potential for combating 
drug-resistant diseases. This aspect of the study was published in the Digest Journal of 
Nanomaterials and Biostructures [6]. 
Chapter 4 reports on the synthesis of a novel class of medicinally useful heterocyclic 
compounds. The synthesized 3,5-dicyanopyridines were characterized by IR, NMR and HRMS. 
Inhibition of α-glucosidase and the antibacterial activities of the molecules were then evaluated. 
Although no antibacterial activity was detected, interestingly five of the nine compounds 
showed good inhibition of α-glucosidase which was closely aligned to the commercially 
available inhibitor, acarbose. Compounds were studied for their binding affinity for the active 
site of α-glucosidase enzyme. Computational modeling studies revealed that the newly designed 
heterocycles were effective in binding to the active site of α-glucosidase thereby providing a 
seemingly useful synthetic pathway that may yield even more potent anti-diabetic molecules. 
Chapter 5 describes the application of cyclodextrins in the conjugation and formulation of the 
antibacterial drug chloramphenicol with silver nanoparticles. Cyclodextrins, which an 
important class of supramolecules capable of encapsulating hydrophobic drugs into their 
cavities; provide novel applications in pharmaceutical fields in improving the therapeutic value 
of drug substances. In this study, a suitable cyclodextrin that encapsulates chloramphenicol was 
selected using a combination approach that includes molecular docking, semi-empirical and 
molecular dynamics. Based on the docking score and binding free energies γ-cyclodextrin 
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inclusion complexes of chloramphenicol were found to be more stable as compared to α- and 
β-cyclodextrin inclusion complex of chloramphenicol. In addition γ-cyclodextrin capped silver 
nanoparticles were synthesized and used to generate a nanocomposite with chloramphenicol. 
The nanocomposite has produced synergistic antibacterial effect against Pseudomonas 
aeruginosa (ATCC 27853), Enterococcus faecalis (ATCC 5129), Klebsiella pneumoniae 
(ATCC 700603) and Staphylococcus aureus (ATCC 43300). This aspect of the research study 
was published in Journal of Inorganic Biochemistry [7]. 
In addition, since cyclodextrin complexion has been shown to result in controlled release that 
directly affects drug efficacy, inclusion phenomena of the anti-inflammatory drug antipyrine 
with different cyclodextrins was studied by computational and experimental methods. 
Interestingly, the inclusion complex was found to be non-toxic towards the MDCK-1 cell line, 
highlighting its potentially safe pharmaceutical application. The aspects of this research have 
been accepted for publication in Journal of Molecular Structure [8] and presented as additional 
work in this thesis as Appendix 1. 
Chapter 6 highlights the importance of salt formation chemistry in the pharmaceutical industry. 
The solubility of the pharmaceutical substances is a key determinant of its bioavailability. Many 
novel pharmaceutically active compounds fail at clinical trials due to limited solubility. In 
chapter 6 we demonstrated the application of quinic acid in increasing the solubility of 
antibacterial drugs ciprofloxacin and norfloxacin by salt formation chemistry. The novelty 
aspect of this study is that organic salts generated have increased the solubility of the drug 
substances whilst keeping their lipophilicity higher when compared to their respective salts with 
inorganic acids. Thus we propose higher membrane permeability of the organic salts based on 
ion pairing mechanism. Additionally, it was found that quinic acid was not toxic and when used 
as a counter ion did not increase the toxicity of drug substances.  Hence we also propose further 
studies for development of new combination therapy based on salt formation chemistry. 
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2 Literature Review 
2.1 Introduction 
In recent years, an increase in the incidence of both communicable and non-communicable 
diseases has become a major health concern [1]. Communicable or contagious diseases are a 
group of diseases mainly originating from infectious microbial organisms such as bacteria, 
fungi and viruses and are transmissible directly (from person to person) or indirectly (by a 
vector). Non-communicable diseases (NCDs) which cannot transfer from person to person 
include a wide range of ailments such as diabetes, heart disease, cancer and chronic lung 
diseases mostly affecting different organs of the body [2]. In 2013 an estimated 6.4 million 
deaths were reported due to infectious diseases and 39 million deaths were due to non-infectious 
causes. Further, 5.8 million deaths due to infectious diseases and 83 million deaths due to NCDs 
is expected by 2050 [3]. 
Another report suggests that NCDs are the leading cause of death worldwide accounting for 
nearly 63% of all deaths globally in 2008 [4]. There also exists a link between infectious and 
non-infectious diseases and often prevalence of one kind of disease encourages the onset of 
other diseases. For example, the prevalence of diabetes increases the chance for Mycobacterium 
tuberculosis infection [5]. Similarly, people infected with HIV and who are on long-term 
antiretroviral treatment are at higher risk of non-infectious metabolic disorders such as cardiac, 
renal, gastrointestinal, neurological and psychiatric diseases [6]. In addition, viral infections 
such as hepatitis B and C have been reported to predispose cancer [7].  
Thus both communicable and non-communicable diseases pose a significant burden on global 
healthcare management systems and society. To meet these ever-pressing challenges demands 
that continuous investment and research into developing cost-effective treatment protocols are 
sustained. This literature study strives to provide an all-inclusive account of two medically 
orientated threats namely bacterial infections and diabetes. 
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2.2 Bacterial infections 
Several bacterial species are becoming an increasingly important cause of invasive infection 
worldwide [8]. According to the World Health Organization (WHO) reports, 1.5 million people 
died in 2014 of Mycobacterium tuberculosis infections and 48 000 were infected with 
multidrug-resistance tuberculosis [9]. The other major bacterial infections causing  great 
number of morbidity and mortality worldwide [8]. There is a rapid emergence of bacterial 
resistance to most of the mainstream antibiotics, creating ineffective therapeutic agents and also 
making the process of drug discovery more difficult [10]. It is worth noting that despite 
continuous efforts by global pharmaceutical companies, only two new classes of antibiotics viz 
oxazolidinone (linezolid) and cyclic lipopeptide (daptomycin) have been introduced into the 
market in the last decade [11, 12]. Hence, there is a constant and more focused effort needed 
for the rapid discovery of novel scaffolds to compete with the emergence of bacterial resistance. 
2.2.1 Antibiotic scaffolds 
Most antibiotics available at present mainly target five bacterial processes such as cell wall 
biosynthesis (β-lactams, vanomycin, daptomycin), translation (tetracyclines, aminoglycosides, 
chloramphenicol, oxazolidinones, macrolides, streptogramins, fusidic acid), folic acid 
biosynthesis (sulfonamides), transcription (rifamycins) and DNA replication (quinolones) [13, 
14]. Fig. 2.1 represents different classes of antibiotics that are either naturally derived or 
chemically synthesized. Depending on the mode of action, antibiotics are classified as 
bactericidal (β-lactams, flouroquinolones) since they kill bacteria by disrupting cell wall and 
bacteriostatic (chloramphenicol, macrolides) as they are responsible for halting bacterial 
replication by interfering with cell metabolism. 
2.2.2  Antibiotic resistance  
The antibiotic resistance is increasing globally and many infections are becoming untreatable 
[10]. As mentioned in  2.2.1 above sections, most of the antibiotics target only five cellular 
processes in the bacteria, and this limited spectrum of targets contributes to the easy and rapid 
development of antibiotic resistance [15]. The overuse and misuse of antibiotics is an additional 
factor contributing to the development of antibiotic resistance [16]. 




Figure 2.1 General structure of the different classes of antibiotics [17]. 
Some bacteria are naturally resistant to antibiotics, while others acquire resistance by different 
mechanisms such as mutations in genes, acquisition of new gene elements encoding for 
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defensive enzymes and proteins, down regulation of porins that allow the influx of the 
antibiotics, acquisition of efflux pumps to prevent accumulation of the antibiotic inside the 
bacteria, and altered cell wall synthesis processes so that antibiotics no longer interfere [18]. 
Mutations in DNA gyrase enzymes, gyrA and gyrB, results in resistance towards quinolones in 
E. coli and S. pneumoniae [19, 20]. Mutations affecting the RNA polymerase β subunit have 
resulted in the E.coli resistance toward rifampicin [21]. Exogenous horizontal gene 
transmission of resistance elements to human pathogenic S. aureus from soil bacteria belonging 
to the class Streptomyces genus is believed to have contributed to S. aureus resistance toward 
vancomycin [22]. Acquisition of the gene expressing β-lactamase resulted in the resistance to 
β-lactam antibiotics via the enzymatic hydrolysis of β-lactam antibiotics mechanism in the 
members of the Enterobacteriaceae and S. aureus family [23, 24]. Down regulation of genes at 
transcriptional level that are responsible for the expression of porin OprD, prevented 
penetration of carbapenems in P. aeruginosa [25] and over expression of the MexXY efflux 
pump was found to be associated with fluoroquinolone resistance in P. aeruginosa  clinical 
isolates [25]. In response to presence of antibiotics, bacteria also express a variety of enzymes 
such as group transferases (acyltransferases, acetyltransferases, phosphotransferases, 
thioltransferases, nucleotidyltransferases,  glycosyltransferase), redox enzymes, epoxidases, 
esterases, etc. which can effectively modify and degrade the antibiotics thereby preventing them 
from binding to their targets [26]. A report by Shi et al. suggest that resistance to 
aminoglycosides was due to the aminoglycoside-kinase mediated transfer of a phosphate group 
to a hydroxyl nucleophile on the aminoglycoside [27]. Different types of chloramphenicol 
acetyltransferases have been found to be responsible for the inactivation of chloramphenicol 
[28]. Similarly, evolution of several multidrug resistant strains of Mycobacterium tuberculosis, 
P. aeruginosa , Acinetobacter baumannii, and K. pneumoniae against most of the potent drugs 
like rifampicin, isoniazid, β-lacatams, ethambutol and fluoroquinolones by various mechanisms 
has compromised the effectiveness of this class of antibiotics [8, 29]. 
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2.2.3  Toxicity and limitations of antibiotics 
The antibiotics belonging to the class aminoglycosides can accumulate in the epithelial cells 
causing nephrotoxicity, followed by renal impairment [30], whilst the use of the broad-spectrum 
antibiotic chloramphenicol is limited by its bone marrow toxicity [31]. Tetracyclines were 
found to compete with calcium for incorporation into bone, hence unsafe for consumption by 
children and pregnant women [32]. Fluoroquinolones and β-lactams have been shown to cause 
serious side effects in the central nervous system and cardiovascular system [33, 34]. 
Streptogramins are associated with side effects such as headache, arthralgias and myalgias [35], 
and macrolides have been linked to ototoxicity via damage to the cochlea [36]. Thus the use of 
antibiotics is restricted due to their toxicity. 
2.3 Diabetes mellitus 
Diabetes is one of the most common non-communicable metabolic disorders, characterized by 
increased blood glucose levels as a consequence of insulin deficiency or insulin resistance [37]. 
Both the impaired insulin level or defective insulin action leads to the derangements in the 
catabolism and anabolism of carbohydrates, lipids and proteins; resulting in heterogeneous 
disorders such as hyperglycemia and glucose intolerance [38]. When left untreated, diabetes 
leads to more serious consequences such as visual impairment and possibly blindness, 
cardiovascular disease, renal failure and even premature death [38]. The prevalence of diabetes 
in all age groups of both developed and developing countries is increasing at an alarming rate 
and is expected to raise to epidemic proportions by 2030 [39].  
2.3.1 Classification 
Diabetes mellitus has been mainly classified into four types based on its etiology and clinical 
presentation [38]. Type-I diabetes also called juvenile diabetes is insulin dependent and occurs 
mainly in children due to the destruction of insulin producing pancreatic beta cells by beta-cell 
specific autoimmune processes [40, 41]. Type-II diabetes is also called non-insulin dependent 
diabetes, and is a manifestation of insulin resistance and deficiency [38], whilst gestational 
diabetes is a temporary clinical condition in pregnant women [38]. Other types of diabetes may 
occur due to various reasons such as genetic defects, surgical causes, use of drugs, etc. [38]. 
Type-I and II diabetes are most prevalent, and epidemiology suggest that 5-10% of the diabetic 
population is of type-I while type-II accounts for 80-90% of the diabetic population [42]. 
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Type-II diabetes mellitus is the most prevalent in modern society since the modern life style of 
inappropriate diet, inadequate levels of physical activity and obesity are the main contributing 
factors for onset of type II diabetes mellitus [43]. Other reasons for prevalence of type II 
diabetes include body cell resistance to insulin, increased hepatic glucose production, lowered 
insulin-mediated glucose transport, and impaired beta cell functioning [43]. 
2.3.2 Biochemistry of diabetes  
Diabetes is directly linked to defects in glucose metabolism, the primary source of energy for 
respiring cells [44]. Insulin, a polypeptide hormone synthesized within the beta cells of the 
islets of Langerhans in the pancreas, plays an important role in regulating blood glucose levels 
[44]. The main events of carbohydrate metabolism such as glucose transport across muscle and 
adipocyte cell membranes, regulation of hepatic glycogen synthesis, and inhibition of 
glycogenolysis and gluconeogenesis are controlled by insulin [45]. Insulin binds to receptor 
sites on the peripheral side of the cell membrane and mediates the transport of glucose into 
respiring cells [45, 46]. Insulin regulates the catabolism and anabolism of glucose and thus have 
a controlling effect on both glycolysis and glycogenesis [46]. The end result of all these events 
is a reduction in blood glucose concentration [46]. The optimum concentration of insulin in the 
blood stream is critical in maintaining glucose homeostasis and in clearing the postprandial 
glucose load [47]. Insufficient amounts of insulin or poor cellular response to insulin as well as 
defective insulin leads to improper handling of glucose by the body cells or inappropriate 
glucose storage in the liver and muscles. This ultimately leads to persistent high levels of blood 
glucose resulting in the condition called hyperglycemia [47]. As hyperglycemia persists, the 
body cells become devoid of glucose, which forces the cells to seek alternative energy sources, 
and cells turn to ketogenesis a process that makes use of fatty acids stored in adipose tissue 
[47]. The excess glucose from the blood and ketone bodies generated in ketogenesis or fatty 
acid catabolism are excreted via urine, thereby leading to glycosuria and ketonuria, which 
characterizes diabetes mellitus [48]. The excess ketone bodies in the blood can result in 
ketoacidosis [48], and if left untreated, coma and death can follow [48]. The chronic 
hyperglycemia arising from diabetes mellitus accompanies long-term damage, dysfunction, and 
failure of various organs, especially the eyes, kidneys, nerves, heart, and blood vessels [48]. 
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2.3.3 Managing diabetes 
Diabetes can be managed by healthy eating, regular physical activity and medication [49]. 
Controlled diet combined with physical activity can help in establishing metabolic control and 
bringing down blood glucose levels in cases of early stage of diabetes [49]. However, in most 
cases lifelong maintenance of blood glucose levels using exogenous insulin and 
pharmacotherapy is required [50]. For type-I diabetes, multiple daily insulin injections or a 
continuous infusion of insulin is given. For type-II diabetes, along with insulin supply, other 
approaches to control hyperglycemia and enhance insulin secretion are required [51]. There are 
several antidiabetic medications commercially available which target different metabolic 
processes. These therapeutic agents can be broadly classified as insulin secretion enhancers 
(sulfonylureas and meglitinides), hepatic gluconogenesis suppressors (biguanides), insulin 
sensitizers (thiazolidinediones rosiglitazone and pioglitazone), α-glucosidase inhibitors 
(acarbose, voglibose and miglitol), dipeptidyl-peptidase IV inhibitors (omarigliptin, 
gemigliptin, trelagliptin), and sodium–glucose co-transporter 2 inhibitors (empagliflozin, 













Figure 2.2 Major classes of antidiabetic medications. 
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2.3.4 Toxicity and limitations of anti-diabetic medication 
Antidiabetic drugs such as sulfonylureas and meglitinides may lead to weight gain, 
hypoglycemia and decreased kidney function [52]. Further, sulfonylureas are only useful in 
people with type-II diabetes whose beta cells still produce insulin [53]. Biguanides cannot be 
used in patients with renal impairment due to its side effect of lactic acidosis, and buformin and 
phenformin which belong to this class have been withdrawn from the market [54]. The risk of 
other side effects of metformin such as diarrhea, dyspepsia, weight gain and hypoglycemia 
increases when taken in combination with sulfonylureas [54]. Insulin sensitizers cause weight 
gain, fluid retention, and anemia that increases heart disease and bone fractures [55]. 
Pioglitizone, an insulin sensitizer increases the risk of bladder cancer [56]. Side effects of 
dipeptidyl-peptidase IV inhibitors include nasopharyngitis, headache, nausea, heart failure, 
hypersensitivity, skin reactions and joint pains [57]. Gastrointestinal problems (flatulence and 
diarrhea) are commonly observed with α-glucosidase inhibitors, also their use is limited in 
patients with significant renal impairment [58, 59]. Sodium–glucose cotransporter 2 inhibitors 
are associated with treatment-emergent adverse events such as urinary tract and genital 
infections, back pain, polyuria, dysuria, and dyslipidemia [60]. 
Thus there is a significant need for the discovery and development of safer medicinal 
compounds with novel scaffolds to ensure that treatments are available for both multi-drug 
resistant bacteria species and diabetes mellitus. The limitation to the current treatment is that 
some of them are expensive and harbor adverse effects on patients. Hence there is a need for 
new viable chemotherapies. Drug discovery is a vast area of research and bringing new 
therapeutic agents into the market involves strategic compilation of thousands of different 
compounds from a variety of sources and their biological testing in high throughput screening. 
The traditional approach of drug discovery involves the isolation of bioactive compounds from 
the plant origin or to design and chemically synthesize novel organic or inorganic 
pharmaceuticals in the laboratory. Among the different kinds of medicinal compounds, 
aromatic functionalized heterocycles are excellent scaffolds and indispensable for preparing 
diversity-oriented compounds for medicinal and pharmaceutical applications. There is a 
compelling need to synthesize and evaluate more heterocycles for various biological 
applications. Recently, nanomaterials have drawn much attention in the medical field [61]. Due 
to their unique size and shape-dependent optical properties, metal-nanoparticles have found 
potential applications in medicine and hence there is a high demand for biodegradable materials 
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that are compatible with biomedical applications [61]. The organic-inorganic hybrid materials 
or nanocomposites can be generated by combination of organic drugs and inorganic metal 
nanoparticle for potential therapeutic applications [62]. 
2.4 Heterocyclic molecules 
Heterocyclic molecules form the largest class of organic compounds which are present in many 
natural products, biomolecules, and a wide variety of drugs. Pyridines are an important class of 
six membered nitrogen-containing aromatic heterocycle present in numerous derivatives of 
biological relevance and pharmacologically significant compounds [63]. Pyridines exhibit a 
broad range of biological activity such as antimicrobial, anti-inflammatory, anti-asthmatic, 
antidepressant, antidiabetic, inhibiting acetylcholinesterase, treating hypertension or 
hypotension, inhibiting HIV protease, preventing or inducing apoptosis, act as Ca2+ channel 
blockers, hepato-protective and show antitumor properties [64-67]. Pyridines are also utilized 
in agrochemistry for their herbicide, insecticide, and antifungal properties [68]. Pyridine-
derived organic materials and polymers have applications in organic photovoltaic devices [69] 
and organic light-emitting devices [70]. Pyridines like DMAP have been used as 
organocatalysts and several pyridine metal chelates have been used as efficient organometallic 
catalysts in organic synthesis [71, 72]. Thus, the pyridine nucleus occupies an important 
position in many pharmaceutical, agrochemical and material products. 
Diversifications in the functional group or pharmacophore substitutions at different positions 
of the pyridine core have produced numerous compound libraries with diverse biological 
activity. Of particular note, 3,5-dicyanopyridines represent an important class of medicinally 
privileged heterocyclic scaffold [73]. In this class, particularly 2-amino-4-aryl-6-sulfanyl 
substitution (Fig. 2.3) pattern has drawn much attention currently for a variety of biological 
activity [74]. These multi-substituted pyridine compounds exhibit a broad range of biological 
activities such as anti-bacterial, antiprion, antihepatitis B virus, and anticancer [74]. 
Additionally, a few compounds of this class have been recognized as highly selective agonists 
for adenosine receptors and are recommended for the development of new medication for the 
treatment of Parkinson’s disease, hypoxia/ischemia, epilepsy, kidney disease, and Creutzfeldt–
Jacob disease [75]. 




Figure 2.3 Structural representation of some medicinally useful 2-amino-3,5-dicyano-6-sulfanyl 
pyridines scaffolds. 
 
Fig. 2.3 demonstrates some medicinally useful 2-amino-3,5-dicyano-6-sulfanyl pyridine 
scaffolds that are used against a wide range of biological targets. Potent antibacterial activity 
of several pyridine-3,5-dicarbonitrile derivatives of type 1 (Fig. 2.3) against both gram-positive 
and gram-negative bacterial strains have been reported [76-78]. Compounds of type 2 (Fig. 2.3) 
were found to be potential anti–HSV1 agents [79]. Perrier et al. and May et al. demonstrated 
the compounds of type 3 (Fig. 2.3) to bind cell-surface glycosylphosphatidylinositol-anchored 
proteins and prevent their post-translational conversion to protease resistant isoforms, thus 
helping to prevent prion induced neurodegenerative diseases [80-82]. Based on structure-based 
drug discovery, Bowman et al. proposed that compounds of the type 4 (Fig. 2.3) can be good 
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anticancer agents [83]. Pharmacophore model analysis by Deng et al. confirmed that compound 
5 (Fig. 2.3) is a potent HIV-1 integrase inhibitor [84], and compound 6 (Fig. 2.3) was found to 
be a phosphodiesterase inhibitor and hence used as potent drug for the treatment of 
cardiovascular diseases [85]. 
The 2-amino-3,5-dicyano-6-sulfanyl pyridines have been used as selective non-ribose agonists 
for the adenosine receptor [86]. Adenosine receptors (AR) play an important role in signal 
transduction across the membrane and hence are described as potential targets in the treatment 
of cardiovascular diseases (angina pectoris, atrial fibrillation, infarct), metabolic diseases 
(diabetes, dyslipidemia), Parkinson’s disease, hypoxia/ischemia, asthma, kidney disease, 
epilepsy and cancer [87-90]. Due to their agonist activity, 2-amino-3,5-dicyano-6-sulfanyl 
pyridines have found application in treatment of various ailments. For example, Capadenoson 
7 (Fig. 2.3), a selective adenosine A1 AR agonist, acts as an anti-anginal agent [91, 92]. Lee et 
al. discovered that the A1 AR subtype agonists reduce the nephrotoxic effects of 
aminoglycosides by controlling renal drug accumulation [93]. Substituted 2-thio-3,5-dicyano-
4-phenyl-6-aminopyridine compounds of the formula 7 (Fig. 2.3) are adenosine A1 receptor 
agonists which may be used in combination with aminoglycosides for the protection of kidney 
from toxic effects caused by aminoglycosides during treatment of infectious diseases in humans 
[94]. BAY60-6583 compound type 8 (Fig. 2.3) is reported to mediate anti-inflammatory, 
kidney-protective, cardio-protective effects by specifically binding to A2B subtype adenosine 
receptors [95]. Structurally similar compounds aminocyanopyridines have shown mitogen 
activated protein kinase-activated protein kinase-2 inhibition and thus possess application in 
the treatment of autoimmune diseases and cancer [96]. In addition, it has recently been shown 
that similar heterocyclic compounds could be an attractive class of corrosion inhibitors [97] and 
thus have industrial application as well. 
2.4.1 Synthesis of 2-amino-3,5-dicyano-6-sulfanyl pyridines 
Synthesis of 3,5-dicyanopyridine scaffolds can be carried out under many different reaction 
conditions using various catalysts. One of the most facile and convenient procedures is one-pot, 
three-component condensation between aldehyde, malononitrile, and a thiol to make the 3,5-
dicyanopyridine core. This multicomponent method is very rapid and economical due to the 
commercial availability of the starting materials. The reaction has been carried out in the 
presence of a wide variety of catalysts like organic bases (Et3N, DABCO, piperidine, 
morpholine, thiomorpholine, pyrrolidine, N,N-DIPEA, pyridine, 2,4,6-collidine, DMAP, 
aniline, N-methylaniline, N,N-dimethylaniline, and N,N-diethylaniline) [98, 99], inorganic 
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bases (K2CO3) [100], Lewis acids (Sc(OTf)3, ZnCl2)  [101, 102], ionic liquids [103, 104] and 
boric acid [98]. Nanoparticles of SnO [105], TiO2 [106], CaO [107], Fe2O3 [108], ZnO [109] 
and SiO2 [110], have also been reported to effectively catalyze the multicomponent reaction for 
the synthesis of 2-amino-3,5-dicyano-6-sulfanyl pyridines.  
The reaction mechanism for this multicomponent condensation has been proposed to proceed 
via Michael addition onto Knoevenagel adduct [75, 111] (Fig. 2.4). Initially, in a base catalyzed 
condensation reaction between the aldehyde and one equivalent of malononitrile, formation of 
Knoevenagel adducts 1 (Fig. 2.4) takes place. This reaction is followed by the nucleophilic 
addition of the thiol group to the unsaturated carbon of one of the nitrile groups of Knoevenagel 
adduct resulting in intermediate 2 (Fig. 2.4). 1,4-Michael addition of the second equivalent of 
malononitrile on the intermediate followed by immediate cyclisation and tautomerization gives 
1,4-dihydropyridine intermediate 5 (Fig. 2.4). This undergoes aromatisation via oxidation to 
yield sterically accessible pyridine-3,5-dicarbonitrile as the final product. 
 
 
Figure 2.4 Reported mechanism for the synthesis of pyridine-3, 5-dicarbonitriles [111]. 
 
In view of the medicinal importance of pyridine- 3,5-dicarbonitriles and our continued interest 
in the development of new medicinally important compounds, in this research work, we discuss 
the synthesis and evaluation of 2-thio-3,5-dicyano-4-aryl-6-aminopyridines as antidiabetic and 
antibacterial agents. We used relatively simple base-catalyzed reaction for the synthesis of 2-
thio-3,5-dicyano-4-aryl-6-aminopyridine compounds using commercially available 
malononitrile, different substituted benzaldehydes, and thiols as starting material. Inexpensive 
and readily available triethylamine was used as the catalyst and ethanol was used as the solvent.  
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2.5 Nanotechnology as a platform for the development of novel therapeutics 
Nanoparticles are any material with nanoscale dimensions of the order of 100 nm or less [112]. 
When the materials are miniaturized to nanoscale, they behave differently than the bulk one 
and often exhibit significantly novel and improved physical, chemical, and biological properties 
based exclusively on their size and morphology [112]. The new and improved materials 
generated by using nanotechnology, prompt new developments in the fields of electronics, 
catalysis, imaging and medicine [113]. Thus, the field of nanotechnology has become a very 
active area of research in modern science, attracting attention of researchers from almost every 
field of science [113]. 
2.5.1 Silver and gold nanoparticles 
Although extensive research in nanoscience and nanotechnology has only started recently, the 
use of nanoscale gold and silver particles from the ancient time is well documented. Stained 
glass artisans were created by trapping silver and gold in the glass matrix and this is one of the 
most documented example of nanotechnology known in history [114]. Ancient ceramic 
technology used gold nanoparticles to get metallic luster on ceramics and this can be traced 
back to the 9th - 17th century [114]. The use of noble metals and their derivatives for medicinal 
purposes has evolved from the ancient times. The Vedic period in ancient India witnessed the 
use of mixtures of gold powder (known as 'Bhasma') and herbs to improve immunity to fight 
against anemia, asthma and muscle weakness [115]. In China, ailments such as smallpox, skin 
ulcers and measles were treated using gold compounds. Various types of silver compounds such 
as silver powder, silver oxide and silver zeolite have been in use from ancient times as 
antimicrobial agents [116]. Recently, much progress has been made in nanotechnology and 
silver nanoparticles (AgNPs) and gold nanoparticles (AuNPs)  have become more valuable with 
a wide range of applications [117].  
Nanoparticles possess a high percentage of atoms present on the surface, and hence higher 
surface area to volume ratio compared to the bulk materials [114] which makes the nanoparticle 
behave differently from bulk materials. The nanoparticle state is considered as the intermediate 
state, between atomic/molecular state and bulk state and hence their unusual properties cannot 
be explained by using either quantum mechanics or classical physics [118]. The optical, 
magnetic and electrical properties of nanoparticles strongly depend on the size and shape of the 
particles and can be altered by controlling their geometry [118]. Hence, study of the synthesis 
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and application of novel nanoparticles is very attractive and highly focused within the last 
decades [114]. Metal nanoparticles are one of the most wide-spread and diverse among the 
different types of nanoparticles [119]. Amongst them, AgNPs and AuNPs are well known and 
have numerous applications in electronics, catalysis, imaging and medicine [120]. 
2.5.2 Therapeutic properties and applications of silver and gold nanoparticles 
Recently there has been significant progress in the design and study of metal-derived 
nanomaterials for therapeutic and biomedical applications [121]. Particularly, noble metals with 
their intrinsic properties such as resistance to corrosion, thermal stability and decreased toxicity 
have attracted much attention. When reduced to nanosize, the noble metals acquire special 
characteristics such as high surface-to-volume ratio and tunable broad optical properties 
prompting their versatile application in diagnostics and therapeutics [121]. The AgNPs and 
AuNPs which can be easily prepared and attached to various biomolecules have a wide range 
of applications in the fields of diagnostics, surgery and medicine [122]. 
The optical properties of both AgNPs and AuNPs can be tuned to desirable wavelengths by 
controlling their size, shape and composition on their surface. Moreover, nanoparticles can 
efficiently absorb and convert light or radiofrequencies into heat. These unique properties 
enable nanoparticles to be used for imaging and photo-thermal applications [123]. Also, facile 
surface chemistry of nanoparticles allow the functionalization of the surface with moieties such 
as antibodies, peptides, nucleic acids and therapeutic agents, so that the bio-conjugated metal- 
nanoparticles can be used for specific purposes [123]. 
2.5.3 Antimicrobial properties 
The broad-spectrum antimicrobial activities of metal-nanoparticles against bacteria, fungi, and 
virus is well known [124]. The unique physicochemical properties of noble metal-nanoparticles 
together with their high surface area-to-volume ratios are contributing factors towards their 
effective antimicrobial activity [124]. In addition, the production of nanoparticles is cost 
effective and unlike the classical antibiotics, metal-nanoparticles are less prone to resistance as 
they attack multiple sites on the microorganism [124]. As more and more multidrug-resistant 
bacterial strains are emerging, there is a high demand for new antibiotics with novel modes of 
action. Therefore, AgNPS and AuNPs have become an attractive source of drug candidates 
[124]. 
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Several mechanisms have been proposed for the antibacterial activity of metal-nanoparticles. 
The main events involved in the mechanism of action are: production of reactive oxygen species 
that damage cellular components, cell membrane destruction and increased permeability, and 
denaturation of proteins and nucleic acids thus disrupting replication and enzyme activity [125]. 
The antimicrobial effects of AgNPs were most extensively studied and different mechanisms 
have been proposed to explain the high antimicrobial activity of AgNPs. According to the 
chemiosmotic mechanism proposed by Dibrov et al., low concentrations of Ag+ induces 
massive proton leakage through the Vibrio cholerae membrane, which results in cell death 
[126]. A case study on E. coli as a model for gram-negative bacteria by Sondi et al. confirms 
that AgNPs damaged the cell membrane of E. coli by forming pits in the cell wall of the bacteria, 
while the AgNPs were found to accumulate in the bacterial membrane [127]. Similarly, Amro 
et al. suggest that metal depletion causes irregular-shaped pits in the outer membrane releasing 
lipopolysaccharides, resulting in altered membrane permeability and cell death [128]. 
Mechanistic studies on E. coli and S. aureus by Feng et al. revealed that silver ion released from 
the nanoparticles bind to the functional groups of DNA and proteins causing their denaturation 
and cell death [129, 130]. Kim et al. proposed the free radical mechanism wherein free radicals 
generated by AgNPs induced cell membrane damage [131]. Nagy et al. proposed that the 
antibacterial mechanism of AgNPs is due to the exhaustion of the antioxidant capacity of the 
cell. In response to silver ions released from AgNPs/zeolite composite, upregulation of several 
antioxidant genes as well as genes coding for metal transport, metal reduction, and ATPase 
pumps was observed in S. aureus and E. coli, confirming oxidative stress driven cell death 
[132]. Owing to their antibacterial properties, silver-impregnated bacteriostatic water filters 
(NATURE2 G45-VC40) have been in use for safe drinking water and swimming pool filters 
[133]. Several colloidal nanosilver algaecides (Algaedyn, MicroSilver BG-R) are also 
commercially available and can safely be used as disinfectants even in high amounts [133]. 
AuNPs are relatively less toxic than their silver counterparts, but fewer studies were performed 
with regard to their antibacterial properties. AuNPs when irradiated with focused laser pulses 
of suitable wavelength, were able to kill bacteria [134] and Li et al. reported that biocompatible 
cationic and hydrophobic functionalized AuNPs effectively suppressed growth of multi-drug 
resistant bacteria [135]. Poly-allylamine hydrochloride coated anionic AuNPs were reported to 
cause E. coli cell lysis, revealing that cationic coated AuNPs are more toxic than anionic coated 
ones [136]. Anti-protein A antibody conjugated AuNPs were employed to kill the gram-positive 
bacterium S. aureus by means of laser-induced overheating effects [137]. AuNPs conjugated 
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with the antibiotics ampicillin, kanamycin and streptomycin produced synergistic antibacterial 
effects against E. coli, M. luteus and S. aureus [138]. Thus, it can be concluded that AuNPs can 
be promising potential antibiotic agents for treating serious bacterial infections, but which have 
minimal side effects. 
2.5.4 Tumor targeting 
Classical therapies for cancer are plagued by severe side effects such as toxicity, due to their 
inability to differentiate between cancerous and normal cells [139]. Hence, therapies 
differentiating and targeting malignant cells are of high importance in medicine. The potential 
therapeutic application of noble metal-nanoparticles represents an attractive platform for cancer 
therapy in a wide variety of targets. AuNPs have been shown to bind to heparin-binding 
glycoproteins thereby inhibiting their subsequent signaling events [140], a passive anticancer 
targeting mechanism that demonstrates the intrinsic anticancer properties of the AuNPs [140]. 
Nanoparticles can easily be functionalized with a variety of hydrophobic and hydrophilic 
biological molecules such as polyethylene glycol, antibodies, peptides and nucleic acids to 
specifically target extracellular and intracellular pathways, and thus their antitumor action can 
be actively directed towards a particular target [141]. AgNPs were found to be potentially 
cytotoxic against acute myeloid leukemia (AML) cells, as well as the human breast cancer cells 
MDA-MB-231 and MCF-7 [142-144], and their cytotoxicty involved a similar mechanism of 
action to that of their antibacterial activity [145]. 
AuNPs conjugated with epidermal growth factor receptor antibody (anti-EGFR) were used for 
the selective photothermal therapy (PTT) of human epithelial cancer cells, A431 [146]. VEGF 
antibody attached AuNPs induced a higher level of apoptosis in B-chronic lymphocytic 
leukemia cells when compared to free AuNPs and antibodies [147]. A9 RNA aptamer 
conjugated multifunctional AuNPs were successfully used for surface-enhanced Raman 
scattering (SERS) based photo thermal therapy of LNCaP prostate cancer cells [148]. 
Thermal ablation or hyperthermia is a method of tumor targeting, where nanoparticles are used 
to heat up the cancerous cells beyond their temperature tolerance limits [149]. Due to surface 
plasmon resonance (SPR), nanoparticles have the capacity to absorb light and convert the 
absorbed light into localized heat which can be employed for photothermal therapy [149]. When 
the temperature increases above 42°C, cell viability is strongly reduced and at even high 
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temperatures denaturation of proteins, apoptosis and tissue ablation can occur. Monoclonal 
antibodies (anti-HER2) conjugated to gold nanocages were used to induce a near-infrared 
region based photo thermal therapy for breast cancer cells (SK-BR-3) targeting their over 
expressed epidermal growth factor receptors (EGFR) [150].  
Most of the clinically used organic drug molecules used in the treatment of cancer are low 
molecular weight compounds that can readily diffuse into both cancerous and healthy tissues 
[139, 151]. A consequence of this is the severe side effects in healthy cells and reduced efficacy 
at the target site [139]. Nanoparticles can be used as vectors to achieve targeted delivery and 
optimized bio-distribution of drugs in cancer cells/tissue. Dhar et al. demonstrated that a Pt(IV) 
complex, which is normally inactive, can be made active against several cancer cell lines when 
attached to polyvalent oligonucleotide gold nanoparticle conjugates [152]. AuNPs have also 
been used as vehicles for the delivery of the anticancer drug paclitaxel [153]. AuNPs have 
shown potential as intracellular delivery vehicles for antisense oligonucleotides [154] and for 
therapeutic siRNA by providing protection against RNAses [147]. Simultaneous imaging and 
therapy of breast cancer in vitro using silica-gold nano shells has also been reported [155]. 
Thus, noble metal-nanoparticles have theranostic application since they are being explored 
simultaneously as diagnostic and therapeutic tools. To achieve desired effects in therapy, it is 
critical to use rationally designed and engineered NPs that can be targeted to tissues of interest. 
2.5.5 Diagnostics and imaging 
Surface plasmon resonance is the characteristic property of all metal nanoparticles since the 
interaction of radiation with the free electron on the metal surface causes them to oscillate [156]. 
SPR originates when the photons resonate with the free electrons on the metal particle surface 
at a certain wavelength [156]. Various factors such as dielectric constant of the metal and 
medium, size, shape and capping of the organic molecule present on the surface of the 
nanoparticles influence SPR [156]. SPR can be observed in UV-Vis spectroscopy for AgNPs 
and AuNPs, which qualifies them for application in sensing, diagnostics and as optical 
materials. SPR oscillation also strongly enhances their light absorption and scattering properties 
(Rayleigh and Raman) of metal nanoparticles, which can be exploited in cancer imaging 
technology [157]. 
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Diagnostic applications of nanoparticles are focused on early disease detection, visualization 
and quantification of the patho-physiological abnormalities, and image-guided therapy and 
treatment [151]. Conventional diagnosis and imaging techniques using organic dyes have 
drawbacks like short imaging times due to rapid renal clearance, renal toxicity, and vascular 
permeation [158]. Also poor photo-stability, low quantum yields and low detection sensitivity 
necessitates high dosage radiation which could damage the healthy tissue [151]. Noble metal-
nanoparticles based imaging probes, good contrast enhancement and diagnostic agents help in 
improving the site-specificity and sensitivity of diagnostic imaging [151].  
In general, nanoparticle-based imaging probes consist of a targeting agent or vehicle 
functionalized on its surface which helps to locate disease biomarkers tagged on the cell surface 
to enable imaging ability and specificity [159]. The diagnostic ability integrated with 
therapeutic properties of nanoparticles enables their application for theranostic purposes. 
Another advantage associated with noble metal-nonmaterial derived imaging probes is that they 
can be used with multiple imaging modalities to yield complementary information compared to 
any single imaging technique [159]. 
Colloidal AuNPs, which are relatively non-cytotoxic are used as important imaging agents in 
biomedical applications. AuNPs are promising imaging and diagnostic agents for cancer due to 
their property of absorbing light in the visible and near-infra red range [160]. For example, poly 
(amidoamine) dendrimers entrapped AuNPs were used to target folate receptors on human 
epithelial carcinoma cells and their fluorescence imaging was conducted using fluorescence 
isothiocyanate (FITC) [161]. Gold nanorods conjugated to anti-epidermal growth factor 
receptor (anti-EGFR) monoclonal antibodies have been used for dark field light-scattering 
imaging of two malignant oral epithelial cell lines, HOC-313 clone-8 and HSC-3n [162]. Anti-
epidermal growth factor receptor (EGFR) conjugated colloidal AuNPs were used for early 
diagnosis of oral cancer based on their surface plasmon resonance [163]. Kim et al. 
demonstrated that PEG-coated AuNPs are useful as computed tomography contrast agents for 
a blood pool and hepatoma imaging [164]. Optical biosensors were developed using triangular 
AgNPs for the system for binding the antigen ADDL, a putative Alzheimer’s disease pathogen 
and anti-ADDL antibodies. This system was developed by Duyne et al. and helped in the 
diagnosis of Alzheimer’s disease [165]. Thus AgNPs and AuNPs have shown great promise as 
molecular imaging probes. 
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2.5.6 Biosensors 
AgNPs and AuNPs based nano-biosensors are of great interest in various applications such as 
environmental protection, biotechnology and food safety. Sugar-coated AuNPs were able to 
detect low concentrations (10 pg/mL) of plant proteinous toxin, ricin and hybrid Au–Ag 
nanoparticles were able to sense 0.1 ng/mL of S. aureus enterotoxin B, a potential application 
for the detection of toxins in food safety [166, 167].  
AgNPs based biosensors for fast monitoring of penicillin with immobilization of penicillinase 
enzyme by physical adsorption method was recently developed by Sistani et al. [168]. Wei et 
al. used AgNPs for sensing in enzymatic assays of calf intestine alkaline phosphatase (CIAP), 
dephosphorylating adenosine triphosphate (ATP) and protein kinase A (PKA) [169]. Using this 
method, the activity of enzymes and inhibitors could be determined. Chen et al. described 
oligonucleotide functionalized AgNPs and AuNPs for the detection of DNA, based on surface 
enhanced resonance Raman scattering assay [170]. Ag@Au bimetallic nanoparticles based 
biosensors developed by Ghodselahi et al. showed a good response to low concentration of 
DNA and has a short response time [171]. 
2.5.7 General methods for the synthesis of silver and gold nanoparticles  
Many different approaches have been developed for the synthesis of AgNPs and AuNPs of 
different sizes and shapes. These methods can be broadly classified into two main types, the 
top-down and the bottom-up approach. 
2.5.7.1 Top-down approach  
This approach involves the miniaturization of the bulk material to nanostructure by using 
different techniques and subsequent stabilization of the resulting nanoscale particles by capping 
agents. The most commonly used methods in this approach are mechanical grinding, 
evaporation-condensation and laser ablation. The absence of impurities and chemical 
contamination are advantages of this method [172, 173].  
Mechanical grinding is the oldest method and involves milling of bulk materials in mechanical 
attrition devices to highly crystalline nanomaterials [174]. The disadvantage of this method is 
that the nanoparticles synthesized contain crystal defects at the surface, due to large strain 
imparted to particles during the milling process [173]. 
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In the evaporation-condensation method and laser ablation method, bulk metal is heated or 
ablated by absorbed pulsed laser beam energy in a liquid medium and the vaporized metal 
condenses to generate nanoparticles. The size and shape of nanoparticles generated by these 
methods mainly depends on the optical property of the metal, laser wavelength, duration of 
laser impulse used, and presence of surfactants in the medium [175]. Synthesis of both AgNPs 
and AuNPs by this method has been reported [175-177]. The disadvantage of these methods is 
the requirement of highly expensive and cumbersome equipment for the generation of high 
temperatures and high power laser beams. 
2.5.7.2 Bottom-up approach 
In this approach, the reduction of various metal ions leads to the formation of atoms, and the 
atoms (building blocks of the nanoparticles) agglomerate into oligomeric clusters which 
eventually convert into colloidal nanoparticle structures. The reduction of metal ions can be 
performed by chemical, thermal [178], microwave [179], sonochemical [180], electrochemical 
[181] and photochemical reduction [182] methods using different salts. A large variety of 
additives such as donor ligands, polymers, and surfactants, are used in these processes to guide 
the nucleation, growth control and stabilization of the resulting nanoparticles. Silver and gold 
nanoparticles with different morphology can be obtained using these methods by varying 
parameters such as, precursor salt, reducing agent and stabilizing agent. The most commonly 
used additives are polymers (polyvinyl pyrrolidone), surfactants (sodium dodecylsulfate), 
dendrimers, and biomolecules such as DNA, sugars, proteins, peptides, and amino acids [183]. 
2.5.7.2.1 Chemical reduction  
Chemical reduction is the most frequently applied method for the generation of AgNPs and 
AuNPs. The synthesis of nanoparticles by this approach is typically carried out using a metal 
precursor, a reducing agent and a stabilizing additive. Chemical reduction by organic and 
inorganic reducing agents of Ag+ and Au+ ions to the metallic Ag0 and Au0, followed by 
agglomeration of the atoms to clusters (nucleation and growth) lead to the formation of 
nanoparticles. Most commonly used reducing agents are sodium borohydride, sodium citrates, 
ascorbates, and hydrazine [184-188]. The size and shape of the resulting nanoparticles depends 
on reaction parameters such as concentration, pH and temperature.  
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The chemical methods for the synthesis of nanoparticles are rapid and can be conducted in large 
scale, but the problem with most of the chemical methods is that they involve the use of toxic 
and hazardous chemicals such as NaBH4, and N2H4; thus limiting the application of 
nanoparticles in the medical field. Also, poor control on growth, shape and stability of these 
nanoparticles necessitates the addition of stabilizing agents. Furthermore, there is evidence to 
suggest that chemically synthesized nanoparticles cause adverse effects on humans, animals, 
plants, and  the environment [189, 190]. 
2.5.7.2.2 Biological methods for the synthesis of nanoparticles 
Many chemical and physical methods that are available for the synthesis of nanoparticles often 
require energy intensive processes such as high temperatures and pressure, toxic radiation, and 
expensive equipment thus making them less feasible [191]. Also, the biomedical applications 
of nanoparticles synthesized by chemical methods are limited due to the toxic chemicals 
adsorbed on their surfaces. To overcome these problems, current studies are embarking on the 
use of green biological methods for nanoparticle synthesis. The merits of these methods involve 
lower reaction temperatures, less cumbersome reaction processes, and non-pure starting 
materials may be used, all of which result in cheaper maintenance. Both prokaryotic and 
eukaryotic organisms have been demonstrated to have strong potential for metallic nanoparticle 
synthesis and nanoparticles obtained from these sources have been evaluated for a wide range 
of applications. 
The silver resistant bacteria P. stutzeri A259, was the first bacterial strain found with capacity 
to form AgNPs from Ag+ ions using its naturally-occurring protective pathway against silver 
ions toxicity [192]. Intracellular AuNPs synthesis by the bacterial species P. boryanum, G. 
ferrireducens, and S. algae is also reported [193]. Extracellular synthesis of AgNPs by B. 
subtilis, B. megatherium, E. coli, E. cloacae and AuNPs by R. capsulata, S.  maltophilia has 
also been reported in  literature [194]. 
One example of a eukaryotic nanoparticle producer is the fungus Phoma, which produces 
AgNPs that exhibit antibacterial properties and these are also employed as catalysts in the oil 
industry [195]. F. oxysporum produces nanoparticles of Ag, Au, Pt, Zr, Cd, Pb and Ti [194, 
196], and intracellular bioreduction of gold ions by V. luteoalbum occurred at lower pH values 
resulted in the formation of smaller and uniformly spherical-shaped AuNPs.  
Chapter 2  Literature Review 
26 
Many plants have been successfully used for efficient and rapid extracellular synthesis of 
AgNPs and AuNPs. Plant mediated green synthesis of AgNPs using Emblica officinalis fruit 
extract and Rhizophora mucronata leaf buds and their application as antibacterial agents has 
been discussed [197, 198]. The AgNPs and AuNPs synthesized by using Butea monosperma 
leaf extract for potential application for cancer therapeutics has been reported by Patra et al. 
[199]. Megarajan et al. reported the photosynthesis of AuNPs using phytoproteins of spinach 
leaves, and their application as catalysts for the degradation of an azo dye, methyl orange [200].  
The mechanism involved in both intracellular and extracellular synthesis of nanoparticles is not 
well understood. However, it is hypothesized that enzymes and other biomolecules such as 
polypeptides, proteins, lipid, flavonoids, terpenoides, ascorbic acids, polyphenols, etc. have the 
main role in the reductive reactions used by various organisms [194]. For instance, extracellular 
synthesis of AgNPs by white rot fungus, Phaenerochaete chrysosporium was proposed to 
initiate by chemical functional groups such as carboxylate anion, carboxyl and peptide bond of 
proteins, and hydroxyl of saccharides present on the cell wall surface [201]. The synthesis of 
AuNPs by Fusarium oxysporum was proposed to be catalyzed by hydrogenase and NADH-
dependent reductase [202]. Similarly, biosynthesis of AuNPs by laccase enzyme isolated from 
Paraconiothyrium Variabile has been reported [203]. Bhattacharjee et al. highlighted the 
dipeptide- and tripeptide-mediated reduction of HAuCl4 to colloidal AuNPs [204]. In yet 
another similar study, a chemically reducing potential around the metal cluster was generated 
due to the interaction with the peptide, and this was expected to drive the reduction of silver 
and gold ions to AgNPs and AuNPs respectively [205]. Although these hypothetical 
mechanisms explain nanoparticle formation in biological systems, a detailed study is needed to 
clarify the processes. 
Many species of bacteria, fungi and algae have the natural ability to produce nanoparticles, and 
faster growth rates of these organisms can be exploited for large scale synthesis of 
nanoparticles. However, maintaining the microbial culture is a tedious process. Nanoparticle 
synthesis using plant extracts is relatively more economical, energy efficient and cost effective. 
Plant extracts are highly convenient due to short reaction times and easy availability of different 
plant materials like leaves that can be harvested without removing the plant from the wild. 
Green synthesized nanoparticles therefore have significant value in medicine due to their 
biocompatibility [191].  
Chapter 2  Literature Review 
27 
2.6 Hypothesis of the study 
Since 3,5-dicyanopyridines bearing the 2-amino-4-aryl-6-sulfanyl substitution pattern present 
in many pharmaceutically important compounds exhibited a wide variety of biological activity 
including antimicrobial and anticancer activity; molecules containing this core structure can be 
synthesized and evaluated for more novel biological applications. Recently metal nanoparticles 
have gained high importance in drug delivery, sensing, imaging and chemotherapy medicine 
due to their unique physical and biological properties. Thus, exploring more of them would 
help to find novel therapeutic agents. The function of hybrid molecules for better therapeutic 
properties and to combat drug resistance has become an important subject of study in the field 
of medicinal chemistry [206]. The hybrid molecules or materials can be generated by organic-
organic or organic-inorganic combination [62, 206]. Organic–inorganic hybrid materials are 
generated using organic and inorganic components either in the form of homogeneous systems 
derived from miscible organic and inorganic components, or in the form of heterogeneous 
systems as nanocomposites [62]. In organic-inorganic hybrids, the association between the 
constituents can be either in the form of chemical covalent linkage or mere physical adsorption 
forces such as van der Waals forces [62, 207, 208]. The co-existence of two different molecules 
with entirely different modes of action in the form of hybrid molecules produce synergistic 
effects and thus offer advantages such as dosage compliance, minimized toxicity, and 
overcoming drug resistance when compared to the parent counterparts [209]. Hence the 
synthesis and evaluation of drug conjugated nanoparticles as organic-inorganic hybrid 
molecules for their antibacterial properties is interesting.  
Developing novel medication without compromising on safety and efficacy is both an 
expensive and time consuming process in the pharmaceutical industry [210]. There are thus a 
large number of drugs that are withdrawn at the clinical trial stage, due to their poor 
pharmaceutical properties such as poor solubility, permeability and tolerability, and also rapid 
metabolism and elimination from the body. Hence along with the discovery and development 
of new drugs, focus must also be on novel strategies to improve current therapies. Modification 
of existing drugs in terms of improved formulation such as salt formation, inclusion 
complexation, repurposing and repositioning to further improve the therapeutic value of current 
chemotherapies will help in more rapid development of treatments. 
In conclusion, the main objective of this this PhD research study was to synthesize and evaluate 
novel pharmaceutical candidates that can be used against microbial infections and diabetes.  
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3.1 Abstract 
The aqueous seed extract of Protorhus longifolia was found to be an efficient reagent for 
simultaneous synthesis and functionalization of silver and gold nanoparticles from 1 mM silver 
nitrate and 1 mM chloroauric acid solution. The progress of the reaction was studied using UV-
Visible spectroscopy. Scanning electron microscopy (SEM) and transmission electron 
microscopy (TEM) techniques were used to study surface morphology, size and crystalline 
nature of nanoparticles. Energy dispersive X-ray analysis confirmed the presence of silver and 
gold element in the nanoparticle samples. The presence of functional groups over the surface 
of nanoparticles was confirmed by Fourier transform infrared spectroscopy (FTIR) studies. Zeta 
potential contributing to the stability of silver and gold nanoparticles was recorded as -21.2 mv 
and -19.7 mv respectively. The modification of the composition and surface morphology of 
nanoparticles was a result of the capping of organic molecules from the seed extract yielding 
novel nanoparticles. These nanoparticles showed potential antibacterial activity against 
bacterial species Escherichia coli (ATCC 35218), Klebsiella pneumoniae (ATCC 700603), 
Staphylococcus aureus (ATCC 43300) and Pseudomonas aeruginosa (ATCC 27853).   
3.2 Key words 
Protorhus longifolia, Green synthesis, Silver nanoparticles (AgNPs), Gold nanoparticles 
(AuNPs), Antibacterial activity 
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3.3 Introduction 
The use of plant extracts for the extracellular synthesis of AgNPs and AuNPs in a bottom-up 
reduction approach has recently been extensively researched [1]. The interest in these bottom-
up methods is based on their ecofriendly nature and less cumbersome reaction procedures. 
Nanoparticles synthesized using chemical methods have limited application as the toxic 
chemicals used in the reaction become adsorbed onto the surface of nanoparticles [2] . 
Intracellular green methods using plants and microbes such as bacteria and fungi generates 
biocompatible nanoparticles, but at relatively slower rates [3]. On the other hand extracellular 
methods involving plant extracts are highly convenient due to short reaction times and easy 
availability of different plant materials as plant organs such as leaves can be harvested without 
removing the plant from the wild. Plant extracts are often a source of bioactive and medicinally 
useful compounds and can be generated using a range of plant tissues [4]. 
In the process of synthesizing nanoparticles from a metal ion solution, medicinally important 
phytochemicals in the plant extracts reduce the metal ions and also functionalize the surface of 
the nanoparticles. This functionalization may in this way increase the biocompatibility of green 
nanoparticles [5]. Steric repulsions between the functionalized molecules can also cause the 
nanoparticles to form stable colloidal solution and hence use of additional stabilizing chemicals 
can be avoided [6]. Silver and gold nanoparticles synthesized by using plant extracts very often 
have unique chemical and biological properties and are the subject of much interest in the field 
of catalysis, electronics and most importantly in the medical field as bactericidal and therapeutic 
agents [7-9]. The chemical composition of plant extract greatly influences on the size and shape 
of the nanoparticles, which in turn effects on the therapeutic and catalytic properties of 
nanoparticles [10]. Hence there is necessity to screen more plant extract for the green synthesis 
of AgNPs and AuNPs of desired size and shape. 
There are at present many reports on the extracellular synthesis of silver and gold nanoparticles 
using various plant parts. Fruit peel of mango [11], lemon [12], Satsuma mandarin [13], were 
used for the synthesis of AgNPs and AuNPs. Root extract of Zingiber officinale [14] was used 
for the synthesis of AgNPs and AuNPS. Sea weed Chaetomorpha linum [15] for the synthesis 
of AgNPs and flower extracts of  Gnidia glauca [16] , Nyctanthes arbortristis [17], Carthamus 
tinctorius L [18] were used for synthesis of AuNPs. Leaf extracts of Gliricidia sepium [19] for 
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the synthesis of AgNPs and even seed extracts of Abelmoschus esculentus [20] and Acacia 
farnesiana [21] have also been used for the synthesis of AuNPs  and AgNPs.  
In this present study we investigate the synthesis and antibacterial activity of silver and gold 
nanoparticles produced using aqueous seed extract of Protorhus longifolia (Bernh.) Engl. as a 
reducing agent. Nanoparticles synthesized using the seeds of other species have exhibited 
bioactivity [22, 23]. Protorhus longifolia belongs to the family Anacardiaceae, which is widely 
distributed throughout South Africa and its bark and leaves are used in traditional medicine to 
treat hemiplegic paralysis, heart burn and bleeding from stomach [24-27]. The seeds of the plant 
however, unexplored for their medicinal use. Protorhus longifolia produce recalcitrant seeds 
that are intolerant of desiccation and possibly sensitive to low temperatures, which effectively 
precludes their storage for any useful period of time [28]. Our interest in using the seeds of 
these species for the synthesis of nanoparticles is based on the fact that recalcitrant seeds have 
been shown to possess a number of antimicrobial agents (e.g. β-1,3-glucanase and chitinase) as 
part of their defense mechanisms against the range of microbes that plague them in the wild 
[29].  
3.4 Experimental Section 
3.4.1 Materials 
Silver nitrate AgNO3 and Chloroauric acid HAuCl4.3H2O were analytical grade reagents 
purchased from Merck Germany. 1% JIK bleach was purchased from Reckitt Benckiser, South 
Africa. Seeds of Protorhus longifolia were collected from Westville campus, University of 
KwaZulu-Natal (GPS co-ordinates -29.817897, 30.942771).  
3.4.2 Preparation of seed extract 
Protorhus longifolia seeds were surface sterilized in 1% JIK bleach, washed with deionized 
water and then the seeds were air dried for 3 days at room temperature (28°C) [28]. The dried 
seeds were ground to a fine powder using a commercial blender. Two grams of the fine seed 
powder was soaked in 25 ml of distilled water and shaken continuously for 24 h. The resulting 
leachate was filtered and stored at 4°C for further use. 
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3.4.3 Synthesis of silver and gold nanoparticles 
For the synthesis of nanoparticles  the method available in the literature was adopted [30]. 2 ml 
of plant extract was added to 25 ml of sterile 1 mM silver nitrate solution and 1 mM chloroauric 
acid solution and incubated with continuous stirring on the rotary shaker at 120 rpm, 30°C for 
24h. Progress in the reaction was monitored by measuring the UV absorbance. The final 
reaction mixture was centrifuged and washed with distilled water to remove any unreacted 
materials. AgNPs were centrifuged (Eppendorf 5810R) at 4000 rpm (Rotor A-4-62) for 20 min, 
whereas AuNPs were centrifuged at 8000 rpm (Rotor F-34-6-38) for 20 min.  
3.4.4 UV-Vis Spectrum analysis 
The reduction reaction of silver and gold ions by aqueous seed extraction was followed by UV 
visible absorption measurements at room temperature as function of time using Specord 210, 
Analytikjena spectrometer. The broad absorbance peaks between 400-500 nm and 500-600 nm 
confirmed the formation silver and gold nanoparticles respectively. 1 mM AgNO3 and 1 mM 
HAuCl4 solution were used as the reference blank solution for these measurements [31]. 
3.4.5 Fourier Transform Infrared (FTIR-ATR) Spectroscopy Measurements 
The nanoparticle pellet obtained after the washing was dried in a desiccator containing calcium 
chloride and the dry pellet obtained was thereafter used for the FTIR studies using Perkin Elmer 
Precisely Spectrometer 100 FTIR-ATR to identify the functional groups present on the surface 
of nanoparticles. 
3.4.6 Scanning Electron Microscopy Measurements 
Morphological studies of the synthesized AgNPs and AuNPs were carried out using scanning 
electron microscopy (FEGSEM ZEISS ULTRAPLUS). Samples prepared by adding a drop of 
sonicated nanoparticle solution over the carbon tape glued over copper grid. The samples thus 
obtained were coated with carbon and observed at 10000 X magnification. The energy 
dispersive X-ray analysis (EDX) was done at 20 kV using AZTEC software for the analysis. 
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3.4.7 Transmission Electron Microscopy (TEM) Measurements 
Both silver and gold nanoparticle solution obtained after the purification were sonicated for 15 
min to disrupt any possible aggregates [32]. A small amount of this sonicated solution was 
placed on carbon coated copper grid and dried under infrared light for solvent evaporation. 
High-resolution TEM images were obtained on JEOL TEM model no 2100 operating at 
accelerating voltage of 200 kV and 0.23 nm resolution.  
3.4.8 Zeta potential measurements 
The Zeta potential of green synthesized AgNPs and AuNPs was determined using Zetasizer 
Nano ZS90 (Malvern Instruments Ltd., UK). Water was used as dispersant and samples were 
sufficiently diluted to ensure that the light scattering intensity (between 6E+004 and 1E+006) 
was within the instrument sensitivity. Measurements were done at 25°C and medium refractive 
index was 1.330. Measurements were carried out in triplicates [33]. 
3.4.9 Antibacterial activity 
Minimum Inhibitory Concentration 
MIC, defined as the lowest concentration of an antimicrobial agent that inhibits the growth of 
a microorganism after overnight incubation, was determined by monitoring the growth of 
bacteria in a microplate reader (Synergy HT, BioTek Instruments) at 630 nm by micro dilution 
method as per NCCLS guidelines [34]. The bacterial test cultures used in this study were 
Escherichia coli (ATCC 35218), Klebsiella pneumoniae (ATCC 700603), Staphylococcus 
aureus (ATCC 43300), Enterococcus faecalis (ATCC 5129) and Pseudomonas aeruginosa 
(ATCC 27853). Serial twofold dilutions of AgNPs and AuNPs solution were prepared in sterile 
96-well plates over the range of 200-1.25 μg/ml [32] . The wells were then inoculated with 
diluted overnight broth culture initially adjusted to 0.5 McFarland turbidity standards and 
incubated at 35°C for 24 hours. Neomycin (Sigma) served as a positive control; MIC was 
recorded as the lowest concentration at which no growth was observed. All the experiments 
were carried out in triplicates. 
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3.5 Results and Discussion 
3.5.1 UV -Visible studies 
Surface plasmon resonance a unique optical phenomenon of metal nanoparticles, in the UV 
region enables their easy detection. This property arises due to surface plasmon oscillation of 
free electrons [35]. Nanoparticles show strong absorbance in the UV region due to this 
phenomenon and the wavelength at which absorbance occurs is a characteristic property of 
particular metal nanoparticle and also depends on the size and shape of particles [36]. Fig. 3.1 
illustrates the UV-visible absorbance spectra of reaction mixture containing aqueous seed 
extract with silver nitrate (1 mM) and chloroauric acid (1 mM) at various time intervals. After 
the addition of the seed extract, the silver nitrate solution changed to brown and gold chloride 
solution changed to wine red. The intensity of the color and absorbance of both the solutions 
increased with the time as the reaction proceeded.  
Both the AgNP and AuNP reaction mixtures showed a single broad surface plasmon resonance 
band between the wavelength 400-500 nm and 500-600 nm respectively. The change of color 
of reaction mixture within 15 min indicated that reduction of Ag+ and Au3+ is a rapid reaction. 
The reactions were carried out for 24 h to make sure they run to completion.  
 
 
Figure 3.1 UV–Vis spectra recorded as a function of reaction time a) AgNPs and b) AuNPs. 
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3.5.2 FTIR-ATR studies 
The IR spectrum results showed that some organic biomolecules from seed extract had become 
associated with the surface of silver and gold nanoparticles to form a capping agent. The steric 
repulsion between the capped molecules contributes to the stability of nanoparticles. The major 
IR bands at 3258, 1629, 1514, 1055 cm−1 for AgNPs (Fig. 3.2a) and the IR bands at 3263, 1739, 
1635, 1530 and 1160 cm−1 for AuNPs (Fig. 3.2b) were observed. The broad spectrum of IR 
peak at 3260 cm−1 for both AgNPs and AuNPs referred to the strong stretching vibrations of -
OH functional group. The band at 1160 cm-1 and 1055 cm-1 can be assigned to the ether linkages 
or –C-O- functional group. To a large extent, these bands might be the product of -C-O- groups 
of the polyols such as flavones, terpenoids and the polysaccharides of seed extract. The 
absorbance band centered at 1635 cm-1 and 1629 cm-1 is associated with the stretching 
vibrations of –C=C- or aromatic groups. The band around 1739 cm-1 for AuNPs can be assigned 
to C=O stretching vibrations of the carbonyl functional group in ketones, aldehydes, and 
carboxylic acids. The spectrum also exhibits two intense bands at 2851 cm-1 and 2919 cm-1, for 
AuNPs which is assigned to the symmetric and asymmetric stretching vibration of sp3 












Figure 3.2 FTIR ATR spectra of a) AgNPs and b) AuNPs. 
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3.5.3 SEM and TEM Analysis 
The AgNPs and AuNPs from the reaction mixture were repeatedly centrifuged and redispersed 
in sterile distilled water prior to SEM and TEM analysis to remove any unreacted plant material 
and metal ions. SEM analysis confirmed that particles are of a nano-size. The spherical shape 
of the nanoparticles is shown in the SEM images (Fig. 3.3a and 3.3b). The EDX analysis 
confirmed that the particles were composed of elemental silver and gold (Fig. 3.3c and 3.3d). 
TEM analysis showed that both silver and gold nanoparticles were poly-dispersed and 
predominantly spherical or polyhedral in shape. The majority of the silver nanoparticles were 
20-30 nm in size whereas AuNPs were in the range of 10-20 nm. Fig. 3.4A, a and Fig. 3.4B, a 
shows clear morphology of silver and gold nanoparticles. The Selected area diffraction pattern 
clearly indicated that the AgNPs and AuNPs formed by the reduction of metal ions by the seed 
extract are polycrystalline in nature with clear lattice fringes (Fig. 3.4A, b and Fig. 3.4B, b) 
characteristic of crystalline nature of nanoparticles [37, 38]. 
 






































Figure 3.4B a) HRTEM micrograph b) Lattice fringes c) SAED pattern and d) Histogram of AuNPs. 
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3.5.4 Zeta potential measurements 
The electric charge on the surface of nanoparticles can be measured in terms of Zeta potential. 
Zeta potential was found to be −21.2 mV for AgNPs and -19.5 mV for AuNPs (Fig. 3.5). The 
negative zeta potential confirms the negative charge on the surface of colloidal nanoparticles. 
The coulombic repulsion forces induced by surface negative charge minimize the aggregation 
and thus contribute to the stability of the green synthesized nanoparticles [33]. 
 
 
Figure 3.5 Zeta potential graphs of a) AgNPs and b) AuNPs. 
 
3.5.5 Antibacterial Studies 
The use of nanoparticles functionalized with antibacterial compounds is an interesting strategy 
to overcome the problem of multidrug resistance by bacteria [39]. Inorganic metal nanoparticles 
have been shown to target multiple components of the cell and hence, there is less scope for 
bacteria to develop resistance [40]. The antibacterial mechanisms of action of metal 
nanoparticles include cell wall disruption followed by leakage of cell content, binding of metal 
ions to DNA and proteins which results in inactivation or severe alteration of cellular 
metabolism [41]. Further properties of nanoparticles such as high surface area, slow and steady 
release of metal atoms compared to salt or bulk metal add to their antimicrobial properties. 
In the present study silver and gold nanoparticles showed good antibacterial activity against 
tested pathogens (Table 1). These results also showed that AgNPs had higher antibacterial 
activity than AuNPs. This is in accord with other studies which have shown AgNPs to be more 
antibacterial than AuNPs, largely due to the relatively inert chemical nature of gold [40]. E. coli 
was the most sensitive to silver nanoparticles (MIC 3.12 µg/ml) followed by P. aeruginosa and 
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S. aureus (MIC 50 µg/mL). These results are in agreement with other studies [42]. E. faecalis 
was resistant to silver and gold nanoparticles. Similar results were observed in a previous study 
where silver nanoparticles were more active against gram negative bacteria than gram positive 
bacteria and this was attributed to change in the cell wall composition of bacteria [43]. Gold 
nanoparticles were effective at 200 µg/ml amongst the varied concentration range against the 
tested pathogens. The seed chemical content adsorbed onto the surface of nanoparticles could 
have added to their antibacterial activities and thus nanoparticles may have acted as carriers or 
drug delivery systems for the antibacterial content of plant material functionalized on their 
surface [32]. Recent reports also suggest similar mechanism where gold nanoparticles 
functionalized with small molecules have shown good antibacterial activity [44]. 
Table 3.1 Minimum inhibitory concentration of Protorhus longifolia seed extract derived silver and 
gold nanoparticles against bacteria. 
Compound Minimum Inhibitory Concentration (µg/ml) 
 Gram negative Gram positive 
 E. coli K. pneumoniae P. aeruginosa S. aureus E. faecalis 
AgNPs 3.12 100 50 50 NA 
AuNPs 200 200 200 200 NA 
 
3.6 Conclusion 
In conclusion, we successfully synthesized silver and gold nanoparticles using aqueous seed 
extract of recalcitrant seeded Protorhus longifolia and confirmed the antibacterial activity of 
resultant nanoparticles. The reduction reaction for the synthesis of nanoparticles was 
moderately rapid under the ambient conditions and reaction handling was easy since it does not 
require boiling or subsequent treatment. The nanoparticles produced showed distinct poly-
dispersity. The IR studies confirmed the capping of organic contents of seed extract of 
Protorhus longifolia onto the surface of nanoparticles. The capping of nanoparticles by organic 
molecules found in the seed extract and the negative charge of nanoparticles is suggested to 
have added to their stability. Further in yet to be reported research work we have also confirmed 
the antimicrobial activity of crude seed extract of Protorhus longifolia. Together these findings 
would significantly contribute to the advancement in the formulation of novel phytochemical 
based green material as antimicrobial agents.  
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Investigation of 3, 5-dicyanopyridine scaffolds as antidiabetic and 
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4.1 Abstract 
In this study, 3,5-dicyanopyridines have been evaluated as a small key organic molecule for 
their application as potential treatment of type-II diabetes mellitus and bacterial infections. 
Several molecules were synthesized with high yields in a single-step multicomponent approach, 
and then characterized by IR, NMR and HRMS. Inhibition of α-glucosidase and the 
antibacterial activities of the molecules were then evaluated. Five of the nine compounds tested 
showed good inhibition of α-glucosidase, which were similar to that of the standard drug 
acarbose. Molecular docking analysis was then conducted to further explain these results. 
However, no significant antibacterial activities were observed for these compounds. 
4.2 Key words 
 3, 5-dicyanopyridine, α-glucosidase inhibition, antibacterial activity, molecular docking 
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4.3 Introduction 
The increased world-wide prevalence of the metabolic disorder, diabetes mellitus, across all 
age groups is making a significant and growing contribution to morbidity and mortality rates 
[1]. Diabetes mellitus is mainly classified into two types; type I diabetes and type II diabetes 
[2]. Type I diabetes is insulin dependent and results from impaired functioning of pancreatic 
beta cells which cause cessation of insulin production [2]. Type II diabetes is non-insulin-
dependent  and results from the combination of insulin resistance and deficiency [3, 4]. Type II 
diabetes accounts for 85-95% of all modern diabetes cases [4]. Recent studies concluded that 
genetic predisposition, environmental factors, life style with wrong dietary habits, decreased 
physical activity, and stress all contribute to the occurrence of type II diabetes [4, 5]. The most 
common biochemical abnormality associated with diabetes mellitus is chronic hyperglycemia, 
a metabolic condition characterized by raised blood glucose levels and increased glucose 
intolerance [2]. The disruption of carbohydrate, fat and protein metabolism due to defects in 
insulin secretion or action can  lead to hyperglycemia [2]. If untreated, the chronic high blood 
glucose levels can lead to complications including impaired vision or even blindness, nerve 
damage and kidney failure [6]. The long-term severe clinical manifestations of diabetes include; 
retinopathy, nephropathy and neuropathy [4]. Diabetic patients also face an increased risk of 
developing cardiac, peripheral arterial and cerebrovascular disease [6]. 
Complications associated with diabetes are prevented by administering therapeutic agents 
which manage blood glucose levels by targeting α-glucosidase; an enzyme which plays a 
pivotal role in the digestion of starch to glucose in the intestine, thereby elevating postprandial 
glucose concentrations [7]. This approach is particularly more effective in individuals with type 
II diabetes mellitus and the examples of drugs which inhibit α-glucosidase activity include 
acarbose, miglitol and voglibose (Fig. 4.1) [8, 9].  These compounds mainly suppress the 
absorption of carbohydrates in the small intestine and thus have a controlling effect on 
postprandial  hyperglycemic events [10]. However their use is limited by unwanted side effects 
such as hypoglycemia, myocardial infarction, weight gain, increase in insulin resistance, 
flatulence and diarrhea [11]. There is therefore a need to discover novel α-glucosidase inhibitors 
which can be employed as safer anti-diabetic agents with minimal side effects. Several pyridine 
and pyrimidine derivatives have been recently reported to significantly inhibit α-glucosidase 
activity [12]. These findings have therefore prompted the need to investigate the structurally 
similar 3,5-dicyanopyridine frame-works for α-glucosidase inhibitory activity. 3,5-
dicyanopyridines are important and medically useful heterocyclic scaffolds which have been 
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utilized in the generation of a library of compounds with diverse medicinal applications [13, 
14]. Alterations of substituents at the pyridine core have produced structures with different 
biological activities such as; antimicrobial [15], anticancer [16], and cardiovascular agents [17]; 
inhibitors of prion replication [18], potassium channel openers with application in treating 
urinary incontinence [19], inhibitors of IKK2 with a potential for treating hepatitis B virus 
(HBV) infection [20], and also show agonistic activity for human adenosine A2B receptors with 
a potential for treating Parkinson’s disease, hypoxia/ischemia, asthma, kidney disease, epilepsy 
and cancer [13, 21]. A preliminary evaluation of the molecular interactions of a series of 3,5-
dicyanopyridine compounds with α-glucosidase was performed through molecular docking 
studies using Autodock Vina and it was concluded that these scaffolds are capable of binding 
in the α-glucosidase active site with good affinity. Hence, the synthesis of 3, 5-dicyanopyridines 
was conducted and their α-glucosidase inhibitory activities were evaluated in vitro. Since 
similar compounds have been reported as antibacterial agents, we also investigated the 
antibacterial activity of the molecules synthesized in this study [22]. Herein, we report the novel 
investigation of the anti-diabetic and antibacterial activities of some multicomponent derived 
3,5-dicyanopyridine molecular frameworks. 
 
 
Figure 4.1 Structures of α-glucosidase inhibitors. 
   
Miglitol Voglibose Acarbose 
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4.4 Materials and Methods  
4.4.1 General procedures 
Reagents and chemicals were purchased from Sigma Aldrich, Germany. Organic solvents were 
purified by re-distillation and dried according to standard procedures. Melting points were 
determined on a Thermonik Campbell melting point apparatus. Infrared spectra were recorded 
on a Bruker Infrared Spectrophotometer, Model 599-B. 1H and 13C NMR spectra were recorded 
in DMSO solution at room temperature using a Bruker Avance 400 MHz and Bruker Avance 
600 MHz instruments. Chemical shifts are given in δ (ppm) against the internal standard 
tetramethylsilane. Mass spectroscopy (MS) was carried out on a Waters Micromass LCT 
Premier TOF-MS. 
4.4.2 General procedure for the synthesis of 3, 5-dicyanopyridine 
Synthesis of 1a-1h compounds: The procedure reported by Evdokimov et al. was adopted for 
the synthesis of these compounds [14]. To a solution of aryl or aryl alkyl aldehyde (2 mmol) in 
ethanol, a solution of malononitrile (4.2mmol) in 5 mL of ethanol was slowly added.  To this 
reaction mixture triethylamine (Et3N, 0.1 mmol) was added dropwise at ambient temperature 
and stirred at room temperature (RT) for half an hour. The resulting mixture was heated to 50°C 
and the desired thiol (2.1 mmol) was added. Thereafter the reaction mixture was refluxed for 
4-5 h until the starting material was consumed. When no more starting material appeared on 
thin layer chromatography (TLC), the reaction mixture was allowed to cool to RT. Methanol 
was then added to the dark residue obtained after the removal of excess ethanol under reduced 
pressure, which resulted in the crystallization of the product. Further crystallization was 
conducted until no more side products were observed on the TLC plate.  
Synthesis of compound 1i: A procedure reported by Evdokimov et al. was adopted for the 
synthesis of li [14]. To the solution of aldehyde (2 mmol) and malononitrile (3 mmol) in ethanol, 
100 µL of Et3N in 5 mL of ethanol was added drop wise. To this resulting mixture, ethanedithiol 
(0.55 mmol) was added slowly at RT. The reaction mixture was refluxed for 2h and then 
allowed to cool to RT. The product formed as a precipitate and after cooling, it was isolated by 
filtration. The filtrate was concentrated under reduced pressure to obtain a dark residue. The 
dark residue yielded further 5-10% of product after recrystalization using small amounts of 
methanol. The solids were combined and recrystallized from methanol to yield compound 1i. 
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Figure 4.3 Compounds synthesized in this study. 
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4.4.3 Docking Study 
The crystal structure of α-glucosidase (PDB ID: 3W37) complexed with acarbose was obtained 
from RCSB Protein Data Bank with the resolution of 1.70 Å [23]. This crystal structure was 
used to create separate protein and ligand pdb files using Discovery Studio 4.0 Client software. 
Protein was prepared for docking by removing water molecules and co-crystallized ligands, and 
by adding polar hydrogens. Similarly the pdbqt format of separated ligands was prepared for 
docking after adding polar hydrogens and setting torsions. The 3D structure of synthesized 
ligands were constructed in Chem3D Ultra 8.0 and were subjected to energy minimization and 
geometry optimization  [24]. The pdbqt formats of obtained 3D structures were used for in 
silico protein-ligand docking calculations using AutoDock Vina [25]. The grid box with spacing 
1 Å was constructed around the enzyme active site and the selected values for grid dimensions 
and the center were 16×24×28 and x = 0.11, y = -2.511, and z = -22.097, respectively. The 
validation of docking protocols was performed by re-docking of co-crystallized ligand acarbose 
with protein 3W37. After validation; the same parameters were used for the docking calculation 
of all other ligands. The predicted binding affinity (kcal/mol), which indicates how strongly a 
ligand binds to a receptor, was calculated on the basis of the scoring function used in AutoDock 
Vina. The best molecular interaction was identified using the binding affinity score. The best 
docking poses were visualized using Discovery Studio 4.0 Client software. 
4.4.4 Determination of α-glucosidase inhibitory activity of compounds 
The yeast (Saccharomyces cerevisiae) α-glucosidase inhibitory activity of compounds was 
determined according to the method described by Kim et al and Taha et al., with slight 
modifications [26, 27]. Initially, the effect of the DMSO solvent on enzyme activity was 
studied. From the results we concluded that 30% of DMSO in the total reaction mixture had no 
significant effect on enzyme activity. After standardization, the experiment was conducted in 
24 well plates as follows; briefly, 100 μL of each dilution (1000-15.625 µg/ml) of compound 
in DMSO was added into 24 well plates and thereafter 200 μL of 100 mM phosphate buffer 
was added so that the final concentration of DMSO does not exceed 30%. Similarly, a control 
experiment with 100 μL of DMSO and acarbose at different concentrations (1000-15.625 
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µg/ml) was set. The resulting samples were incubated with 200 µl of 1.0 U/ml a-glucosidase 
solution in 100 mM phosphate buffer (pH 6.8) at 37°C for 15 min. Thereafter 150 µL of 5 mM 
pNPG (4-Nitrophenyl-beta-D-glucopyranoside) solution in 100 mM phosphate buffer (pH 6.8) 
was added and the mixture was further incubated at 37°C for 10 min. The absorbance of the 
reaction mixture was measured at 405 nm using an automated microplate reader (Synergy HT, 
BioTek Instruments) and the inhibitory activity was expressed as the percentage of the control 
sample (100 μL DMSO). All experiments were conducted in triplicate and the results were 





4.4.5 Antimicrobial assay  
The bacterial test cultures used in this study were Escherichia coli (ATCC 35218), Klebsiella 
pneumoniae (ATCC 700603), Staphylococcus aureus (ATCC 43300), Enterococcus faecalis 
(ATCC 5129) and Pseudomonas aeruginosa (ATCC 27853). Initially, the microbial cultures 
were grown overnight and adjusted to a 0.5 McFarland standard using distilled water and lawn 
inoculated onto Mueller-Hinton agar (MHA) plates [28]. A stock solution of 10 mg/ml of each 
compound was prepared and a volume of 20 μL and 10 μL of each sample was inoculated onto 
antibiotic assay discs (6 mm diameter) and placed on the MHA plates. After overnight 
incubation at 37°C, zones of inhibition around the discs were measured using a transparent 
ruler. A control of dimethylsulphoxide (DMSO) only was also used to check its effect on the 
assay.  
4.4.6 Statistical analysis  
Statistical analysis was conducted using IBM SPSS statistics 22 software. The data sets were 
analyzed by one-way ANOVA and the Tukey's post-hoc test. A p-value of <0.05 was 
considered statistically significant. 
X 100 A Control
(Acontrol-Asample) 
% Inhibition activity = 
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4.5 Results and Discussion 
4.5.1 Synthesis and characterization of compounds 
The synthetic scheme for the preparation of compounds is shown in Fig. 2. The multicomponent 
reaction between malononitrile and various benzaldehydes and thiols resulted in the synthesis 
of 1a-1i compounds with good yields.  The purification of these compounds was done by simple 
recrystallization in a methanol solvent. Thus the synthesis process was economical. The 
synthesized compounds were characterized using spectroscopic techniques such as IR NMR 
and were further confirmed by MS. The Scifinder search revealed that compounds 1d, 1e and 
1g have been reported previously [29-31]. The remaining compounds are not reported 
elsewhere, and detailed characterization of the compounds is listed below. 
1a. methyl-3-(6-amino-4-(4-Bromophenyl)-3,5-dicynopyridine-2-ylthio)propanoate : 
White solid; 70% yield; mp 228-230 °C ; C. IR (KBr, cm-1): 3433, 3315, 3214, 2213, 1723, 
1619;    1H NMR (400 MHz, DMSO-d6) δ 7.79 (2H, d, J = 8.5 Hz, H-Ar), 7.50 (2H, d, J = 8.5 
Hz, H-Ar), 3.63 (3H, s, H-CH3), 3.40 (2H, t, J = 6.9 Hz, H-CH2), 2.82 (2H, t, J = 6.9 Hz, H-
CH2), 13C NMR (400 MHz, DMSO-d6) 171.7, 166.5, 159.6, 157.2, 133.1, 131.7, 130.6, 124.0, 
115.2, 115.1, 93.3, 85.8, 51.6, 33.1, 24.9;  HRMS (ESI m/z) [M + H]+: calculated for 
C17H13BrN4O2S, 415.9943, found 415.9882. 
1b methyl 3-(6-amino-4-(4-chlorophenyl)-3, 5-dicyanopyridin-2-ylthio)propanoate: brown 
solid; 74% yield; mp 218-220 °C ; C. IR (KBr, cm-1): 3432, 3316, 3214, 2212, 1717, 1617, 
1549;    1H NMR (400 MHz, DMSO-d6) δ 7. 65 (2H, d, J = 8.6 Hz, H-Ar), 7.57 (2H, d, J = 8.6 
Hz, H-Ar), 3.64 (3H, s, H-CH3), 3.40 (2H, t, J = 6.9 Hz, H-CH2), 2.82 (2H, t, J = 6.9 Hz, H-
CH2), 13C NMR (400 MHz, DMSO-d6) 171.7, 166.5, 159.6, 157.2, 135.2, 132.7, 130.4, 128.8, 
115.2, 115.1, 93.3, 85.8, 51.6, 33.1, 24.9;  HRMS (ESI m/z) [M + H]+: calculated for 
C17H13ClN4O2S, 372.0448, found 372.0389. 
1c. methyl 3-(6-amino-3, 5-dicyano-4-phenylpyridin-2-ylthio)propanoate: yellow solid; 
68% yield; mp 208-210 °C ; C. IR (KBr, cm-1): 3395, 3324, 3230, 2210, 1712, 1647, 1550;    1H 
NMR (400 MHz, DMSO-d6) δ 7. 56 (3H, m, H-Ar), 7.52 (2H, m, H-Ar), 3.64 (3H, s, H-CH3), 
3.40 (2H, t, J = 7.0 Hz, H-CH2), 2.82 (2H, t, J = 7.0 Hz, H-CH2), 13C NMR (400 MHz, DMSO-
d6) 171.7, 166.5, 159.7, 158.3, 133.9, 130.3, 128.7, 128.4, 115.3, 115.2, 93.4, 85.8, 51.5, 33.1, 
24.9;  HRMS (ESI m/z) [M + H]+: calculated for C17H14N4O2S, 338.0837, found 338.0790. 
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1d. 2-amino-6-(benzylthio)-4-p-tolylpyridine-3,5-dicarbonitrile [29]: White solid; 80% 
yield; mp 210-212 °C ; C. IR (KBr, cm-1): 3470, 3441, 3327, 3212, 2216,1614, 1525, 1495;    
1H NMR (400 MHz, DMSO-d6) δ 7. 51 (2H, d, J = 7.3 Hz, H-Ar), 7.40  (2H, d, J = 7.9 Hz, H-
Ar), 7.33  (4H, m, H-Ar),  7.26  (1H, m, H-Ar),  4.50 (2H, s, H-CH2), 2.38 (3H, s, H-CH3), 13C 
NMR (400 MHz, DMSO-d6) 166.2, 159.5, 158.4, 140.2, 137.5, 131.5, 130.9, 129.3, 129.1, 
128.4, 128.3, 127.2 115.3, 115.2, 93.2, 85.9, 67.4, 33.1, 20.9;  HRMS (ESI m/z) [M + H]+: 
calculated for C21H16N4S, 356.1096, found 356.1054. 
1e. 2-amino-6-(benzylthio)-4-(4-bromophenyl)pyridine-3,5-dicarbonitrile [30]: White 
solid; 72% yield; mp 202-204 °C ; C. IR (KBr, cm-1): 3435, 3324, 3219, 2211, 1628, 1492 ;    
1H NMR (400 MHz, DMSO-d6) δ 7. 77 (2H, d, J = 8.56 Hz, H-Ar), 7.50 (4H, m, H-Ar), 7.32 
(2H, m, H-Ar), 7,25 (1H, m, H-Ar)  4.5 (2H, s, H-CH2),  13C NMR (400 MHz, DMSO-d6) 
159.4, 157.3, 137.5, 133.1, 131.7, 130.5, 129.3, 128.4, 127.3, 124.0, 115.1, 115.0, 33.1;  HRMS 
(ESI m/z) [M + H]+: calculated for C17H13BrN4S, 420.0044, found 420.0000. 
1f. 2-amino-6-(benzylthio)-4-phenethylpyridine-3,5-dicarbonitrile: light yellow solid; 70% 
yield; mp 220-222 °C ; C. IR (KBr, cm-1): 3443, 3331, 3213, 2208,1621, 1528;   1H NMR (400 
MHz, DMSO-d6) δ 7. 47 (2H, d, J = 7.6 Hz, H-Ar), 7.30 (4H, m, H-Ar), 7.24 (2H, m, H-Ar), 
7.18 (2H, d, J = 7.34 Hz H-Ar)  4.46 (2H, s, H-CH2), 2.94 (2H, m, H-CH2), 2.85 (2H, m, H-
CH2)  13C NMR (400 MHz, DMSO-d6) 165.9, 159.6, 159.4, 139.4, 137.4,129.2,128.5, 128.4, 
128.1, 127.2, 126.5,114.8, 114.7, 93.2, 85.9, 35.5,34.6, 33.0 HRMS (ESI m/z) [M + H]+: 
calculated for C22H18ClN4S, 370.1252, found 370.1190. 
1g. 2-amino-4-(4-chlorophenyl)-6-(phenylthio)pyridine-3,5-dicarbonitrile[31]: White 
solid; 78% yield; mp 222-224 °C ; C. IR (KBr, cm-1): 3486, 3340, 3220, 2213, 1625, 1647, 
1541, 1519;    1H NMR (400 MHz, DMSO-d6) δ 7. 66 (2H, m, H-Ar), 7.60 (4H, m, H-Ar), 7.50 
(3H, m, H-Ar), 13C NMR (400 MHz, DMSO-d6) 166.1, 159.5, 157.5, 135.3, 134.8, 132.7, 
130.4, 129.7, 129.4, 128.9, 127.0, 115.2, 114.8, 93.3, 87.1; HRMS (ESI m/z) [M + H] +: 
calculated for C19H11ClN4S, 362.0393, found 362.0349. 
1h. 2-(4-methoxyphenylthio)-6-amino-4-phenethylpyridine-3,5-dicarbonitrile: light yellow 
solid; 70% yield; mp 206-208 °C ; C. IR (KBr, cm-1): 3425, 3328, 3229, 2210, 1636, 1591, 
1532;    1H NMR (400 MHz, DMSO-d6) δ 7. 35 (3H, m, H-Ar), 7.23 (3H, m, H-Ar), 7.12  (2H, 
m, H-Ar), 7.04 (1H, m, H-Ar) 3.7 (3H, s, H-CH3), 2.99 (2H, m, H-CH2), 2.89 (2H, m, H-CH2), 
13C NMR (400 MHz, DMSO-d6) 165.7, 159.9, 159.6, 139.4, 130.2, 128.5, 128.1, 126.6, 119.5, 
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115.8, 114.8, 114.5, 55.3, 35.6, 34.6;  HRMS (ESI m/z) [M + H]+: calculated for C22H18N4OS, 
386.1201, found 386.1155. 
1i. 2-((2-(6-amino-3,5-dicyano-4-phenethylpyridin-2-ylthio)ethyl)sulfanyl)-6-amino-4-
phenethyl pyridine-3,5-dicarbonitrile : White solid; 50% yield; mp 262 °C ; C. IR (KBr, cm-1): 
3462, 3429, 3331, 3223, 2209, 1627, 1555 ;  1H NMR (600 MHz, DMSO-d6) δ 7. 32 (4H, t, J 
= 7.54Hz, H-Ar), 7.22 (6H, m, H-Ar), 3.51 (4H, bs, H-CH2), 2.99 (4H, m, H-CH2), 2.89 (4H, 
m, H-CH2), 13C NMR (600 MHz, DMSO-d6) 166.6, 160.2, 160.1, 140, 129, 128.6, 126.9, 
115.3, 115.1, 94.5, 86.8, 35.9, 35.1, 29.7;  HRMS (ESI m/z) [M + H]+: calculated for 
C22H18N4OS, 586.1722, found 586.1688. 
4.5.2 Docking Results.  
Molecular docking analysis for the compounds was carried out using a crystal structure of α-
glucosidase (PDB ID: 3W37), and the binding affinity of the compounds to the enzyme active 
site was then explored. The initial molecular docking validation was performed by re-docking 
acarbose on the protein α-glucosidase (3W37). The confirmation that resulted was compared 
with the experimental co-crystalized structure of acarbose obtained from source pdb files. The 
finest overlapping was observed between the re-docked confirmation and crystal structure as 
shown in Fig. 4.4 and the docking score for acarbose was found to be -8.9. With these 
satisfactory results, the molecular docking calculations for the energy minimized 3D structures 
of the desired ligands were preceded using the same coordinates obtained during the validation. 
The binding scores and observed amino acid interactions of compounds in the enzyme active 
site were reported in Table 4.1. The best binding poses obtained for each ligand-protein 
complex were shown in Fig. 4.5. The compound 1f showed the best affinity with a docking 
score of -8.6, which was similar to that of acarbose. Compounds 1d, 1e, 1f, 1g, 1h and 1i also 
displayed good affinity towards the enzyme active site, with docking scores of -8.1, -8.1, -8.6, 
-7.3, -8.4 and -7.9 respectively. These compounds had aryl or aryl alkyl substituents at position 
6 of the pyridine ring (Table 4.2). The poor docking scores for the compounds; 1a, 1b, 1c, -6.4, 
-6.4, -6.2, respectively, indicated that when the aryl alkyl groups at position 6 of the pyridine 
ring were replaced by alkyl groups, affinity decreased drastically. Additionally, the docking 
studies revealed that the hydrophobic interaction such as π- π stacking between aromatic rings 
were the dominant forces involved in the interaction of compounds in the active pocket of 
enzymes, as fewer or no intermolecular hydrogen bonds were formed with the compounds 
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having best activity. Thus molecular docking identified the best affinity with the molecular 
framework of compound 1f out of all the synthesized compounds. Since the conversion of 
nitrile groups to other functional groups can easily be affected, docking with different functional 
groups such as amine, amide and acid at 3 and 5 positions of the pyridine ring was conducted. 
The change of this nitrile functionality with other functional group did not improve the affinity 
to a significant effect (Table 4.2). Hence our synthesis was confined to nitrile derivatives and 
further conversion was not conducted.  
Table 4.1 Binding energies calculated for the compounds using Autodock Vina software. 
Compound Affinity (kcal/mol) Hydrogen bond interactions Ligand binding site interactions 
Acarbose -8.9 ALA234, ASN237, ARG552, 
ARG552 
ASP357, ILE358, TRP467, HIS626, 
TRP329, TRP432, ASP469, MET470, 
PHE601, ARG552, ASP232, SER497, 
PHE236, ASP568, ALA234, ASN237, 
SER 497 
1a -6.4 none HIS626, MET470, PHE476, PHE601, 
TRP432, TRP467, TRP329 
1b -6.4 - ALA234,ASP232, PHE476, MET470 
1c -6.2 ASP 232 ALA234,ASP232,ARG652, PHE476, 
TRP432, HIS626, PHE601 
1d -8.1 ASP 232 ASP357, HIS626, ALA234, ASP232, 
PHE476 
1e -8.1 ASP232 ASP357, ASP232, ASN237, HIS626,  
ALA234, PHE476 
1f -8.6 - ARG552, PHE601, TRP329, TRP432, 
PHE476, LYS506 
1g -7.3 - ARG662, ASP232, HIS 626, TRP467, 
TRP329,TRP432 PHE 601, PHE236, 
ASP568, MET470 
1h -8.4 - PHE601, TRP329, ARG552,TRP432, 
PHE476 
1i -7.9 ARG552 ALA602, PHE601, PHE236, TRP329, 
ASP232, ARG552, TRP432 
 
  
Chapter 4  Research Results II 
64 
Table 4.2 Binding energies calculated for different derivatives of pyridine using Autodock Vina. 
 
 
Compound Docking scores 
 R1=R3=CN R1=R3=COOH R1=R3=CONH2 R1=R3=CH2NH2 
1a -6.4 -6.2 -6.6 -6.7 
1b -6.4 -6.5 -6.2 -6.5 
1c -6.2 -6.2 -6.4 -6.5 
1d -8.1 -7.6 -7.9 -7.4 
1e -8.1 -7.4 -7.7 -7.3 
1f -8.6 -8.3 -8.4 -7.9 
1g -7.3 -6.7 -7.2 -6.8 
1h -8.4 -8.2 -8.1 -7.8 
1i -7.9 -8.5 -8.6 -7.9 





Figure 4.4 Best docked confirmation of acarbose overlapped with the X-ray binding mode of native 
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Figure 4.5 Binding mode of compounds 1a-1i and acarbose docked in their best conformation into 
the binding site of α-glucosidase (3W37); Hydrogen atoms are not shown for clarity. 
4.5.3 α-Glucosidase inhibitory activity 
The α-glucosidase inhibitory activities of 3, 5-dicyanopyridine scaffolds were evaluated and 
the results are shown in Table 4.3. The data in Table 4.3 suggests that compounds 1a and 1b 
exhibited activities weaker than that of acarbose, whereas compound 1c did not show any 
activity at the tested concentration range. These compounds have alkyl side chains at the 6th 
position of the pyridine ring and the docking studies predicted that alkyl chains entered into the 
active pocket. Low binding scores indicated the loose fitting of alkyl chains inside the active 
pocket and as a consequence, weaker or no activities were observed for these compounds. 
However, when alkyl side chains were replaced by aryl or aryl alkyl groups at the 6th position, 
the activity of the compounds was drastically improved. The compounds 1d, 1e, 1f, 1g and 1h 
showed improved activity in comparison to 1a, 1b and 1c. At a concentration of 125 μg/ml, all 
these compounds exhibited approximately 90% inhibition and at 62.5 µg more than 50% 
inhibition was observed except for the compound 1f. The binding affinity of compound 1f was 
higher than that of compounds 1d, 1e and 1g, although relatively better activities were observed 
for the compounds 1d, 1e and 1g than 1f. Careful analysis of the best scored poses of these 
compounds showed that along with π-π interaction, compounds 1d and 1e also formed hydrogen 
bonds with the ASP 232 of the active site, while compound 1g had a different binding pose with 
aryl groups at 4 position entering the active site. These differences could have caused a better 
affinity between the protein and the compounds 1d, 1e and 1g than with compound 1f. The 
dimer 1i also exhibited good inhibitory activity with more than 50% inhibition at a 
concentration of 62.5 µg/ml. Interestingly, the amine group of the pyridine ring in all the 
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compounds displayed no apparent role in active site binding as no hydrogen bond interactions 
were observed between the amine group of the compound and active site amino acids of α-
glucosidase. The trends observed in the biological activity were well correlated with the 
predictions made by docking studies and indicated that the presence of aryl groups at both the 
4th and 6th positions of the pyridine ring (Table 4.2) is crucial for the best activity. 
Experimental results revealed that, although the π–π stacking interactions were found to be the 
major forces in the ligand -protein complex formation, hydrogen bond interactions also played 
an important role in the inhibitory activities. Introducing polar functional groups such as 
hydroxyl and nitro groups in the benzene ring at the 4th and 6th position of the pyridine ring 
could help in increasing the affinity of the compounds for binding to the active site by forming 
hydrogen bonds inside the active pocket. Thus both the theoretical and experimental results 
obtained in this study helped us to find a logical method for further improvement of compound 
activity.  
Table 4.3 The percentage inhibition values for the inhibition of α-glucosidase by test compounds. 
Compound Concentration (µg/ml) 
1000 500 250 125 62.5 31.25 15.625 
1a 93.73±1.48a 86.03±1.72 a 12.07±5.4b ND ND ND ND 
 
1b 89.47±2.67 a 76.50±1.39b ND ND ND ND ND 
 
1c ND ND ND ND ND ND ND 
 
1d 90.47±1.29 a 93.37±0.68 a 92.90±0.44 a 92.82±0.41 a 71.57±2.48 b  11.9±3.08c ND 
 
1e 94.67±0.19 a 94.73±0.14 a 94.52±0.10 a 93.82±0.92 a 64.65±0.59 b 10.96±0.50c 5.89±0.38d 
 
1f 94.97±0.30 a 94.10±0.21 a 93.38±0.34 a 77.74±3.05b 12.7±1.09c ND ND 
 
1g 94.57±0.6 a 94.68±0.17 a 94.78±0.1 a 92.72±0.97 a 78.69±1.6 b 23.25±1.90c 6.57±4.24d 
 
1h 93.59±0.99 a 93.91±0.31 a 89.42±3.5 a  27.64±4.24b ND ND ND 
 
1i 93.38±1.67a 91.79±0.48 a 91.19±2.26 a 88.15±2.86 a  59.73±2.10 b 12.11±4.12c ND 
 
Acarbose 95.87±1.98 a 93.82±2.12 a 92.89±0.71 a 85.15±1.65b 65.63±0.64c 39.67±3.80d 14.50±1.65e 
ND, No inhibition detected 
All values are expressed as mean ± standard deviation of experiments performed in triplicate. Statistical analysis 
showed that samples with different superscript letters were significantly different from each other (p < 0.05; one-
way ANOVA, Tukey’s post-hoc test). 
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4.5.4 Antibacterial activity 
No significant zone of inhibition was observed for any of the compounds tested in this study. Hence we 
conclude that these compounds do not exhibit antibacterial properties. 
4.6 Conclusion 
In this study, α-glucosidase inhibitory and antibacterial activities of derivatives containing 3,5-
dicyanopyridine were evaluated for the first time. These compounds were synthesized in a 
single step multi-component protocol with good yields from commercially available reagents. 
The binding affinities of the 3, 5-dicyanopyridine with α-glucosidase were calculated using 
Autodock Vina software. The invitro α-glucosidase inhibitory results demonstrated that, 
compounds of the type 1c, 1d, 1e, 1f and 1g showed significant α-glucosidase inhibition. 
However these compounds did not demonstrate any antibacterial activity. After carefully 
examining the theoretical and experimental inhibitory activities, a basic 3, 5-dicyanopyridine 
organic framework which could fit effectively in the enzyme’s active site and inhibit its activity 
was discovered. This will enable us to design more active analogues of these compounds with 
the further introduction of polar groups such as hydroxyl and nitro groups and which are capable 
of forming hydrogen bonds with amino acids in the enzyme’s active site. The findings reported 
in this study may thus help in the development of a new class of antidiabetic compounds.  
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5.1 Abstract 
Computational studies were conducted to identify the favourable formation of the inclusion 
complex of chloramphenicol with cyclodextrins. The results of molecular docking and 
molecular dynamics predicted the strongest interaction of chloramphenicol with γ-cyclodextrin. 
Further, the inclusion complex of chloramphenicol with γ-cyclodextrin was experimentally 
prepared and a phenomenon of inclusion was verified by using different characterization 
techniques such as thermogravimetric analysis, differential scanning calorimetry, 1H nuclear 
magnetic resonance (NMR) and two dimensional  nuclear overhauser effect spectroscopy 
(NOESY) experiments. From these results it was concluded that γ-cyclodextrins could be an 
appropriate cyclodextrin polymer which can be used to functionalize chloramphenicol on the 
surface of silver nanoparticles. In addition, γ-cyclodextrin capped silver nanoparticles were 
synthesized and  characterized using UV-visible spectroscopy, scanning electron microscopy 
(SEM), transmission electron microscopy (TEM), energy dispersive X-ray analysis (EDX), 
Fourier transform infrared spectroscopy (FTIR) and zeta potential analysis. Molecular 
recognition of chloramphenicol by these cyclodextrin capped silver nanoparticles was 
confirmed by surface enhanced raman spectroscopy (SERS) experiments. Synergistic 
antibacterial effect of chloramphenicol with γ-cyclodextrin capped silver nanoparticles was 
evaluated against Pseudomonas aeruginosa (ATCC 27853), Enterococcus faecalis (ATCC 
5129), Klebsiella pneumoniae (ATCC 700603) and Staphylococcus aureus (ATCC 43300). The 
results from the antibacterial experiment were favourable thus allowing us to conclude that the 
approach of modifying organic drug molecules with cyclodextrin capped inorganic silver 
nanoparticles could help to enhance thei antibacterial activity. 
 
5.2 Key words 
Chloramphenicol, inclusion complex, binding free energies, silver nanoparticles, synergistic 
antibacterial activity  
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5.3 Introduction 
The necessity for the discovery of new therapeutic drug formulations to treat bacterial infection 
is increasing due to the emergence of drug resistance. However, the process of discovering, 
developing and clinically testing new antibiotics is time consuming and expensive [1]. In 
addition, the rapid development of resistance to newly introduced chemotherapeutic agents in 
bacteria makes the process of drug development more difficult. Hence, finding new strategies 
to make better use of existing medicine to overcome the problem of resistance has become an 
important area of research. This approach is economically sensible since the toxicological and 
pharmacological properties of the drugs are well known, which would also support rapid 
development of the new treatment [2].  
Several approaches have been reported for overcoming the bacterial resistance for existing 
chemotherapeutic agents, one of which being combination therapy [2]. Combination therapy is 
a standard method in which two or more drugs with different modes of action are combined in 
a precisely controlled manner to maximize therapeutic efficacy and thus combating the problem 
of drug resistance. Recently, the application of inorganic material in association with organic 
drug molecules in combination therapy is drawing much attention [3]. For example, activity of 
amoxicillin, ampicillin, erythromycin, kanamycin and chloramphenicol was found to be 
enhanced in the presence of silver nanoparticles [4, 5]. Similarly, the coating of vancomycin, 
streptomycin, gentamycin, neomycin and acridine derivatives gold nanoparticles has improved 
their antibacterial efficacy [6-8]. Such strategies of combining antibiotics with inorganic 
materials can be very effective due to the ability of inorganic metal ions to target multiple sites 
of a biological system [3]. In this approach, drugs can be functionalized on the solid core surface 
of metal nanoparticles either by covalent or noncovalent interactions. Covalent linking requires 
additional chemical modification of drug molecules, which could result in the alteration of the 
properties of drug molecules [9]. However, non-covalent strategies to functionalize the drug 
molecules on the surface of nanoparticles involves only electrostatic and van der Waal’s 
interactions, and thus drugs can be used in their native form [9]. 
Silver nanoparticles can be a preferred choice among other non-materials for such organic-
inorganic combination antibacterial therapy, due to their innate antibacterial properties and their 
affinity to bind to organic molecules [10]. In addition, the large surface area of nanoparticles 
provides an opportunity for high drug loading and attachment of other surface constituents [10]. 
The antibacterial properties of silver nanoparticles together with the supramolecular chemistry 
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of cyclodextrins (CD) can provide an excellent platform as drug delivery systems with potential 
combination therapeutic applications. The supramolecular chemistry associated with 
cyclodextrins can result in noncovalent incorporation of organic molecules on the surface of 
nanoparticles, thus enhancing the molecular recognition properties of silver nanoparticles. The 
phenomenon of molecular functionalization of organic molecules on the surface of inorganic 
nanoparticle using cyclodextrins has recently been well demonstrated [9, 11, 12]. Since the 
cyclodextrins are available with various cavity sizes, fabrication of nanoparticles with them 
could generate nanomaterials for a variety of biomedical applications.  
In this study, γ-cyclodextrin capped silver nanoparticles (CDAgNPs) were prepared and their 
application in improving the antibacterial efficacy of chloramphenicol (CMP) was investigated. 
Our interest in using the cyclodextrin capped nanoparticles for the enhancement of antibacterial 
efficacy of CMP is based on the fact that cyclodextrins can cause localized high concentration 
of drug on the surface of nanoparticles by encapsulating them into their hydrophobic cavity, 
thereby making the drug effective at lower dosages [13]. Another advantage of this approach is 
that it does not involve chemical modification of the drug thereby allowing the drug to be used 
in its native form.   
5.4 Materials and Methods 
5.4.1 Computational studies 
5.4.1.1 Molecular docking analysis 
To perform molecular docking, the 3D structure of CMP was built in Gauss view software and 
energetically minimized by Austin model 1 (AM1) in the Gaussian 09 software package [14]. 
The 3D structures of α-CD (PDB code: 2ZYM) [15], β-CD (PDB code: 3CGT) [16] and γ-CD 
(PDB code: 2ZYK) [17] were collated from  protein data bank (PDB). Further, these structures 
were pre-processed for docking using Dock prep in the Chimera software package [18]. During 
this process, the missing hydrogen atoms and the atomic charges were added. The binding site 
was defined at the centroid of cyclodextrins. Molecular docking was carried out independently 
to generate the inclusion complex of CMP with three different cyclodextrins using AutoDock  
[19].  
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5.4.1.2 Molecular dynamics analysis 
The inclusion complexes of CMP with three different cyclodextrins were subjected to molecular 
dynamics (MD) studies. The software package of AMBER 14 (Assisted Model Building with 
Energy Refinement) was used to conduct MD simulation (GPU version of PMEMD engine 
integrated with AMBER 14) [20]. The LEAP module was used to add hydrogen atoms, counter 
ions, charge, solvated water, and simulation box. The system of the inclusion complex was 
contained in solvated TIP3P water box [21, 22]. The atom types for the inclusion complexes 
were set using Antechamber module. Conjugate gradient energy minimization was run up to 
1000 steps. During the simulation, all the residues in the inclusion complex were allowed to 
move. The simulations were set to 50 ps of heating from 0 to 300 K with the harmonic restraints 
of 5 kcal mol-1 Å-2 for solute atoms and a Langevin thermostat with a 1ps random collision 
frequency. Further, the system was equilibrated for 500 ps at 300 K. MD runs were set for 10 
ns in an isothermal isobaric (NPT) ensemble using a Berendsen barostat with a target pressure 
of 1 bar. After the MD simulation, the trajectories were visualized using graphical user interface 
of the UCSF Chimera package [18]. The binding free energies were then computed for all three 
inclusion complexes of chloramphenicol. Molecular Mechanics–Poisson–Boltzmann surface 
Area (MM–PBSA) was employed to calculate the binding free energies. The binding free 
energies were averaged over 200 snapshots taken from the post-equilibrated 10 ns MD 
trajectory [23-28]. 
5.4.2 Preparation of inclusion complexes and physical mixture 
The inclusion complex of CMP was prepared by the freeze drying method described by 
Lakkakula et al. [29]. Chloramphenicol (Duchefa Biochemie; 0.1 g) and γ-CD (Wacker 
Chemie; 0.402 g) were dissolved in 25 ml of double distilled water in 1:1 molar ratios and 
stirred at room temperature for 24 h. The clear solution obtained was frozen at -72°C and 
lyophilized to yield a white amorphous solid. Physical mixture of CMP and γ-CD was obtained 
by mortaring a 1:1 mixture of each sample. 
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5.4.3 Synthesis of γ-CD capped silver nanoparticles 
Methodology reported by Premkumara et al. was employed for the synthesis of nanoparticles 
[30]. Briefly, 50 ml of 5 mM γ-cyclodextrin and 100 ml of 20 mM sodium hydroxide solution 
were added to 50 ml of 2.5 mM silver nitrate (Merck). The resulting black solution was 
incubated at 30°C in an orbital shaker at 150 rpm for 24 h. The solution turned yellow after 24 
h and the presence of nanoparticles in the solution was confirmed by UV absorbance. The 
reaction mixture was subsequently centrifuged at 12000 rpm (Eppendorf 5810R, Rotor F-34-6-
38) for 10 minutes and the pellet obtained was washed three times with 50 ml deionized water 
to remove excess base. The resulting pellet of CDAgNPs was suspended in 10 ml deionized 
water and used as the stock solution for all the experiments. 
5.4.4 Characterization of the inclusion complex and silver nanoparticles 
Powder X-ray diffraction (XRD) patterns were obtained at ambient temperature by employing 
Bruker D8 Advance instrument equipped with an Anton-Paar XRK 900 reaction chamber and 
a Cu radiation source with a wavelength of 1.5406 Å. Infrared spectra of CMP, cyclodextrin 
and inclusion complex were recorded on a Perkin Elmer Spectrum 100 FT-IR spectrometer 
with universal ATR sampling accessory. Thermogravimetric analysis-differential scanning 
calorimetry (TGA-DSC) was performed on SDT Q600 TA instrument at a heating rate of 10°C 
min-1 over a wide temperature range (25-800°C) under nitrogen atmosphere. SEM 
morphological images of the samples were obtained using a scanning electron microscope 
(FEGSEM ZEISS ULTRAPLUS)  with an excitation voltage of 20 kV and 10000 X 
magnification. Samples were placed on adhesive carbon tape glued over aluminium stub and 
made electrically conductive by thin gold coating in vacuum prior to the analysis. Nuclear 
magnetic resonance (NMR) experiments were conducted on a Bruker AvanceIII 600 MHz 
spectrometer at 30°C. Samples were dissolved in deuterium oxide. Chemical shifts (δ) were 
recorded using tetramethylsilane (TMS) as an internal standard and the spectra obtained were 
referenced to the residual water signal of D2O. The spectrometers were equipped with a BBOZ 
probe. In the 1H-1H NOESY experiment, the mixing time was 300 ms and relaxation time was 
1s.  
The reduction reaction of silver ions to silver nanoparticles was confirmed by UV visible 
absorption measurements at room temperature as a function of time using Specord 210, 
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Analytikjena spectrometer. The nanoparticle pellet obtained after washing was freeze dried and 
used for the FTIR studies (Perkin Elmer Precisely Spectrometer 100 FTIR-ATR). 
Morphological studies of the synthesized CDAgNPs were carried out using scanning electron 
microscopy (FEGSEM ZEISS ULTRAPLUS). Samples were prepared by adding a drop of 
sonicated nanoparticle solution over the carbon tape glued over an aluminium grid. The samples 
obtained were then coated with a gold layer and observed at 10000 X magnification. The energy 
dispersive X-ray analysis (EDX) was performed at 20 kV using AZTEC software for the 
analysis. The silver nanoparticle solutions obtained after the purification step were sonicated 
for 15 minutes to disrupt any possible aggregates and small amount of the resulting suspension 
was placed on carbon coated copper grids and dried by solvent evaporation. High-resolution 
TEM images were obtained on a JEOL TEM model no 2100 operating at an accelerating voltage 
of 200 kV and 0.23 nm resolution. The zeta potential and zeta size of the synthesized CDAgNPs 
was determined at 25°C using a Zetasizer Nano ZS90 (Malvern Instruments Ltd., UK). The 
ICP-OES instrument (PerkinElmer Precisely, optima 2100 DV) equipped with WinLab32 
software was used to measure the concentration of silver nanoparticles. A 1 ml stock solution 
of CDAgNPs was digested with 8 ml of 65% nitric acid on a hot plate set at 900C and the 
resulting solution was diluted to 100 ml [31]. The Silver nitrate solution of concentration 1.625-
50 ppm was used to generate a standard curve, which were then used for measurement of the 
unknown concentration. A nitric acid blank prepared similar to the unknown sample was used 
to compensate for the effect of nitric acid during analysis. The Raman and surface enhanced 
raman spectroscopy (SERS) experiments were conducted using a Raman spectrometer 
(Manufacturer: Delta Nu, Model: Advantage 532). The instrument was equipped with solid 
state 532 nm Nd:Yag crystal laser and charged couple device (CCD) detector.  
5.4.5 Chloramphenicol γ-cyclodextrin capped CDAgNPs composite preparation 
and characterization 
Briefly, to a 5 ml of 1 mg/ml stock solution of γ-cyclodextrin capped CDAgNPs, 5 ml solution 
of 1 mg/ml of CMP was added. The resulting solution was incubated at 30°C in an orbital shaker 
at 150 rpm for 24 h. The effect of CMP coating on size and stability of γ-cyclodextrin capped 
CDAgNPs was assessed by zeta potential and zeta size at 25°C using a Zetasizer Nano ZS90 
(Malvern Instruments Ltd., UK).   
 




5.4.6 Antibacterial activity 
The synthesized γ-cyclodextrin capped CDAgNPs, CMP and CMP coated CDAgNPs were 
tested for their antibacterial activity against Pseudomonas aeruginosa (ATCC 27853), 
Enterococcus faecalis (ATCC 5129), Klebsiella pneumoniae (ATCC 700603) and 
Staphylococcus aureus (ATCC 43300) by micro broth dilution method in 96 well micro titre 
plates using Tryptic Soy (TS) broth [32]. Three day old single colonies of these organisms from 
the TS agar plates were inoculated into TS broth and sub-cultured at 37°C with shaking at 160 
rpm for 24 h. 0.5 McFarland standards of each organism were prepared by adjusting the optical 
density of overnight cultures at 600 nm. The percentage inhibition of growth of the bacteria by 
the test samples was determined by monitoring the growth of bacteria in an automated 
microplate reader (Synergy HT, BioTek Instruments) at 600 nm [32, 33]. Serial two-fold 
dilutions (100 µl) of CDAgNPs, CMP and CMP coated CDAgNPs solutions were prepared in 
sterile 96 well plates using stock solutions of CDAgNPs (5 mg/10 ml), CMP (5 mg/10 ml) and 
CMP coated CDAgNPs solutions (5 mg of CDAgNPs + 5 mg of CMP in 10 ml). The wells 
were then inoculated with 100 µl of diluted broth culture (initially adjusted to 0.5 McFarland 
turbidity standards) and incubated at 37°C for 24 h. Control wells were prepared by adding 100 
µl of sterile distilled water and 100 µl of bacterial suspension. All the experiments were carried 





Where, I is the percentage inhibition of growth, C24 and C0 are the optical density at 600 nm of 
the control wells of the organism at 24 h and 0 h respectively, T24 and T0 are the optical density 
at 600 nm of the sample wells at 24 h and 0 h respectively. 
 
5.4.7 Statistical analysis 
Statistical analysis was conducted using IBM SPSS statistics 22 software. The data sets were 
analysed by one-way ANOVA and the Tukey's post-hoc test. A p-value of <0.05 was 
considered statistically significant. 
(C24-C0)
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5.5 Results and discussion 
5.5.1 Prediction of the binding mode of chloramphenicol inside cyclodextrins  
The results of molecular docking were ranked based on docking scores and root mean square 
deviation (RMSD) (Table 1). The top ranked pose of CMP with its corresponding cyclodextrin 
was chosen as the best inclusion complex for further molecular dynamics analysis. The 
inclusion complex of CMP with γ-CD was found to be the strongest with a docking score of -
5.3, when compared to α-CD and β-CD, which had scores of -4.7 and -5.2 respectively. Top 
three ranked docking scores of CMP varies from (-5.3 to -5.2) for γ-CD, (-5.2 to -5.2) for β-CD 
and (-4.7 to -4.6). The maximum docking score of (-5.3) and lowest RMSD values were 
obtained for the complex of CMP with γ-CD (Table 5.1). These results suggested the 
favourable formation of CMP inclusion complexes with γ-CD. This could be due to larger 
cavity volume of γ-CD to accommodate CMP inside the cavity. The lower cavity volume of α-
CD did not help to sandwich the CMP inside the cavity leading to lower docking scores. In the 
binding pose of CMP -γ CD, chlorine atoms and aromatic nitro group of CMP were respectively 
oriented toward the primary and secondary hydroxyl rim of cyclodextrins. A similar binding 
mode was also obtained in the CMP - β-CD inclusion complex. The CPM formed three 
hydrogen bonds with γ-CD (2º OH, NH and nitro group of CPM) and one hydrogen bond with 
β-CD (NH of CPM) as well as α-CD (2º OH). In the inclusion complex of CPM-α-CD, the 
aromatic nitro group of CPM penetrated the cavity whereas the rest of the molecule remained 
out of the cavity (Fig. 5.1a). However, the entire molecule penetrated the cavity in β-CD (Fig. 
5.1b) and in γ-CD (Fig. 5.1c). The formation of three hydrogen bonds in CPM- γ-CD suggests 
a strong stability as well as tight interaction of CPM with γ-CD and the favourable formation 
of inclusion complexes. 2º OH and NH group of CPM served as hydrogen bond donors whereas 






Figure 5.1 The binding mode of CMP inside the cavity of a) α-cyclodextrin b) β-cyclodextrin and c) 
γ-cyclodextrin. 
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Table 5.1 Docking scores of chloramphenicol with three different cyclodextrins. 
Cyclodextrin Ligand Docking Scores RMSD 
  1st Rank 2nd Rank 3rd Rank 1st Rank 2nd Rank 3rd Rank 
α-CD CMP -4.7 -4.6 -4.6 0 3.6 1.3 
β-CD CMP -5.2 -5.2 -5.2 0 3.8 3.9 
γ-CD CMP -5.3 -5.3 -5.2 0 0.6 2.9 
 
5.5.2 Host-guest interactions of chloramphenicol and cyclodextrins 
Molecular dynamic simulation was performed to refine the stable conformation of the inclusion 
complex of chloramphenicol with cyclodextrins, and was followed to compute the binding free 
energies of the inclusion complexes. Further, this study helped to understand the guest-host 
interactions in the form of binding free energies. The estimated binding free energies were 
found to be -12.6103 kcal/mol, -24.0756 kcal/mol and -29.7697 kcal/mol for the inclusion 
complex of CMP-αCD, CMP-βCD, and CMP-γ CD respectively (Table 5.2). The results of MD 
suggested the favourable formation of inclusion complexes of CMP from γ-CD (Fig. 5.2). The 
higher binding energy of the CMP-γ CD inclusion complex is attributed to larger cavity volume 
of γ-CD. The van der Waals interaction energy was found to be a crucial factor in determining 








Figure 5.2 The minimum energy conformation of chloramphenicol with a) α-cyclodextrin b) β- 
cyclodextrin and c) γ-cyclodextrin obtained from molecular dynamic simulations. 








5.5.3 X-ray powder diffractometry 
The X-ray diffraction pattern of synthesized inclusion complexes were compared with pure 
CMP, γ-CD and their physical mixture. Inclusion complex formation is accompanied by 
changes in the crystalline properties of the guest and host molecules involved, which can be 
studied by observing disappearance, decreased intensity, broadening and appearance of new 
peaks in the diffractogram [34]. As shown in Fig. 5.3, the diffractogram of γ-CD has several 
sharp peaks at 2θ = 12, 16.5, 19 and 22 (Fig. 5.3b) whereas CMP has sharp peaks at 2θ = 13, 
16, 18, 19.5, 21, 24.5 (Fig. 5.3a), indicating that both the host and guest are crystalline in nature. 
The diffractogram of the physical mixture (Fig. 5.3c) of CMP and γ-CD was found to be 
different from that of native CMP and γ-CD. However, the presence of sharp peaks indicates 
only a partial inclusion, and thus it can be concluded that simple mixing did not result in the 
formation of complete inclusion complexes. Inclusion complexes produced a completely 
different diffractogram (Fig. 5.3d) to that of CMP and γ-CD, and contained broad peaks 
confirming the change in crystalline properties of guest CMP and host γ-CD. These significant 
changes in 2 values and appearance of new crystalline phase confirms the encapsulation of 
guest CMP by host γ-CD [35, 36].  
Inclusion complexes ΔGbind ΔGgas ΔGsol 
CMP/α-CD -12.6103±11.3191 -16.1487±14.4924 3.5383±3.3728 
CMP/β-CD -24.0756±02.0881 -26.4006±02.3139 2.3250±0.8135 
CMP/γ-CD -29.7697±03.3833 -29.3537±03.6753 -0.4160±0.5021 
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5.5.4 FTIR-ATR spectroscopy measurements 
FTIR spectra of CMP, γ-CD, physical mixtures and inclusion complexes are presented in Fig. 
5.4. The major changes observed in FTIR is that the band at 3270 cm-1 corresponding to 
hydroxyl groups of γ-CD was broadened in the inclusion complex compared to free 
cyclodextrin. CMP was characterized by the presence of broad bands at 3257 cm-1, 3079 cm-1, 
2961 cm-1, and 2903 cm-1 for the primary and secondary OH groups and NH group. The peak 
at 1682 cm-1 is due to the carbonyl frequency. The peaks at 1516 cm-1 and 1343 cm-1 indicates 
the presence of nitro groups. The position of these bands is slightly shifted to a higher frequency 
of 1520 cm-1 and 1346 cm-1 in the inclusion complex. These changes in the FTIR spectroscopy 
suggests the existence of van der Waals interaction between CMP and γ-CD [37].  
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Figure 5.4  FTIR spectra of a) CMP b) γ-CD c) Physical mixture and d) Inclusion complex. 
 
 
5.5.5 Scanning electron microscopy 
The surface morphology of CMP appeared as irregularly shaped structures (Fig. 5.5a), whereas 
pure γ-CD appeared as parallelogram shapes (Fig.5.5b). The physical mixture appeared as a 
mixture of both of the components described above (Fig. 5.5c). However, inclusion complexes 
were seen as a single component with regular rectangular or cuboidal shapes unlike the physical 
mixture where individual components (CMP and γ-CD) could be identified. (Fig. 5.5d). These 
drastic changes resulting in the single solid morphology confirms interaction between CMP and 
γ-CD, which is a consequence of inclusion complex formation [38]. 
Chapter 5  Research Results III 
83 
 
Figure 5.5 The morphological appearance of a) CMP b) γ-CD c) Physical mixture and d) Inclusion 
complex. 
5.5.6 Thermogravimetric and differential scanning calorimetric analyses 
Thermal degradation studies were conducted on CMP, γ-CD, and their physical mixture and 
inclusion complexes under nitrogen atmosphere. The percentage of weight loss as a function of 
temperature is plotted in Fig. 5.6 in the temperature range of 25°C to 800°C. The CMP started 
to decompose at approximately 200°C and the maximum weight loss appeared at 280°C (Fig. 
5.6a). Two weight loss events were observed for host γ-CD (Fig. 5.6b). The dehydration of 
cyclodextrin appeared first between 25°C and 125°C, followed by maximum weight loss at 
325°C, due to decomposition of cyclodextrin macrocycles. Inclusion complexes underwent 
weight loss in three different stages (Fig. 5.6d). The first weight loss was at 59°C which could 
be due to dehydration. The second weight loss begun at approximately 225°C with maximum 
weight loss at 255°C, whilst the third weight loss appeared at 290°C. The second weight loss 
could be due to the decomposition of cyclodextrin macrocycles indicating that cyclodextrin 
decomposes first, followed by decomposition of the encapsulated CMP at 290°C. In addition, 
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decomposition of free CMP started at 200°C and free cyclodextrin at 298°C, but for the 
inclusion complex the decomposition started at 225°C indicating that thermal stability increased 
for the guest CMP and decreased for the host cyclodextrin when they form inclusion complexes 
[39]. Furthermore, the DSC curve of CMP showed a sharp endothermic peak at 152°C with no 
weight loss, suggesting crystalline CMP melted at this temperature. This peak did not appear 
in the DSC thermogram of inclusion complexes, indicating that chloramphenicol is 
encapsulated by cyclodextrin which results in loss of its crystalline nature [40]. Thus DSC 
analysis further confirms the formation of inclusion complexes. The DSC curve of the physical 
mixture also contained the endothermic peak at 152°C (Fig. 5.6c) indicating that simple mixing 
















Figure 5.6 TGA (solid line) and DSC (dashed line) curves of a) CMP b) γ-CD c) Physical mixture and 
d) Inclusion complex. 
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5.5.7 NMR analysis 
The formation of inclusion complexes was studied by 1H NMR. Fig. 5.7 shows the 1H NMR 
spectra of CMP, CD and their inclusion complex. The values of chemical shift for different 
protons are listed in Tables 5.3 and 5.4. Since the chemical shift values of CMP and γ-CD were 
merging in the 1H NMR spectrum of inclusion complex, the exact δ values were determined by 
correlating protons with corresponding carbons in HSQC spectrum (Fig. 5.8a). It was found 
that the H3 and H5 protons of γ-CD are shifted the most, confirming the presence of guest CMP 
in the cavity of γ-CD [41]. The lipophilic microenvironment in the cyclodextrin cavity will be 
highly affected when non polar guests form inclusion complexes and hence protons lying inside 
the cyclodextrin cavity H3 and H5  will be the most shifted in 1H NMR spectra [41]. 
Furthermore, all the protons of cyclodextrin shifted up-field, whilst the protons of CMP 
behaved differently. The protons named H1’ and H6’ shifted up-field, while all other protons 
of CMP shifted downfield. These changes in the shifts can be considered as direct evidence for 
the existence of noncovalent interaction between host γ-CD and guest CMP [42]. 
 













γ-CD proton δ(free) δ(complex) Δδ = δ(free) - δ(complex) 
H1 5.0544 5.0388 0.0156 
H2 3.5994 3.5918 0.0076 
H3 3.8779 3.8481 0.0298 
H4 3.5335 3.5223 0.0112 
H5 3.7975 3.7610 0.0365 
H6 3.8140 3.7987 0.0153 
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AP proton δ(Complex) δ(free) Δδ = δ(Complex)- δ(free) 
H1' 8.1551 d 8.17895 d -0.02385 
H2' 7.58090 d 7.57070 d 0.01020 
H3' 5.15315 d 5.13330 d 0.01985 
H4' 4.17870 m 4.16540 m 0.01330 

















Figure 5.7 1H NMR spectra of  a) CMP,  b) γ-CD and c) Inclusion complex of CMP with γ-CD. 
To obtain more details about the inclusion structure, a 2D NOESY experiment was conducted 
on the inclusion complex. In the rigid structure of cyclodextrin, H2 and H4 protons arranged 
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outside of the cavity of cyclodextrin [43]. The H4 proton lies towards the narrow end of the 
cavity or the primary face of cyclodextrin and the H2 proton lies towards the large cavity side 
or secondary face of cyclodextrin [43]. H3 and H5 protons are expected to fall inside the cavity 
[43]. In the 2D spectra, there was no NOESY correlation between H1’ and H2’ aromatic protons 
of CMP and H3 and H5 protons of cyclodextrin. However, there was a weak NOESY 
correlation between the H1’ of CMP and H2 proton of cyclodextrin (Fig. 5.8b).  
 
 
Figure 5.8 A) HSQC spectrum of inclusion complexes B) Expanded region of 2D NOESY spectrum 
showing 1H-1H NOE interaction between aromatic protons of CMP and γ-CD. 
a) 
b) 
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At the same time, there was no NOESY interaction with the H4 proton of cyclodextrin which 
is also outside the cavity. These observations collectively suggest that the benzene ring of CMP 
is close to the outer secondary face of the cavity whilst the aliphatic part of CMP lies inside the 
cavity of γ-CD. Molecular models generated in computational studies predicted a similar mode 
of inclusion. 
5.5.8 Characterization of nanoparticles 
The reaction mixture for the synthesis of nanoparticles turned yellowish brown after 24 h 
incubation. The formation of nanoparticles was confirmed by observing surface plasmon 
resonance at 412 nm in the UV visible spectroscopy studies (Fig. 5.9a). The organic capping 
on the surface of nanoparticles was confirmed by IR studies. The steric repulsion between the 
capped molecules contributes to the stability of nanoparticles. The major IR bands at 3000, 
1631, 1514, and 1055 cm−1 (Fig. 5.9b) were observed. The broad nature of the IR peak at 3000 
cm−1 for CDAgNPs referred to the strong stretching vibrations of -OH functional groups of 
cyclodextrin. The bands at 1160 cm-1 and 1055 cm-1 can be assigned to the ether linkages or –
C-O- functional group. The band around 1638 cm-1 for CDAgNPs can be assigned to -COO- 
stretching vibrations of the carbonyl functional group, which could be due to the oxidation of 
the primary hydroxyl groups to carboxylic acid during the synthesis of nanoparticles. SEM 
analysis displayed the particles or cluster-like structures with a size less than 200 nm (Fig. 5.9c), 
and the EDX analysis confirmed that the particles were composed of elemental silver (Fig. 
5.9d). The peaks of carbon and oxygen in the EDX pattern could be due to the presence of 
cyclodextrin capping on the surface of the nanoparticle. The other elemental peaks of gold and 
aluminium are due to the gold coated aluminium grid used for the analysis. TEM analysis 
showed that CDAgNPs were predominantly spherical or polyhedral in shape (Fig. 5.9e), and 
majority of the CDAgNPs were 20-30 nm in size (mean±SD = 23.99±4.36, n=200). The clear 
lattice fringes in the selected area diffraction pattern confirms the presence of polycrystalline 
CDAgNPs in the sample (Fig. 5.9e inset) [44]. The dynamic light scattering experiments 
provided more information about the size and stability of the nanoparticles. The electric charge 
on the surface of the nanoparticles measured in terms of Zeta potential was found to be −30.1 
mV and the average hydrodynamic size was 54.87 nm (Fig. 5.10a and 5.10c). When coated 
with CMP, the Zeta potential of CDAgNPs was slightly decreased to -27.6 mV and the average 
hydrodynamic size was 55.70 nm (Fig. 5.10b and 5.10d). Thus it confirms that the size and 
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stability of the nanoparticles was not altered to a significant extent after the coating with CMP. 
The lower PDI values suggests good mono-dispersity and high surface negative Zeta potential 
indicates good stability of the nanoparticle both in the presence and absence of CMP [45]. The 
concentration of the silver in the 10 ml stock solution of CDAgNPs prepared after purification 














Figure 5.9 a) UV–Vis spectra, b) FTIR ATR spectra, c) SEM morphology analysis, d) EDX pattern, 
e) HRTEM micrograph (inset SAED pattern), f) Histogram. 
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Figure 5.10 Zeta potential of a) AgNPs, b) CMP coated AgNPs and Zeta size of c) AgNPs, d) 
CMP coated AgNPs. 
5.5.9 Raman spectroscopy studies 
Surface enhanced Raman spectroscopy (SERS) is a powerful analytical method and was used 
to investigate CMP coating on the surface of cyclodextrin capped CDAgNPs in aqueous media 
[46]. Cyclodextrin can act as both a reducing and stabilizing agent, and can self-assemble on 
the surface of silver nanoparticles. Furthermore, the lipophilic cavity of cyclodextrin molecules 
provides a microenvironment into which appropriately sized non-polar drug moieties can enter 
to form drug-loaded nanoparticles. Thus, the functionalization of silver nanoparticles with 
appropriate cyclodextrins will introduce the molecular recognition properties to a metal surface 
and increase the ability of nanoparticles to absorb high concentrations of organic compounds 
[47]. The adsorption and sensing of CMP on colloidal γ-CD capped CDAgNPs was studied 
using SERS. Compared with the normal Raman spectrum of CMP in aqueous solution, a 
noticeable enhancement in the intensity and frequency shifts was observed in SERS of CMP 
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indicating that CMP is encapsulated into the cyclodextrin cavity on the surface of the 
nanoparticle. This encapsulation confirms the close contact of CMP to the metal surface 
because when the molecules are close to the metal surfaces, Raman signals appear at a higher 
magnitude. This could be due to the enhancement of polarizability of the molecule by chemical 
or electromagnetic interaction with the metal surface [48]. These interactions enhance the 
electric field of the laser beam, leading to an increase in resonance enhancement of molecules. 
The Raman spectra of CMP solid and CMP solution state in the presence and absence of 
nanoparticles are also presented (Fig. 5.11). Sample preparation for SERS was done according 
to a previous report [49]. Briefly, 1 ml of 3 mM CMP solution was mixed with 1 ml of γ-CD 
capped silver nanoparticles. All of the reported spectra represent an average of three scans with 
20 s integration time at medium laser power. An assignment of SERS bands was performed by 
the comparison of the Raman spectra of both compounds in the solid state and in solutions. 
In the Raman spectra of cyclodextrin capped CDAgNPs, the dominant peak was observed at 
1414 cm-1 and can be assigned to symmetric stretching vibration of the carboxylate functional 
group [50]. The presence of this peak supports the concept that primary hydroxyl groups of 
cyclodextrin were oxidized to carboxylic acid while silver ions were reduced to silver metals 
[30]. Further, the strong intensity of this peak suggests that carboxylate ion binds to silver metal, 
acts as an anchor, and holds cyclodextrin on the surface of the nanoparticle [50]. The peaks at 
949 cm-1 and 806 cm-1 could be due to the ring breathing vibrations of glucose rings [51].  
The Raman spectra of solid chloramphenicol contained peaks for carbonyl stretching (1692 cm-
1), aromatic ring stretching (1609 cm-1), -NO2 symmetric stretching (1361 cm-1), CH2 twisting 
(1251 cm-1), NH in plane bending (1114 cm-1), C-H out of plane bending (983 cm-1), C-C 
stretching (940 cm-1), -NO2 scissoring (854 cm-1), ring breathing (767 cm-1), and C-Cl 
symmetric stretching (632 cm-1) [49, 52, 53]. An aqueous solution of CMP at a concentration 
of 1.5 mM did not show any of these Raman peaks. However, in the presence of cyclodextrin 
capped CDAgNPs, the intensity of some of the peaks of CMP was significantly enhanced and 
were shifted to lower frequency as compared to pure CMP. The intensity of C=C stretching 
frequency of the benzene ring was most enhanced and appeared at the lower frequency region 
of 1605 cm-1 (SERS experiment) as compared to 1609 cm-1 of pure CMP (Raman 
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spectroscopy). The peaks at 1361, 1297 and 1251 cm-1 were also enhanced and shifted to lower 
frequency at 1350, 1288 and 1244 cm-1, respectively. However the carbonyl frequency of CMP 
did not show up in the SERS spectra. Certain peaks which are strong in conventional Raman 
spectra analysis may not appear in SERS. This could be attributed to the orientation or mode of 
adsorption of respective functional groups on the surface of nanoparticles [53, 54]. Similarly 
for CDAgNPs, the peak observed at 1414 cm-1 can be assigned to -COO- stretching of 
cyclodextrin and this peak shifted slightly to a lower frequency of 1410 cm-1. These major 
changes in the Raman signals confirms that cyclodextrins adsorbed on the surface of CDAgNPs 
acted as a molecular host and expressed their inclusion formation characteristics with CMP on 
the surface of nanoparticles [54]. In a previous study, based on surface plasmon resonance, 
calixarene capped CDAgNPs were found to be ineffective for molecular recognition of CMP 
[55]. Our studies prove thus that cyclodextrins can be more suitable supra-molecules for CMP 











Figure 5.11 Raman Spectrum of a) 1.5 mM CMP solution and b) AgNPs. c) SERS spectrum of CMP, 
d) Raman spectrum of solid CMP. 
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5.5.10 Antibacterial Results 
The antibacterial activity of CDAgNPs, CMP and CMP functionalized CDAgNPs were 
determined by measuring the percentage inhibition of bacterial growth using the quantitative 
micro-titre well dilution method (Table 5.5). Chloramphenicol was found to be active at high 
concentrations against all the bacteria tested. The activity of CMP was found to gradually 
increase with an increase in concentration, with more than 90% inhibition being observed at a 
concentration of 150 μg/ml. CDAgNPs were found to be relatively less active when compared 
to the CMP. P. aerugonisa was the most sensitive to the CDAgNPs, with the highest 
concentration of nanoparticles resulting in 70% inhibition, whereas only 30-40% inhibition was 
observed for the other bacterial species. No significant activity was observed for the 
CMP/CDAgNPs below the concentration of 25 μg/ml. However, when CMP was coated on 
CDAgNPs, the antibacterial activity of CMP was significantly enhanced. The enhanced 
antibacterial activity by synergistic effect of CDAgNPs and CMP were clearly observed at 
lower concentrations. CMP alone exhibited 78% inhibition against P. aeruginosa at a 
concentration of 62.5 μg/ml and in the presence of CDAgNPs at the same concentration, CMP 
completely inhibited (p < 0.05) growth of P. aerugonisa. Similarly, CMP presented 76%, 64% 
and 74.27% activity against E. faecalis, K. pneumoniae, and S. aureus respectively at a 
concentration of 125 μg/ml. In the presence of CDAgNPs at the same concentration, more than 
90% inhibition (p < 0.05) was observed. Similar trends were observed at other lower 
concentrations. The enhanced antibacterial effects can be explained by two mechanisms. The 
CMP can cease the growth of bacteria by affecting the protein synthesis, while silver ions exert 
their bactericidal properties by targeting multiple sites [10, 56]. Thus two different mechanisms 
can cause synergistic activity resulting in the enhanced antibacterial activity. Moreover, the 
inclusion formation ability of cyclodextrins could immobilize the CMP molecules on the 
surface of metal nanoparticles and thus resulting in localized high doses of drug concentration. 
When bacteria are exposed to such localized concentrations of drugs, higher level of interaction 
between the drug and the bacterial cell surface can occur resulting in higher antibacterial 
activity [5]. This phenomenon of localization also makes the nanoparticles an effective drug 
delivery system. Although CMP is classified as a broad spectrum antibiotic, its usage is limited 
by neurotoxicity and bone marrow toxicity in chemotherapy [57]. The antibacterial effects of 
silver combined with molecular recognition properties can be exploited to generate a 
combination therapy in which CMP can be used at lower doses and thus its side effects can be 
minimized.  
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Table 5.5 Percentage inhibition of different bacterial species in the presence of CDAgNPs, CMP 
and CMP coated CDAgNPs at different concentrations 
Microorganism Sample Concentrations (μg/ml)*  
  




































































































ND, No growth inhibition detected 
*All values are expressed as mean ± standard deviation of experiments performed in triplicate. 
Different superscript letters presented in each column are significantly different from each other 
(p < 0.05; one-way ANOVA, Tukey’s post-hoc test) 
5.6 Conclusions 
In this study, three different cyclodextrin supramolecules have been studied for their 
complexing ability with chloramphenicol using molecular modelling techniques. The computed 
binding free energies indicated the strong interaction between γ-cyclodextrin and 
chloramphenicol. To further confirm the results observed in theoretical calculation, the 
inclusion complex of chloramphenicol with γ-cyclodextrin was synthesized and thoroughly 
characterized. The results of computational studies were found to be well correlated with the 
experimental results to explain the favourable formation of inclusion complex. Thereafter γ-
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cyclodextrin capped silver nanoparticles were prepared, characterized and confirmed for their 
ability to molecular recognition of chloramphenicol using surface enhanced Raman 
spectroscopy studies. Also the chloramphenicol γ-cyclodextrin capped silver nanoparticles 
composite was prepared and evaluated for their synergistic antibacterial effects. The 
enhancement in the antibacterial activity of chloramphenicol was observed when applied 
together with cyclodextrin capped silver nanoparticles. Thus it was concluded that cyclodextrin 
capped silver nanoparticles are the attractive supramolecular hosts and can complex a wide 
variety of organic drug molecules on the surface of silver nanoparticles. This property of 
complexing ability of cyclodextrin capped silver nanoparticles can be exploited to generate 
biosensors, drug delivery systems or new and effective pharmaceutical formulations for 
combination therapy. 
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Novel organic salts of fluoroquinolones (ciprofloxacin and norfloxacin) were prepared using 
biocompatible quinic acid in a direct protonation reaction in which water served as the solvent 
followed by the freeze-drying approach. The salts were characterized by spectroscopic 
techniques that included FTIR-ATR, NMR and MS. Additionally salts were also evaluated by 
thermal analysis (DSC and TGA) and X-ray diffraction. The water solubility of the newly-
formed salts was analyzed, followed by determination of their octanol-water partition 
coefficients. The cytotoxicity of newly synthesized salts was evaluated in comparison to their 
commercially available  fluoroquinolone-hydrochloride salts in vitro using the mammalian 
VERO cell line. The results of this study indicate that salts were amorphous and highly water 
soluble when compared to their respective parent pharmaceutical compounds. Interestingly the 
fluoroquinolone-quinic acid salts were similarly biocompatible to their currently available 
fluoroquinolone-hydrochloride salt forms. This study demonstrates that rational design and 
development of innovative salt forms of commercially available drug candidates provides a 
resourceful cost-effective avenue to overcome solubility issues while limiting their toxic side 
effects. 
6.2 Key words 
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6.3 Introduction 
Presently based on economic and market demand, pharmaceutical drug design and development 
generally follows two main processing streams. Firstly, the drive of large pharmaceutical 
corporations to unravel novel therapeutic agents is associated with high risk and enormous 
expense. In the second approach smaller pharmaceutical entrepreneurs reformulate drug 
candidates that are out of patent protection to make them safer, more effective or more cost-
effective to produce. Many pharmaceutical research strategies to design novel pharmaceutically 
active compounds fail at clinical trials due to limited solubility of the proposed novel bioactive 
agent [1]. A diverse range of physiochemical factors including crystallinity (amorphous, 
crystalline), polymorphism, temperature, pH and particle size can negatively affect the 
solubility of otherwise promising bioactive candidates. The solubility or dissolution of the drug 
substances can be improved through material engineering of the drug substance or through 
formulation approaches [2, 3]. Several different strategies to enhance the solubility of poorly 
soluble drug substances include techniques like particle size reduction, solid state engineering, 
solid dispersions, salt formation, microemulsions, liposomes, complexation with cyclodextrins, 
lyophilization, co-solvent systems, micellar/surfactant systems etc. [2, 4]. Salt formation is the 
most commonly used method to enhance the solubility of the drug substances which are either 
weak bases or weak acids and most of the marketable formulation today are in the form of salts 
[5, 6]. When converted into salts, many drugs were found to be more stable, less hygroscopic 
and thus easy to handle than their corresponding free bases or acids which qualify them as the 
preferred forms to be used as the therapeutic agents [6].  
Together with the solubility, the permeability behavior of the salt is a key determinant of its 
bioavailability [7]. Ion pairing is an effective chemical approach to increase the lipophilicity of 
ionized drugs and to enhance their permeability across the membranes [7, 8]. Several organic 
counter ions have been demonstrated to form ion pairs with pharmaceutically active compounds 
[9-12]. Ion pairing gives rise to a neutralized complex, which partitions into the membrane and 
may dissociate to liberate the charged species [13]. Salts of pharmaceuticals with inorganic 
counter ions are highly ionic in nature and have difficulty crossing the membrane in order to 
reach their site of action [14]. The existence of salt in the form of ionic pair is critical for its 
transport across the absorbing membrane [7]. Thus organic counter ions merits over inorganic 
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counter ions in salt formation technique. However, choosing an appropriate organic counter ion 
is important and at the same time very challenging since many of the existing ones like 
trichloroacetate, cholate, alkylsulfates, etc. can be too irritative and impart toxic side effects 
limiting their application [7].  
Quinic acid is a cyclic polyol present in many plant products like coffee beans, cinchona bark, 
tobacco leaves, apples and peaches [15, 16]. Recently, quinic acid has been identified as an 
essential bioactive dietary component which initiates the synthesis of potential antioxidants viz. 
tryptophan and nicotinamide in humans which play a role in DNA repair [17, 18]. Quinic acid 
is endowed with favorable pharmacokinetics properties like greater value of drug score (0.48), 
drug likeness (0.51), less toxicity and was recently shown as a potential drug candidate against 
prostate cancer [19]. The significant biological activities and biocompatibility associated with 
quinic acid has propelled this study to evaluate its application as salt forming active 
pharmaceutical ingredient in combination with fluoroquinolones (ciprofloxacin and 
norfloxacin). Ideally there should be a difference of at least two units between the pKa value of 
acid and base to form a stable salt in water [20, 21]. The pKa of the carboxylic acid group of 
quinic acid is 3.66 [22] and the pKa for basic -NH group of ciprofloxacin and norfloxacin were 
shown to be 8.62 and 8.75 respectively [23]. Hence, quinic acid was strategically selected in 
this study to generate salts of these fluoroquinolones. 
To date, quinic acid and quinic acid derived amphoteric compositions are therapeutically useful 
in the treatment of common dry skin ailments [24, 25]. It is envisaged that antibacterial 
fluoroquinolones may be incorporated into similar quinic acid derived amphoteric 
pharmaceutical compositions to promote simultaneous treatment of dry skin and bacterial 
infections of skin. Fluoroquinolones are classified as amino acid type amphoterics since they 
contain both amino basic group and carboxylic acidic group. Incorporating them in quinic acid 
formulation will help in raising the overall pH of the composition, so that the composition 
becomes less or non-irritating to the skin and also quadruple ionic salt complex formed acts as 
buffering system to control the release of quinic acid into the skin [25]. Thus, fluoroquinolones 
when coupled to quinic acid could neutralize its undesirable side effects, whilst at the same 
instance quinic acid as counter ion could increase solubility and introduce a secondary activity 
to fluoroquinolone formulations. A symbiotic enhancement in the therapeutic efficacy of both 
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quinic acid and fluoroquinolones may be achieved by administering them together as a salt. 
Hence the study of quinic acid salts of fluoroquinolone drugs is rational and interesting which 
would pave way for new directions in pharmaceutical sectors. 
6.4 Materials and methods 
Ciprofloxacin, norfloxacin and octanol were analytical grade reagents purchased from Sigma 
Aldrich, Germany and quinic acid was purchased from Merck, Germany. Infrared spectra of 
samples were recorded on a Perkin Elmer Spectrum 100 FT-IR spectrometer with universal 
ATR sampling accessory. 1H and 13C NMR spectra were recorded using a Bruker Avance 400 
MHz instrument equipped with BBOZ probe. Chemical shifts are given in δ (ppm) against the 
internal standard tetramethylsilane. Samples for NMR were prepared in deuterium oxide. The 
chemical shifts were referenced to the residual water signal of D2O. MS was carried out on a 
Waters Micromass LCT Premier TOF-MS. Powder X-ray diffraction (XRD) patterns were 
recorded on a Bruker D8 Advance instrument equipped with an Anton-Paar XRK 900 reaction 
chamber and a Cu radiation source with a wavelength of 1.5406 Å at ambient temperature. 
Thermogravimetric analysis-differential scanning calorimetry (TGA-DSC) was conducted on 
SDT Q600 TA instrument. The temperature of samples was increased from 25-800°C at a 
heating rate of 10°C min-1 under nitrogen atmosphere. 
6.5 Experimental 
6.5.1 Synthesis of quinic acid salts of ciprofloxacin and norfloxacin 
6.5.1.1 Ciprofloxacin quinate [Cip] [Qui]:  
Ciprofloxacin (1.00 g; 3.19 mmol) was first added into a flask containing 25 mL of water. A 5 
mL water solution of quinic acid (0.58 g; 3.19 mmol) was slowly added to the ciprofloxacin 
suspension. The reaction mixture was stirred at room temperature for 24 h and the solvent was 
removed by freeze drying. The [Cip] [Qui] product (Fig. 6.1) was obtained as a white 
amorphous solid (1.42 g).  
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6.5.1.2 Norfloxacin quinate [Nor] [Qui]: 
Norfloxacin (1.00 g; 3.13 mmol) was first added into a flask containing 25 mL of water. A 5 
mL water solution of quinic acid (0.601g; 3.13 mmol) was slowly added to the norfloxacin 
suspension. The reaction mixture was stirred at room temperature for 24 h and the solvent was 
removed by freeze drying. The desired [Nor] [Qui] product was obtained as a pale yellow solid 































Figure 6.1 Molecular structure of fluoroquinolone salts with quinate counter ion a) [Cip] [Qui] b) 
[Nor] [Qui] synthesized in this study. 
 
6.5.2 Water Solubility 
Water solubility of the compounds was determined by adding excess compounds to 5 mL of 
water in a sample vial. The vials were maintained at 25°C and agitated vigorously for 24 h. 
Afterwards the vials were centrifuged for 1 h at 3000 rpm and the supernatant was further filter 
sterilized with a 0.45 micron filter. Aliquots of the sterile solution in quart cuvettes were 
analyzed by UV spectroscopy at wavelength 276 nm. The standard curves were established for 
each compound in water using five different concentrations prior to their analysis. The 
experiment was performed in triplicate and the standard deviation was determined. 
 
6.5.3 Determination of octanol-water partition coefficients 
The partition coefficient (Log P) of both quinate and hydrochloride derived salts of 
ciprofloxacin and norfloxacin between n-octanol and water was determined by a slight 
modification of the method described by Ross et al. [26, 27]. A mixture of 1.9 mL of water and 
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2 mL of octanol were shaken for 24 h. To this pre-equilibrated octanol and water mixture was 
added 100 µl of fluoroquinolone salt solutions (1 mg/mL). The resulting mixtures contained in 
vials were vigorously stirred for 24 h at 25°C. The vials were centrifuged at 3000 rpm for 30 
minutes to ensure distinct phase separation of octanol and water. Thereafter the concentration 
of the solute present in both phases was determined by UV spectrophotometry. The partition 
coefficient of salts between the two phases was determined using the following equation. 
 
 
Where Co and Cw refer to the octan-1-ol phase and water phase concentrations, respectively, 
and Ww and Wo the weight of the aqueous and octanol phases in the samples. 
6.5.4 Cytotoxicity studies 
The VERO cell line was obtained from the European Culture Collection of Cell lines (Sigma-
Aldrich) were cultured in RPMI 1640 (without phenol red) growth medium containing 10% 
heat-inactivated foetal bovine serum, 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES), 1 mM sodium pyruvate and 0.1 mg/mL penicillin / streptomycin). Cells (5x104 
cells per well) were plated in 96 well plates (Greiner Bio-One GmbH, Germany) and incubated 
at 37˚C (5 % CO2 incubator) for 24 hours. Subsequently, the spent medium was removed from 
all wells and replaced with fresh fully constituted medium along with quinic acid, ciprofloxacin 
hydrochloride, [Cip] [qui], norfloxacin hydrochloride, and [Nor][qui] at different 
concentrations (62.5 to 250 µM). Plates were further incubated under the same conditions for 
24 h before the addition of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl) 2-(4-
sulphenyl)-2H- tetrazolium (MTS) into each wells to perform CellTiter 96 AQueous One 
Solution Assay (Promega, Madison, WI). Upon incubation for additional 2 h, plates were spun 
down at 3000 rpm for 3 minutes and transferred to new 96 well plates and immediately read 
using Bio-Tek Synergy HT Automated Microplate Reader. Cadmium was used as the control 
and all assays were carried out in quintuplicate (n=5).  
Log P = (Co/Cw) X (Ww/Wo) 
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6.6 Results and discussion 
6.6.1 Characterization of the compounds 
Ciprofloxacin quinate: White solid; 92 % yield; C. IR (KBr, cm-1): 3257, 2919, 2535, 1724, 
1628, 1585;  1H NMR (400 MHz, D2O): δ 8.35 (1H, bs), 7.28 (1H, d, J = 7.30 Hz), 7.10 (1H, 
m),  4.04(1H, q, J = 3.5Hz) , 3.92 (1H, m), 3.51 (5H, m), 3.44 (5H, m), 1.96 (2H, m), 1.86 (1H, 
m) 1.78 (1H, m), 1.32 (2H, d, J = 7.23 Hz)  1.05 (2H, s);  13C NMR (400 MHz, D2O): 181.1, 
175.4, 168.5, 154.3, 151.8, 147.9, 144.5, 144.4, 138.7, 118.3, 118.2 110.5, 110.3, 106.3, 105.5, 
76.8, 75.1, 70.3,  66.9, 46.2, 43.1, 40.5, 37.3, 36, 7.4; HRMS (ESI m/z) [M + H]+ calculated for 
C17H19FN3O3+: 332.1405, found 332.1408; (ESI m/z) [M + H]+ calculated for C7H11O6-: 
191.0561, found 191.0560. 
Norfloxacin quinate: Pale yellow solid; 90% yield; C. IR (KBr, cm-1): 3277, 3046, 2918, 1705, 
1626;  1H NMR (400 MHz, D2O): δ 8.21 (1H, m, H-Ar), 7.08 (1H, m, H-Ar), 6.77 (1H, m, H-
Ar),  4.21(2H, m, H-CH2) , 4.04 (1H, d, J = 2.97 Hz, H-CH2), 3.92 (1H, m, H-CH2), 3.44 (9H, 
m, H-CH2, and H-CH  ), 1.96 (1H, m, H-CH2), 1.86 (1H, m, H-CH2) 1.78 (1H, m, H-CH2), 1.36 
(1H, m, H-CH3): 13C NMR (400 MHz, D2O): 181.2, 174.9, 168.6, 154, 151.5, 147.3, 144.6, 
136.7, 118.8, 110.7, 110.5, 105.9, 105.3, 76.9, 75.1, 70.3,  66, 50.1, 46.2, 43.1, 40.6, 37.3, 13.6; 
HRMS (ESI m/z) [M + H]+ calculated for C16H19FN3O3+: 320.1400, found 320.1406; (ESI m/z) 
[M + H]+ calculated for C7H11O6-: 191.0561, found 191.0560. 
6.6.2 Thermogravimetric and differential scanning calorimetric analyses  
The free base fluoroquinolones and their respective quinate organic salts were characterized for 
their thermal properties using SDT Q600 TA instrument. The solid TGA weight loss and dashed 
DSC thermal curve are displayed in Fig. 6.2. The DSC curve of free bases of ciprofloxacin and 
norfloxacin exhibited sharp endothermal crystal melt event at 278°C and 232°C indicating their 
crystalline nature. After the melt transition the free bases underwent a rapid pyrolysis and 
decomposition which is indicated by irregular changes in the TGA weight loss curves. On the 
contrary, quinate salts of both ciprofloxacin and norfloxacin did not exhibit any sharp crystal 
melting event and they undergo gradual weight loss after the temperature point 230°C. These 
changes in the thermal events confirm salt formation and their amorphous nature. The method 
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used for the synthesis of salts in this study i.e., direct protonation followed by isolation of salt 
from the aqueous phase by freeze drying resulted in amorphous solid formation. In 
pharmaceutical industries amorphous solids are of especially attractive due to their fast 
dissolving nature and improved bioavailability [28].  






































































































































Figure 6.2 TGA and DSC curves of a) Ciprofloxacin, b) Norfloxacin, c) [Cip] [Qui] and d) [Nor] 
[Qui]. 
6.6.3 X-ray powder diffractometry  
The X-ray diffraction pattern of quinic acid, free base and quinate salt forms of 
fluoroquinolones were studied using powder XRD. The powder XRD patterns of quinic acid, 
ciprofloxacin and norfloxacin contained several sharp characteristic peaks due to their 
crystalline nature. The major sharp and intense peaks were observed for quinic acid at 2θ = 
19.23, 21.37, 23.58, for ciprofloxacin at 2θ = 16.81, 21.02, 25.55 and for norfloxacin at 2θ = 
16.86, 18.23, 19.34, 21.44, 22.82, 23.71 (Fig. 6.3). The XRD patterns of salts were distinctive 
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when compared to the parent compounds. The formation of salt resulted in the broadening, 
disappearance or appearance of new peaks. The powder XRD patterns of [Cip] [Qui] showed 
broad peaks at 2θ = 16.76, 20.18, 23.50, 25.92, whilst that of [Nor] [Qui] showed broad peaks 
corresponding to 2θ = 15.60, 19.60, 25.87. These changes in the diffractogram confirm the salt 
formation of fluoroquinolones. Also the broad peaks observed in the diffractogram indicate that 
freeze drying method synthesized salts were amorphous in nature. The amorphous solids which 
lack long range molecular arrangement fail to scatter X-ray and hence produce broad peaks. 
The crystallography studies were well aligned to the results observed for thermogravimetric 
analysis.  
 















Figure 6.3 Diffractograms of a) Quinic acid, b) Ciprofloxacin, c) [Cip] [qui], d) Norfloxacin and e) 
[Nor] [Qui]. 
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6.6.4 Solubility in water  
Solubility values determined at 25°C for unionized fluoroquinolones and their respective 
quinate salts are listed in the Table 6.1. The results indicate that solubility of both ciprofloxacin 
and norfloxacin increased significantly. The solubility’s of ciprofloxacin and norfloxacin were 
found to be 0.14 mg and 0.54 mg/ml respectively [29]. The solubility increased to 409 mg and 
355 mg when converted to quinate salt. This can be explained in that the acid-base reaction 
between quinic acid and fluoroquinolone base resulted in the protonation of secondary amine 
present in the piperazine ring thereby generating ionic species. The interaction of ions with 
water molecules will be higher than compared to their neutral species and thus water solubility 
of salts will be increased [5]. 
Table 6.1 Water solubility at 25°C 
Compound Solubility (mg/mL) Reference 
Ciprofloxacin 0.14 ± 0.01  [29] 
[Cip] [Qui] 409 ± 4.8 This study 
Norfloxacin 0.54 ± 0.02  [29] 
[Nor] [Qui] 355 ± 3.7 This study 
 
6.6.5 Determination of octanol-water partition coefficients 
Octanol-water partition coefficient of quinate and hydrochloride salts of fluoroquinolones were 
determined by a modified shake flask method and are presented in Table 6.2. The experiments 
were performed in triplicate and the results obtained are presented with their standard 
deviations. Quinate salts have higher Log P values than their corresponding hydrochloride salt 
counterparts indicating that organic acid derived salts have higher lipophilicity than inorganic 
acid derived salts. Also the [Nor] [Qui] derivative has a higher Log P value than the [Cip] [Qui] 
salt. Research studies to date reveal that higher lipophilicities indicate an increased capacity of 
pharmaceutical salts to pass thorough cell membranes [30, 31]. As such the quinate counter ion 
employed in this study can facilitate greater permeability of fluoroquinolones than the chloride 
ion across the biological membranes. However, it should be noted that permeability of drugs 
cannot be decided solely based on  Log P values [30]. The hydrochloride salts probably were 
highly ionic and thus will have less affinity towards hydrophobic octanol [32]. On the other 
hand, the quinate counter ion might have formed an ion pair with the fluoroquinolone base and 
thus favoring higher Log P values [33]. 
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Table 6.2 Octanol water partition coefficient 
Compound Log P Std Curve Equation R2 
[Cip] [Qui] 0.544 ± 0.01123 y=0.0894x+0.1109 0.9939 
[Nor] [Qui] 0.773 ± 0.00222 y=0.0921x+0.0011 0.9990 
[Cip] [H] 0.411±0.016731 y=0.0659x+0.0689 0.9998 
[Nor] [H+] 0.499±0.016182 y=0.0691x+0.0867 1 
 
6.6.6 Cytotoxicity studies 
The in vitro cytotoxicity of quinic acid, quinate and hydrochloride salt forms of 
fluoroquinolones were evaluated at three different concentrations against the VERO 
mammalian cell line to assess the impact of quinate salt modification on cellular toxicity when 
compared to their hydrochloride counterparts. Percentage cell viabilities are tabulated in Table 
6.3. Quinic acid was not found to be toxic at all the concentrations tested. A near 100% 
viabilities were observed even at high concentration (250 µM) tested indicating their 
biocompatibility. Both hydrochloride and quinate salts of fluoroquinolones were nontoxic at 
lower concentrations. However, at a higher concentration of 250 µM, they displayed low grade 
toxicity. From the table it can be observed that quinate counter ion did not increase the toxicity 
when compared to hydrochloride salts of fluoroquinolones. Hence, fluoroquinolone salts using 
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Table 6.3 Percentage cell viabilities of VERO cells in the presence of quinic acid, fluoroquinolones 




All values are expressed as mean ± standard deviation of experiments performed in five replicates. Different 
superscript letters (a and b) presented in each column are significantly different from each other (p < 0.05; one-
way ANOVA, Tukey’s post-hoc test) 
 
6.7 Conclusion 
In short, the present study discusses the salt formation of fluoroquinolones using quinate 
counter ion exchange. Solubility of both ciprofloxacin and norfloxacin was significantly 
increased by converting them into the quinate salt forms. As compared to the hydrochloride 
salts, quinate salts of fluoroquinolones have higher octanol-water partition coefficient 
indicating their lipophilic character. This could help in simultaneous increase of solubility and 
permeability of fluoroquinolones. XRD data analysis confirms that the method of direct 
protonation followed by freeze drying yielded amorphous salt forms. Conversion of free bases 
to amorphous may increase the solubility, stability and bioavailability of drugs. The 
cytotoxicity studies indicated that quinic acid is biocompatible and did not increase the toxicity 
of fluoroquinolones when applied as a counter ion. The data from the present study tentatively 
suggests that the novel fluoroquinolone-quinic acid salts are likely potential drug candidates for 
economic development. 
In this regard the following parameters of the novel pharmaceutical salts synthesized in this 
study will be the subject of future research; thermodynamic stability of salt forms, evaluation 
of their membrane absorption and permeability using in vitro tools like parallel artificial 
membrane permeability assay (PAMPA) [34, 35] and profiling salts for their solubility in bio-
relevant dissolution media with differing pH [36]. 
Compound Concentrations (μM) 
 62.5 125 250 
Quinic acid 110.62±6.49a 101.47±5.23a 99.88±7.36a 
[Cip][H] 102.83±7.22a 102.32±8.7a 78.69±5.79b 
[Cip] [Qui] 97.60±8.06a 96.68± 7.66a 72.01±7.54b 
[Nor] [H] 110.23±6.09a 106.77±7.57a 75.68±6.09b 
[Nor] [Qui] 108.02±7.70a 108.91±5.36a 77.70±6.03b 
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7.1 General Discussion and Conclusion 
Traditional methods to develop new medicines involve identifying and compiling a large 
number of promising compounds, which could become a potential therapeutic agent. The 
medicinal compounds are either identified from the natural resources or created in the 
laboratory in large number after strategic designing and thereafter will be subjected to high-
throughput screening to find out a few potential candidates from the large library [1, 2]. 
Recently nanotechnology is making a significant contribution in the field of drug discovery and 
the number of medicinally useful inorganic nanomaterial generated, providing more options in 
the drug discovery [3]. However the process of researching and developing new medication is 
long, expensive and complex [4]. It is thus very hard to source new medicines with fewer side 
effects. On average, it takes at least ten years for a new therapeutic agent to complete clinical 
trials and go into the market [4]. The average cost to research and develop each successful drug 
is estimated to be $2.6 billion [5]. From thousands of compounds screened and assessed in the 
early research and development process, only a few substances pass all of the tests, trials and 
receive approval [6]. The overall probability of clinical success is estimated to be less than 12% 
[5]. Clinical trials also involve the risk of exposing human volunteers to potentially harmful 
substances or possibly ineffective treatments. The increasing number of high profile drug 
withdrawals from the market due to later detection of associated adverse reactions is another 
issue [7, 8]. Hence conversion of well-designed compounds to an approved medical drug is an 
uphill task. 
Alternatively, methods to further improve the existing medicinal compounds is of value, since 
safety and efficacy of those compounds is already characterized and quick development of new 
treatments can be expected [9]. Thus investigation and improvement of existing medicine has 
become an important aspect of the modern pharmaceutical sector. Better management of 
existing medication as well as cost reduction and harm of drug discovery on human health care 
is global priority.  
This thesis is focused on both identifying likely targets as new therapeutic agents and strategies 
to improve the existing medication. Chapters 3 and 4 focused on finding new antibacterial and 
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anti- diabetic compounds, while chapters 5 and 6 were concerned with different strategies to 
improve existing medication. Although, this PhD research study initially focused on designing 
new and/or improving currently available antibacterial agents. The antidiabetic evaluation was 
only initiated since similar compounds were previously shown to have antidiabetic activity [10]. 
In Chapter 3, we described that biomolecules present in aqueous seed extract of Protorhus 
longifolia could be used to reduce silver and gold ions to their respective metal nanoparticles 
in a green synthesis protocol. This environmentally benign reaction for the synthesis of 
nanoparticle was rapid and readily conducted at room temperature. Surface plasmon resonance 
in the UV visible region for AgNPs at 400-500 nm and for AuNPs at around 500-600 nm 
confirmed their formation. The IR spectrum confirmed the presence of organic functional 
groups on the surface of nanoparticle. The poly-dispersed nanoparticles were 10 nm-30 nm in 
size. Zeta potential of -21.2 mv for AgNPs and -19.7 mv for AuNPs was contributing to the 
stability of nanoparticles. Green synthesized AgNPs and AuNPs showed potential antibacterial 
activity against bacterial species Escherichia coli (ATCC 35218), Klebsiella pneumoniae 
(ATCC 700603), Staphylococcus aureus (ATCC 43300) and Pseudomonas aeruginosa (ATCC 
27853). Our results showed that AgNPs were comparatively more potent than AuNPs as 
antibacterial agents. In this study we demonstrated that phytochemical based formulations 
constituting inorganic nanoparticle capped with medicinal compounds from the plant extract 
form novel potent antimicrobial agents.  
In Chapter 4, by using traditional approaches we attempted to find out a new class of possible 
antidiabetic heterocyclic molecules. Chapter 4 interrogates the potential of heterocyclic 
compounds as antibacterial agents. Since this class of compounds was also found to be good 
anti-diabetic agents [10], anti-diabetic testing was also performed. As such this chapter provides 
a brief discussion on the synthesis, characterization and evaluation of α-glucosidase inhibitory 
and antibacterial activities of 2-amino-3, 5-dicyano-6-sulfanyl pyridines scaffolds. The 2-
amino-3, 5-dicyano-6-sulfanyl pyridines core structures are known to possess various 
biological activities. In this study along with antibacterial activity, for the first time we have 
evaluated the α-glucosidase inhibitory activity of these compounds. Compounds were 
Chapter 7  General Discussion and Conclusion 
115 
synthesized in a single step multi-component protocol with good yields from commercially 
available reagents. Our results show that 2-amino-3, 5-dicyano-6-sulfanyl pyridine derivatives 
have poor antibacterial activity. However they possess good α-glucosidase inhibitory activity. 
Five of the nine compounds tested showed good inhibition of α-glucosidase enzyme, which was 
similar to the standard drug acarbose. The prediction of binding affinities of the compounds 
towards the enzyme model by molecular docking analysis helped us to explain the experimental 
results observed. We were able to show that aromatic substitution at position 4 and 6 of the 
pyridine ring increased the α-glucosidase inhibitory activity. Thus both the theoretical and 
experimental inhibitory activities, helped us to find a novel 3, 5-dicyanopyridine organic 
framework with potential anti-diabetic activity.  
Thus the study highlights the importance of pyridine compounds as anti-diabetic agents. The 
bioactivity can be improved upon by taking the most active molecules from this study and 
building new molecules by introducing different functional groups capable of forming 
hydrogen bonds with amino acids in the enzyme’s active site. The easy one pot multi-
component method involving benzaldehyde, thiol and malononitrile can yield compounds with 
broader substitutions of interesting bioactivities. Also metal complexes can be synthesized 
using these molecules and thus more bioactivities like anticancer can be introduced into these 
molecules. 
Since the aim of this project is to make a significant contribution to the pharmaceutical industry; 
once two new classes of potential antibacterial and antidiabetic agents were generated, attention 
then turned to improving the currently available medication. Some of the identified 
shortcomings of the commercially available treatment are resistance, toxicity, and low 
solubility, with the last factor having a huge impact on permeability and thus efficacy. 
In Chapter 5, we demonstrated a novel hybrid material constituting cyclodextrin capped AgNPs 
and antibacterial drug chloramphenicol for the application in combination therapy to overcome 
resistance and toxicity problems. Cyclodextrins attached to the surface of silver nanoparticles 
acted as both stabilizing and drug encapsulating agents. Initially α-, β- and γ-cyclodextrin 
supramolecules have been studied for their complexing ability with chloramphenicol, using 
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molecular modeling techniques. The computed binding free energies indicated the strong 
interaction between γ-cyclodextrin and chloramphenicol. To further confirm the results 
observed in theoretical calculation, the inclusion complex of chloramphenicol with γ-
cyclodextrin was synthesized and thoroughly characterized. Thereafter γ-cyclodextrin capped 
silver nanoparticles were prepared, characterized and confirmed for their ability of molecular 
recognition of chloramphenicol using surface enhanced Raman spectroscopy studies. The 
chloramphenicol γ-cyclodextrin capped silver nanoparticles composite showed enhanced 
antibacterial activities against different bacterial species and clearly demonstrated that the 
organic-inorganic hybrid materials or nanocomposites can be an ideal platform for combination 
therapy. Thus this study has opened a new perspective of a novel combination therapy. Further 
studies can be considered for loading of other antimicrobial and anticancer drugs and multiple 
drug substances within the similar system but with a variety of inorganic material such as 
AgNPs, AuNPs and other metal nanoparticles to generate new treatments.  
In Chapter 6, we demonstrated the salt formation of fluoroquinolones using quinate counter ion 
exchange. In a bid to further improve currently available antibacterial agents, solubility of both 
ciprofloxacin and norfloxacin was significantly increased by converting them into the quinate 
salt forms. As compared to the hydrochloride salts, quinate salts of fluoroquinolone’s have 
higher octanol-water partition coefficient indicating their lipophilic character. This could help 
in simultaneous increase of solubility and permeability of fluoroquinolones. XRD data analysis 
confirms that the method of direct protonation followed by freeze drying yielded amorphous 
salt forms. Conversion of free bases to amorphous may increase the solubility, stability and 
bioavailability of drugs. The cytotoxicity studies indicated that quinic acid is biocompatible and 
did not increase the toxicity of fluoroquinolones when applied as a counter ion. The utility of 
the present work may be further improved by studying thermodynamic stability of salt forms, 
assessing drug absorption and permeability using in vitro tools like parallel artificial membrane 
permeability assay (PAMPA) and profiling salts for their solubility in bio-relevant dissolution 
media with different pH [11]. 
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A 1.1 Abstract 
Molecular docking, semi-empirical and molecular dynamics studies were conducted for α, β 
and γ- cyclodextrin-associated inclusion complexes of antipyrine. The results of molecular 
modeling were systematically analyzed to determine the stability of inclusion complexes. In 
preliminary computational screening, β and γ-cyclodextrin inclusion complexes of antipyrine 
were found to be more stable as compared to α-cyclodextrin based on docking score and binding 
free energies. Further, inclusion complex of antipyrine with γ-cyclodextrin was prepared by 
freeze drying method. Formation of the inclusion complex was investigated by solid state 
characterization techniques such as thermogravimetric analysis, differential scanning 
calorimetry, X-ray diffraction, Fourier transform infrared spectroscopy and scanning electron 
microscopy. The changes observed in decomposition temperature, diffractogram, vibrational 
frequencies and morphological appearance confirmed the formation of inclusion complex. In 
addition, results from 1H NMR and 2D NOESY studies supported the inclusion phenomenon. 
The results obtained from computational studies were found to be in consistent with 
experimental data to ascertain the encapsulation of antipyrine into γ-cyclodextrin. The inclusion 
complex was found to be non-toxic towards MDCK-1 cell lines. Thus, this approach may be 
helpful in the formulation of drug molecules using cyclodextrins. 
A 1.2 Key words 
Molecular modeling, binding free energies, antipyrine, γ-cyclodextrin, inclusion complex  
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A 1.3 Introduction 
Cyclodextrins (CDs) are truncated, cone-shaped cyclic host materials made up of α-D-
glucopyranose units linked by α-1,4 glycosidic bonds [1]. They are commercially available in 
the form of α, β and γ with varying number of glucose units (6-8) and cavity size (5-9 Å) [2]. 
The α-D-glucopyranose of cyclodextrin exists in stable 4C1 chair conformation, with 
hydrophobic ether linkages and carbon skeletons of glucose units inside and hydrophilic 
hydroxyl groups outside the cavity of CD [3]. This structural arrangement makes the CDs 
amphiphilic in nature.  Cyclodextrins have the ability to form supramolecular host-guest 
assemblies with a variety of organic and inorganic molecules. The driving forces for this 
phenomena include weak van der Waals forces, hydrogen bonding  and charge transfer 
interactions between the host and guest molecule [4]. The process is also influenced by 
thermodynamic factors such as enthalpy and entropy changes associated with replacement of 
water molecules from the CD cavity by hydrophobic molecules [4]. There is a huge interest in 
the cyclodextrin-based pharmaceutical formulation due to their ability to improve water 
solubility, stability and bioavailability of a variety of potential drugs [5]. Furthermore, CDs are 
biodegradable and do not require additional treatment to remove them after application [6]. The 
cyclodextrin derived materials can also effectively remove the organic and inorganic pollutants 
present in water [3, 7, 8]. CDs and their chemical modifications thus provide novel applications 
in both pharmaceutical and environmental related fields.  
Antipyrine (AP; 2,3-dimethyl-1-phenyl-5-pyrazolone) is an inhibitor of cyclooxygenase and is 
known for anti-inflammatory, analgesic and antipyretic activity in clinical therapy [9]. 
Antipyrine and their derivatives have also been reported for a variety of pharmacological 
activities [10, 11]. AP is a commonly used non-steroidal anti-inflammatory drug (NSAID) and 
is also one of the pharmaceutical products that contaminate water sources [12]. The most 
common side effects of NSAIDs include ulcer perforation and upper gastrointestinal bleeding. 
These side effects can be minimized by complexion with CDs, as they release the drug in a 
controlled manner thereby making drugs effective at lower dosages [13].  
The long term exposure of AP through water contamination exerts toxic effects causing damage 
to lungs and mucosa [14]. Recently, chlorination of water, use of activated persulfate and 
hydroxide radicals were discussed for the degradation of AP or phenazone-like compounds in 
the water [15-17]. However, the use of cyclodextrin-derived polymers and materials could be 
an interesting strategy for the treatment of AP contamination as they are harmless to nature. 
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Hence, understanding the host-guest relationship between AP and CDs will help in designing 
suitable CD-based material for water treatment. The study of AP inclusion complexes is thus 
significant in view of both pharmaceutical and environmental interests. 
The inclusion complex of AP with β-CD in the solid state has previously been studied and it 
was suggested that the existence of AP in a betainic state which forms a weak inclusion with β-
CD in the solution state [18]. Furthermore the formation of inclusion complex was characterized 
by thermal analysis [18]. However, to the best of our knowledge the role of γ-CD in the 
formation of inclusion complex with AP has not been described. In this study, we detail the 
molecular modeling of inclusion complexes of AP with α, β and γ cyclodextrins, using semi-
empirical AM1 calculation methods. In addition, the synthesis, characterization and 
cytotoxicity of AP/γ-CD inclusion complex has been discussed in detail.  
A 1.4 Materials and Methods  
A 1.4.1 Computational Studies 
A 1.4.1.1 Preparation of 3D structures of α-, β- & γ-cyclodextrins and antipyrine 
The crystal structures of α-CD (PDB code: 2ZYM) [19], β-CD (PDB code: 3CGT) [20] and γ-
CD (PDB code: 2ZYK) [21] were extracted from protein data bank (PDB). The structure of AP 
was obtained from Pubchem (CID: 2206). The missing hydrogen atoms to CDs and atomic 
charges to CDs as well as AP were added using CHIMERA software package [22]. These 
structures were used as a starting point to perform the computational studies.  
A 1.4.1.2 Molecular docking 
The complexes of AP with α-, β- and γ-CD were generated from molecular docking approaches. 
Molecular docking was carried out using AutoDock software which employs Lamarckian 
genetic algorithm [23]. The Lamarckian aspect is an added feature that allows individual 
conformations to search their local conformations. AutoDock uses a grid based method to allow 
rapid evaluation of the binding free energy. The solution of AutoDock is based on the energy 
scores of final docking energy (FDE) and the estimated final energy of binding (EFEB). The 
energies comprise van der Waals, electrostatic interactions, the loss of entropy and the number 
of hydrogen bonds. To perform molecular docking, CDs were defined as a receptor and AP was 
defined as a ligand. The binding site was located using GRID and the GRID was defined from 
the centroid of the cavity of CDs. The top ranked complex of AP with α-CD, β-CD and γ-CD 
were separately stored for AM1 and AMBER studies. 
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A 1.4.1.3 Semi-empirical calculation 
The complexes of AP with three different CDs were optimized by AM1 method using 
Gaussian03 software packages [24]. Analytical frequencies were also computed at the same 
level to characterize the optimized structures as minima or transition states (one negative 
frequency) on the potential energy surface. Partial atomic charges were estimated by 
performing Mulliken population analysis. 
A 1.4.1.4 Molecular dynamics simulations 
Molecular dynamics (MD) simulations were carried out using AMBER 12 software packages 
running under GPU version of PMED engine [25]. The atom types were modeled using 
ANTECHAMBER module of AMBER software packages [26]. The FF99SB force field was 
used to describe the solvent system [27]. The hydrogen atoms were added to the α-CD, β-CD 
and γ-CD using LEAP module incorporated in AMBER. The system was neutralized by the 
addition counter ions either Na+ or Cl-. The system was embedded within an orthorhombic box 
(8 Å) composed of TIP3P water molecules [28]. Periodic boundary conditions were maintained. 
The long range electrostatic interactions were treated based on particle mesh Ewald method 
[29]. A restraint potential of 500 kcal/mol A2 was applied to the solute. Initial energy 
minimization was performed for 2500 steps using steepest descent algorithm. Further, 2500 
steps of unrestrained conjugate gradient minimization were carried out. Canonical ensemble 
(NVT) MD simulations were then carried out for 50 ps, with gradual heating from 0 to 300K 
with harmonic restraints of 5 kcal/mol A2 was applied to all solute atoms and a Langevin 
thermostat with a random collision frequency of 1/ps. The systems were subsequently 
equilibrated at 300 K in the NPT ensemble for 500 ps, during which no restraints were imposed 
and a Berendsen barostat was used to maintain the pressure at 1 bar. The bonds of all hydrogen 
atoms were constrained using SHAKE  algorithm [30]. For MD runs, SPFP precision model 
was used [31]. Production MD runs were performed for 10 ns in an isothermal isobaric (NPT) 
ensemble using a Berendsen barostat with a target pressure of 1 bar. The trajectories were saved 
and analysed in every 1ps using CPPTRAJ module integrated with amber 12. 
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A 1.4.1.5 Binding free energy calculation 
The binding free energies for the α-CD, β-CD and γ-CD associated inclusion complex of AP 
was carried out using Molecular Mechanics- Poisson-Boltzmann surface Area (MM-PBSA) 
[32, 33]. The binding free energies were averaged over 200 snapshots taken from the post 
equilibrated 10ns MD trajectory at 10 ps intervals. To determine the individual energy 
contribution towards total binding free energy between AP and cyclodextrin, a decomposition 
analysis of the interaction energy was computed by MM/PBSA binding free energy 
decomposition protocol in Amber 12. The following equation (Eq.1) was employed to compute 
the binding free energies. 
ΔGbind = Gcomplex – Greceptor – Gligand     (Eq.1) 
A 1.4.2 Preparation of inclusion complex and physical mixture 
The inclusion complex of AP was prepared by freeze drying method [34]. A solution of γ-CD 
(Wacker Chemie; 1.38 g) and AP (Fluka; 0.2 g) prepared in 25 ml of double distilled water in 
1:1 molar ratio and stirred at room temperature for 48 hrs The resulting clear solution was frozen 
at -72 °C for 4 hrs and freeze-dried to yield a white amorphous solid. On the other hand, sample 
of physical mixture was obtained by mortaring 1:1 mixture of each reactant. 
A 1.4.3 Characterization of the inclusion complex 
Powder X-ray diffraction (XRD) patterns were recorded on a Bruker D8 Advance instrument 
equipped with an Anton-Paar XRK 900 reaction chamber and a Cu radiation source with a 
wavelength of 1.5406 Å at ambient temperature. Infrared spectra of AP, CD and inclusion 
complex were recorded on a Perkin Elmer Spectrum 100 FT-IR spectrometer with universal 
ATR sampling accessory. Thermogravimetric analysis-differential scanning calorimetry (TGA-
DSC) was conducted on SDT Q600 TA instrument. The temperature of samples was increased 
from 25-800°C at a heating rate of 10°C min-1 under nitrogen atmosphere. Morphological 
studies of the samples were performed using scanning electron microscope (FEGSEM ZEISS 
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ULTRAPLUS). Samples for SEM analysis were prepared by fixing powdered sample on 
adhesive carbon tape glued over metal stub and thin gold coating was added to make samples 
more electrically conductive. The samples were observed at 10000X magnification with an 
excitation voltage of 20 kV. 1H nuclear magnetic resonance (NMR) spectra were recorded on a 
Bruker AvanceIII 400 MHz spectrometer. 13C APT, COSY, HSQC and NOESY spectra were 
recorded on a Bruker AvanceIII 600 MHz spectrometer at 30°C. Chemical shifts (δ) were 
recorded using tetramethylsilane (TMS) as the internal standard. The spectrometers were 
equipped with a BBOZ probe. In the 1H-1H NOESY experiment, the mixing time was 300 ms 
and relaxation time was 1s. Samples were prepared in deuterium oxide. The chemical shifts 
were referenced to the residual water signal of D2O.  
A 1.4.4 Cytotoxicity studies 
The MDCK-1 cell line (European Collection of Cell Cultures, Sigma-Aldrich) was cultured in 
RPMI 1640 growth medium containing 10% heat-inactivated fetal bovine serum, 2 mM 
glutamine, 1 mM sodium pyruvate, 25 mM 2-[4-(2-hydroxyethyl)-1-piperazinyl] 
ethanesulfonic acid (HEPES), and 0.1 mg/mL penicillin/streptomycin. Cells were plated at a 
density of 1 × 104 cells/mL (100 μL/well) 96 well plates (Sigma-Aldrich) and incubated at 37 
°C for 24 hours. Thereafter, spent media were removed from all wells and fresh fully constituted 
media containing AP, free CD or inclusion complexes at varying concentrations (7.8-500 µM) 
were added. Plates were incubated at 37 °C for a further 24 hours before the CellTiter 96 
AQueous One Solution Assay (Promega, Madison, WI) was performed. This assay was carried 
out as per manufacturer’s instructions to assess cell viability by measuring the cellular reduction 
of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphenyl)-2H- tetrazolium 
(MTS). Absorbance readings for the MTS assay were performed using an Automated 
Microplate Reader (Synergy HT) from Bio-Tek Instruments. Untreated cells were used as the 
control. All samples were assayed on two separate occasions and in triplicate. 
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A 1.5 Results and discussion 
A 1.5.1 Prediction of the binding mode of antipyrine inside cyclodextrins  
The possible binding mode of the inclusion complex of AP with α-, β- and γ-CD was identified 
from molecular docking approaches. The top ranked pose of AP inside CD was considered as 
a favorable binding mode. In docking pose, the phenyl ring of AP was slightly penetrated inside 
the cavity of α-CD and the pyrazole ring was found to be positioned away from the cavity (Fig. 
A 1.1 a). This could be attributed towards lower cavity volume of α-CD. In the inclusion 
complex of AP-β-CD, the phenyl ring was deeply penetrated toward the primary hydroxyl rim 
of β-CD whereas the pyrazolone ring oriented toward secondary hydroxyl rim (Fig. A 1.1 b). 
In case of AP-γ-CD inclusion complex, the entire skeleton of AP was completely sequestered 
due to larger cavity volume (Fig. A 1.1 c). The docking scores of the inclusion complex 
suggested the favorable formation of inclusion complex of AP with β-CD (-4.7) and γ-CD (-










Figure A 1.1 The binding mode of AP inside the cavity of a) α-cyclodextrin b) β-cyclodextrin 
and c) γ-cyclodextrin.  
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Table A 1.1 Docking scores of antipyrine with three different cyclodextrins 
Cyclodextrins Ligand Docking Scores 
α-CD AP -0.7 
β-CD AP -4.7 




A 1.5.2 Conformational analysis of antipyrine inside cyclodextrins 
The top ranked pose of AP obtained molecular docking using three different CDs was subjected 
for geometry optimization in order to determine the stable conformation and interactions. The 
geometry optimization was carried out using semi-empirical method since the inclusion system 
constitutes larger number of atoms (AP-α-CD: 152 atoms; AP-β-CD: 173 atoms and AP-γ-CD: 
194 atoms). The approach reduces the computational cost as compared to ab initio studies. AM1 
is one of the most accurate semi-empirical computational methods. The method ignores or 
approximates the some of the integrals employed in ab initio methods. In this study, the 
geometry optimization was carried out based on AM1 method. In the optimized geometry of 
AP-γ-CD inclusion complex, antipyirine achieved twisted conformation with a bond angle of 
(1=117.25) across C-N-N bond and (2=116.32) across C-N-C bond. This angle was found 
to be diminished as compared to the optimized geometry of AP alone (1=123.41; 2=126.65). 
In the optimized geometry of AP -γ-CD inclusion complex, AP enters into the γ-CD cavity from 
its phenyl ring and deeply penetrated into the cavity towards the edge of primary hydroxyl 
group of sugar unit (Fig. A 1.2).  This can be related to appearance of NOESY peaks between 
H6 of γ-CD and aromatic protons of AP. The distance between the hydrogens of AP and γ-CD 
were found to be in the range of 2.3-5 Å, suggests the transfer of spin polarization between the 
protons of AP and γ-CD possible. This was further confirmed by the appearance of several 
NOESY interactions in 2D NMR studies. The carbonyl IR frequency was also shifted to low 
indicating a strong hydrogen bond with cyclodextrin protons, which can be possible when 
pyrazolone ring of the AP is inside the cavity. Thus FTIR spectra also correlate with molecular 
models obtained. 




Figure A 1.2 The optimized geometry of antipyrine with a) α-cyclodextrin b) β-cyclodextrin and 
c) γ-cyclodextrin. 
A 1.5.3 Host-guest interactions of antipyrine and cyclodextrins 
To analyze the guest-host interactions of AP with CD, the binding affinity of AP with three 
different CDs were computed based on MD simulation (Table A 1.2) (Fig. A 1.3). The binding 
free energies were calculated using MM-PBSA method.  The binding free energy for the 
complexes of AP with α, β and γ-CD was found to be 13.82 kcal/mol, 21.13 kcal/mol and 19.52 
kcal/mol respectively. The results indicate the favorable formation of inclusion complex of AP 
with β-CD and γ-CD over α-CD. A similar trend was also observed in molecular docking 
analysis.  
The van der Waals and electrostatic interactions were found to be main forces contributing for 
ligand binding. The van der Waals interaction was higher in both AP-β-CD (-28.1691±0.1321 
kcal/mol) and AP- γ-CD (-24.9421±0.0997 kcal/mol) complexes due to closer contacts of guest 
and host moiety , whereas it was found to be -13.8241±0.1547 kcal/mol in case of AP-α-CD 
inclusion complex due to lack of encapsulation. The electrostatic interaction between AP and 
γ-CD is highly favorable (-7.1133±0.2069 kcal/mol) as compare to β-CD (-7.0764±0.1501 
kcal/mol) and α-CD (-5.1102±0.2311 kcal/mol) suggesting β-CD and γ-CD as the suitable 
encapsulating material for AP. The quantitative information of van der Waals interaction, 
electrostatic interaction, binding free energy can be useful to understand the guest-host 
interactions of AP-CD inclusion complexes and to determine its favorable formation. 
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Figure A 1.3 The energy minimum conformation of antipyrine with a) α-cyclodextrin b) β-
cyclodextrin and c) γ-cyclodextrin obtained from molecular dynamics simulations. 
 
Table A 1.2 The computed binding free energies of the inclusion complexes 
 
A 1.5.4 X-ray powder diffractometry 
The X-ray diffraction pattern of AP, γ-CD, physical mixture and inclusion complex were 
studied using powdered XRD. The formation of inclusion complex causes major changes in the 
diffraction pattern of both guest (AP) and host (CD). The changes were observed in the form 
of disappearance, decreased intensity, broadening and appearance of new peaks. The powder 
XRD patterns of AP and γ-CD showed strong sharp peaks due to their crystalline nature. Sharp 
and intense peaks were observed for AP at 2θ = 10.2 (d = 7.38), 24 (d = 3.72) and for γ-CD at 
2θ = 12 (d = 6.92), 16.5 (d = 4.47), 19 (d = 4.18) and 22 (d=3.85) (Fig. A 1.4). These peaks 
were not found in the diffractogram of inclusion complex, instead broad peaks were observed 
confirming the amorphous nature of inclusion complex. Thus by converting guest molecule to 
amorphous, the solubility of AP may increase [35]. However intense sharp peaks found in the 
physical mixture at 2θ = 12.5 (d = 7.31) and 20.5 (d = 4.37) which indicates simple mixing did 
not result in the formation of inclusion complex. The changes in diffractogram confirms the 
formation of inclusion complex and similar results have been observed in other cases [36, 37]. 
Inclusion complexes ΔGbind ΔEele ΔEvdW ΔGgas ΔGsol 
AP-α-CD 13.8241±0.1547 5.1102±0.2311 17.5783±0.1600 22.6886±0.2683 8.8645±0.1654 
AP-β-CD 21.1339±0.1296 7.0764±0.1501 28.1691±0.1321 35.2455±0.2041 14.1117±0.1239 
AP-γ-CD 19.5201±0.1244 7.1133±0.2069 24.9421±0.0997 32.0554±0.2246 12.5353±0.1329 
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A 1.5.5 FTIR-ATR spectroscopy measurements 
The formation of inclusion complex was studied from the changes in the infrared vibrational 
frequencies of chemical bonds resulting from the inclusion phenomenon. The formation of 
inclusion complex alters the molecular interactions such as hydrogen bonding, dipole-dipole 
interaction [38], which results in the IR frequency shift of functional groups [39]. The FTIR 
spectrum of γ-CD (Fig. A 1.5) was characterized by a broad band at 3260 cm-1 for the primary 
and secondary OH groups. The position of this band is shifted to higher frequency 3295 cm-1 
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cm-1 confirm the presence of AP in the complex. In inclusion complex the carbonyl frequency 
of AP was shifted from 1659 to 1615 cm-1. The lowering of carbonyl group frequency of AP 
could be due to its reduced double bond character resulted from its involvement in the hydrogen 
bonding interaction with hydroxyl groups of γ-CD. The close proximity of carbonyl groups to 
hydroxyl groups of γ-CD (2 Å) was found in the optimized geometry of inclusion complex. The 
intensity of peaks at both functional group and finger print region for AP was also significantly 
reduced in the inclusion complex. These variations in the IR spectrum of the inclusion complex 
can be attributed to intermolecular interactions between the AP and γ-CD [40].  
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A 1.5.6 Thermogravimetric and differential scanning calorimetric analyses 
Thermal degradation properties of the samples were studied by thermogravimetric analysis 
where the weight loss of the sample was studied as a function of temperature under nitrogen 
atmosphere. The change in the thermal stability of AP and γ-CD on formation of inclusion 
complex was studied by comparing TGA and DSC curves (Fig. A 1.6). The AP exhibited single 
weight loss between the temperature 210-335°C. On the other hand, the encapsulating γ-CD 
exhibited weight loss at two different points. The first weight loss at 25-125°C was due to 
dehydration and another weight loss at 290°C was due to decomposition of γ-CD. In inclusion 
complex the corresponding weight loss for AP was observed at 255°C suggesting the increased 
thermal stability of AP (Fig. A 1.6 d).  
The DSC analysis of samples provided further evidence for the formation of inclusion complex. 
The DSC thermogram of AP showed a sharp endothermic peak at about 110°C (Fig. A 1.6 a) 
which was consistent with its melting point. Similar peak was also observed in the DSC curve 
of physical mixture (Fig. A 1.6 c). However, DSC of inclusion complex did not show up this 
endothermic peak (Fig. A 1.6 d). The loss of endothermal melting peak of crystalline AP 
confirms the formation of inclusion complex [41].  These findings were found in agreement 
with the XRD analysis results. The change in intermolecular interaction caused by the formation 
of inclusion complex results in the loss of crystallinity of antipyrine and thus no endothermic 
peak was observed for the inclusion complex. The DSC of γ-CD and physical mixture also 
exhibited broad endothermic peak between 310°C to 330°C respectively. 
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A 1.5.7 Scanning electron microscopy 
The change in the structure and physical appearance of substances on the formation of inclusion 
complex was studied by SEM technology. The AP appeared as irregular plate like structures 
(Fig. A 1.7 a) whereas γ-CD appeared as parallelogram shapes (Fig. A 1.7 b). Physical mixture 
contained morphology of both the components (Fig. A 1.7 c). In the inclusion complex, a single 
component with completely different and irregular amorphous morphology was observed (Fig. 
A 1.7 d). The morphological changes which appeared in SEM images confirm the existence of 
interaction between AP and γ-CD [42]. 
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A 1.5.8 NMR analysis 
1H NMR and two dimensional NOESY spectroscopy provides detailed information about 
inclusion mode [43, 44]. The significant chemical shift variations of host γ-CD and guest AP 
protons that occurred in the 1H spectrum provided preliminary evidence for the formation of 
inclusion complexes in solution. The magnetic anisotropy of the aromatic ring of AP in the 
hydrophobic cavity of γ-CD results in these chemical shift changes [45]. Fig. A 1.8 represents 
1H NMR spectra of γ-CD, AP and their inclusion complex. Peak assignments for the protons of 
γ-CD in 1H NMR was performed according to the previous report [46]. From the 1H NMR 
spectrum of the inclusion complex, it is evident that all the cyclodextrin protons, namely, H1-
H6 chemical shifts were slightly shifted up-field and protons of AP shifted downfield, resulting 
from inclusion of the guest molecule into the hydrophobic cavity of γ-CD . The 1H chemical 
shifts of γ-CD in the presence and absence of AP are shown in Table A 1.3 and A 1.4. It is 
observed that the protons named H3 and H5 of γ-CD shifted the most. Since these protons lie 
inside the cavity, they are the ones most affected, and this thus confirms the formation of 
inclusion complex.  
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Table A 1.3 1H NMR chemical shifts corresponding to γ-CD in the presence and absence of AP 
 
γ-CD proton δ(free) δ(complex) Δδ = δ(free) - δ(complex) 
H1 5.0428 5.0322 0.0106 
H2 3.5871 3.5786 0.0085 
H3 3.8672 3.8399 0.0273 
H4 3.5217 3.5121 0.0096 
H5 3.7817 3.7582 0.0235 
H6 3.8046 3.7883 0.0163 
 
Table A 1.4 1H NMR chemical shifts corresponding to AP in the presence and absence of γ-CD 
 
AP proton δ(Complex) δ(free) Δδ = δ(Complex)- 
δ(free) 
H1' 7.2996 d 7.2216 d 0.078 







H4' 5.344 5.306 0.038 
H5' 2.23 2.175 0.055 
H6' 3.177 3.089 0.088 
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Figure A 1.8 1H NMR spectra of a) AP, b) γ-CD and c) Inclusion complex of AP with γ-CD. 
 
 
The NOESY spectrum of the inclusion complex exhibited interesting NOE interactions between 
the AP and γ-CD protons. NOE interactions are highlighted in Fig. A 1.9 a. Protons in the 
vicinity of  2-5 Å shows NOE correlations in 2D NMR [47]. The protons H1'-H4' of AP 
exhibited prominent NOE interactions with protons of γ-CD i.e. H2, H3, H5 and H6 (Fig. A 
1.9 b). These NOE peaks were further confirmed by studying sequential COSY (Fig. A 1.10) 
coupling in HSQC (Fig. A 1.11) spectrum. The characteristic well separated anomeric protons 
(H-1) of the glucose unit of γ-CD and the methyl and methylene protons of AP were the most 
convenient points for the elucidation of 2D NMR spectra of the inclusion complex. Using these 
protons as a reference, chemical shifts and correlations of all other protons of γ-CD were 
confirmed. After the assignment of protons, the corresponding carbon atoms were identified 
using the HSQC spectrum. To further confirm our observation in the NOESY spectrum, we 
studied the molecular models. It was observed that the aromatic ring of AP was close to the 
edge of primary hydroxyl groups of γ-CD and distance between the H1'-H4' of AP and H3, H5 
and H6 protons of γ-CD was found to be in the range of 2.4-5Ǻ. It seems that NOESY 
interactions are possible. Interestingly there were also NOESY interaction between aromatic 
protons of AP (H1', H2' and H3') with H2 of γ-CD and methyl (H5' and H6') and methylene 
(H4') protons of AP Fig. A 1.9 a. Thus the major changes in the δ values of H3 and H5 protons 
lying inside the cavity of γ-CD and NOE interaction between the AP and γ-CD confirms the 
formation of inclusion complex.  





Figure A 1.9 a) 2D NOESY spectrum of inclusion complex b) Expanded region of 2D NOESY 
spectrum showing 1H-1H NOE interaction between aromatic protons of AP and γ-
CD. 
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Figure A 1.10 COSY spectrum of inclusion complex. 
 
Figure A 1.11 HSQC spectrum of inclusion complex. 
A 1.5.9 Cytotoxicity 
The in vitro comparison of cytotoxicity of free AP, γ-CD and inclusion complex was assessed 
to verify its safe application in pharmaceutical formulations. For all the tested concentrations 
(7.8-500 µM) of AP, γ-CD and inclusion complex, cell viabilities greater than 85% were 
observed indicating that γ-CD inclusion did not induce or increase the toxicity of AP. Hence, 
cyclodextrin based approach for the design of new formulations of AP would be an interesting 
strategy. 
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A 1.6 Conclusion 
In this study, molecular modeling techniques were employed to identify the possible 
conformation of inclusion complexes of AP. Based on the computed binding free energies β-
CD and γ-CD were found to be a suitable polymers for encapsulation. The encapsulation of AP 
inside the cavity of γ-CD was thoroughly characterized by calorimetric and spectroscopic 
techniques. In addition, the toxicity profile of the inclusion complex (AP-γ-CD) was also 
investigated. The inclusion complex of AP-γ-CD was found to be non-toxic against MDCK-1 
cells even at high concentration. The approach of making use of inclusion complexes may help 
in the design and development of γ-CD associated pharmaceutical formulations. In addition, 
the knowledge gained in this study may be applied for the treatment of AP contaminated water 
using γ-CD derived polymers and materials. 
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